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Abstract
Continuous manufacturing (CM) is effective for sustainable chemical manufacture, but
production of pharmaceuticals and fine chemicals requires complex, multi-step pro-
cedures often carried out in batch. Gaps in the CM supply chain, such as between
upstream flow synthesis and downstream continuous crystallisation form a major bot-
tleneck in the take-up of CM. The motivation for the research presented in this thesis
was to demonstrate integrated CM of pharmaceuticals and multi-component complexes.
The oximation of 4-hydroxyacetophenone (4HAP) to 4-hydroxyacetophenone oxime (4-
HAPO) and subsequent Beckmann rearrangement of 4HAPO to paracetamol (PCM)
was investigated. A one-pot method was transferred to flow using a packed bed column,
but leaching into the feed limited downstream integration. A two-step approach was
transferred into flow to give 4HAPO and PCM respectively. Synthesis of 4HAPO
was integrated with a compact flow crystalliser with partial success, while a semi-batch
approach showed 4HAPO could be directly crystallised from the flow synthesis effluent.
The catalytic flow hydration of pyrazinecarbonitrile (PyCN) to the drug pyrazinamide
(PZA) was integrated with the segmented flow kinetically regulated automated input
crystalliser (KRAIC). A cooling step introduced controlled nucleation and resulted in a
five-fold reduction in crystal size. The crystallisation technique selectively formed the
γ-PZA polymorph from the aqueous solution without the need for additives.
Production of multi-component complexes, 4-bromo-2-methylaniline (4Br2MA):3,5-di-
nitrobenzoic acid (35DNBA) and 4-iodo-2-methylaniline (4I2MA):35DNBA, was in-
vestigated using antisolvent crystallisation. Crystallisation of 4Br2MA:35DNBA was
transferred into a segmented flow crystalliser and off-line isolation of the precipitate al-
lowed characterisation of 4Br2MA:35DNBA crystals. A novel form of 4I2MA:35DNBA
was isolated and characterised from batch crystallisation experiments. Thermal analy-
sis of the thermochromic behaviour of the cocrystals showed that the single-crystal-to-
single-crystal (SCSC) phase transition may be enabled by water in the bulk sample.
Two flow crystallisers (a tubular mixer reactor and a periodic withdrawal, continuous
stirred tank reactor (CSTR) system) were evaluated for production of a commercial
active pharmaceutical ingredient (API) salt. Crystallisation in the tubular mixer reac-
tor was effective only for short periods at high velocity flow rates. Crystallisation in
the CSTRs successfully operated for twelve residence times (RTs); with a 70 % yield of
the API salt. The API salt formed spherical agglomerates in flow which showed higher
uniformity and lower cake resistance compared to the batch sample.
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1.1 Sustainability and Manufacturing
In 2005, the American Chemical Society (ACS) Green Chemistry Institute (GCI) es-
tablished a round-table for the pharmaceutical industry. Drawing on the expertise
of companies including AstraZeneca, GlaxoSmithKline, Novartis and Pfizer; the ACS
GCI pharmaceutical round-table aimed to motivate the adoption of the 12 Principles of
Green Chemistry.1 In 2007, they established a list of important research areas in which
significant progress is needed in order to adopt green chemistry practices. A second list
was released in 2010, where ten complementary green engineering targets were iden-
tified.2 Of those highlighted, continuous manufacturing and integration of chemistry
and chemical engineering were recognised as top priorities.3 In 2015, United Nations
(UN) launched the 2030 agenda for sustainable development in which they listed 17
Sustainable Development Goals (SDGs). Adopted by every member state, SDGs are a
global strategy to improve health, education, reduce inequality, tackle climate change
and stimulate economic growth for the betterment of people and planet.4 In order to
achieve these goals, the International Council of Chemical Associations (ICCA) has
recognised the important role that the chemical and pharmaceutical industry must
play in order to achieve long-term sustainable practices.5
However, the development of cleaner and more robust chemical manufacturing is a
challenging problem. The chemical industry faces increasing pressure from social, eco-
nomic and environmental factors to deliver greener chemistry while still meeting con-
tinually increasing consumer demand. This is particularly difficult in sectors such as
the pharmaceutical industry, where developing life saving medicine for patients is of
equal importance to tackling pollution. Meeting these growing challenges will require
technologies and processes that reduce environmental impact, improve efficiency and
shift away from depleting finite resources.
The Centre for Sustainable Chemical Technologies (CSCT) at the University of Bath
aims to address current issues from a multidisciplinary approach, drawing on expertise
across faculties. One of the core themes is processes and manufacturing. The CSCT
aims to consider the total supply chain and whole life cycle impact, collaborating with
both industry and international partners to achieve this.6 One of the key areas identified
by the CSCT for development is the use of continuous manufacturing for the production
of fine chemicals and pharmaceuticals.
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1.2 Continuous Manufacturing
Continuous manufacturing (CM) is the concept of continuously charging and discharg-
ing material(s) and product from a system without interruption.7 Within chemical
industries, continuous processing is not a new technique. The most well known mod-
ern continuous chemical process is the Haber-Bosch process, which was developed in
the early 20th century for the production of ammonia (Figure 1-1).8,9 The Haber-Bosch
process, still in use today, was largely fuelled by the economic demand for nitrogen
based compounds. Approximately 80 % of the worldwide ammonia output is used in
fertilisers for agriculture.10 Since then, continuous processing is now used widely for the
mass production of commodity chemicals, polymers and petrochemicals.11,12 In mod-
ern times, effectively all the steps in a petrochemical process from crude oil distillation
through to separation of the final product is performed in a series of continuous flow
reactors and separators.13
Figure 1-1: Schematic of the Haber-Bosch process for production of ammonia
The take-up of continuous process design in most bulk chemical production is relatively
high, however the use of CM in the pharmaceutical and fine chemicals sectors has been
much slower. There are several reasons for this, for example, in the pharmaceuticals
sector stricter quality regulations (required to ensure the product is safe for human
consumption) compared to bulk chemicals limits CM uptake.14 Furthermore, pharma-
ceutical and fine chemical compounds tend to be structurally more complex than bulk
chemicals. As a result, manufacturing fine chemical and pharmaceuticals often requires
intensive, multi-step units of operation. Because of this, CM practices are generally
29
less attractive, as the conversion of existing batch processes to continuous systems re-
quires purchasing of expensive new equipment and complementary control systems. As
an example of the difficulties faced, a recent paper outlined the synthetic route to a
promising anti-tumour drug C52-halichondrin-B amine (E7130) (Figure 1-2).
Figure 1-2: Chemical structure of C52-halichondrin-B amine (E7130)
E7130 is a synthetic derivative of halichondrins, a natural product isolated from marine
sponges. E7130 requires 92 individual synthetic steps to produce E7130 suitable for
clinical trials.15 E7130 is currently produced on the lab-scale in a series of batch reaction
and work-ups. This makes sense from a development standpoint, as it is easy to imagine
that implementing a CM strategy for a 92 step continuous reaction would be extremely
complex. In the adoption of CM, the plight facing the drug development industry
is the fact that the molecular structures of drug molecules are becoming increasingly
complex, which sparks an aversion to modern continuous manufacturing practices.
In contrast to drug development, commodity chemicals require much simpler prepara-
tion procedures and their is a clear economic driver to adopt CM in this case. The bulk
chemicals industry produces huge stockpiles of chemicals in order to meet the demand.
The amounts needed would be impossible to facilitate without the use of CM to reduce
costs (see Table 1.1).9 While the economic driver is still present in fine chemical and
pharmaceutical sectors, this is a much smaller incentive for using CM technology, as
annual product tonnage is orders of magnitude smaller than bulk chemicals production.
Instead other drivers have begun to push the adoption of continuous processing prac-
tices including, reducing development costs,16 increasing production flexibility,17,18 im-
proving health & safety,19,20 decreasing environmental impact,21 increasing product
quality,7,11 greater process automation14,22 as well as sector regulators pushing for
modernisation of fine chemical processing.7,23 Many of these drivers are influenced by
the growing need for sustainable manufacturing practices. As shown in Table 1.1, the
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Table 1.1: Comparing annual product tonnage and waste across industry sectors12
Industry sector Product tonnage kg wastea / kg product
Oil Refining 106 - 108 < 0.1
Bulk Chemicals 104 - 106 1 - 5
Fine Chemicals 102 - 104 5 - 50
Pharmaceuticals 10 - 103 25 - 100
a Defined as all materials except the desired product (including inorganic salts, solvent loss, etc.)
amount of waste per kg of product in the fine chemicals and pharmaceutical industry
is orders of magnitude higher than bulk chemical production. CM has the potential
to help offset waste and can be aligned closely with the principles of green chemistry
(Table 1.2).
Table 1.2: 12 Principles of Green Chemistry24
Number Green Chemistry Principle
G1 Waste Prevention
G2 Atom Efficient
G3 Reduce hazardous chemical usage
G4 Safer molecules by design




G9 Use catalytic amounts of reagents
G10 Design products for degradation
G11 Real-time analysis for pollution prevention
G12 Design safer processes
In particular CM has an affinity with G1, waste prevention, but a range of the other
potential advantages are summarised in Table 1.3.25 While CM offers many advantages,
there are still significant gaps in the technologies available for continuous manufactur-
ing. For instance, many of the downstream technologies concerned with extraction,
separation, isolation and purification can become more complex when transferred into
a continuous process.26 While the use of CM in synthesis is becoming routine, exam-
ples of continuous downstream process operations in fine chemical and pharmaceutical
manufacturing are relatively rare. In particular, continuous crystallisation is proving
to be one of the most challenging aspects in continuous flow and there is a notable gap
in the advances made in continuous crystallisation compared to flow chemistry. How-
ever, if the industry is to adopt an end-to-end manufacturing approach, then significant
strides need to be made in bridging the gap between fields of continuous processing.
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Table 1.3: Relationship between specific benefits of continuous manufacturing and
green chemistry7,11,25







In situ processing of
hazardous
intermediates
Safer handling of toxic material
Shorter supply chains















Reduce required reagent amounts
G12, G9
1.3 Aims and Objectives
The overarching theme of the research presented in this thesis is to address current
challenges in the development of continuous manufacturing for the production of phar-
maceuticals and fine chemicals. The research herein aims to approach continuous
processing challenges from a holistic perspective, establishing procedures and reac-
tor designs that will allow the bridging between upstream synthetic technologies with
downstream crystallisation platforms (Figure 1-3). The ability to seamlessly transfer
from one chemical process to another without downtime or off-line work-up would lead
to greater adoption of continuous processes in the pharmaceutical sector and will be
an essential step in the development of a sustainable chemical industry. The work
presented in this thesis will cover a range of flow technologies and attempt to develop
continuous processes for a range of target molecules. The work carried out will be split
into chapters covering each target molecule and discuss the development of various flow
procedures, with the overall goal of achieving integrated continuous systems. The main
targets will be active pharmaceutical ingredients (APIs) or important intermediates to-
wards API production. These will be covered in Chapter 3, 4 and 6. The other aspect
of the work presented here will cover more novel molecular systems and attempts to
move their production from a small scale batch process to continuous production, this
will be covered in Chapter 5.
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Figure 1-3: The continuous manufacturing pipeline (adapted from Mascia et al.)27
Chapter 3 discusses efforts towards the development of a continuous process for the
delivery of paracetamol (PCM) in a continuous process. The work carried out within
the Centre for Sustainable Chemical Technologies (CSCT) aims to develop a contin-
uous process, using PCM as a model API. The overarching aim of the work is to
develop a route to PCM from renewable feedstocks, circumventing the need for finite
resources. This chapter will be concerned with the final synthetic step in the method
and attempting to add further value to the process by integrating the route with a
continuous crystallisation platform. The work will also outline efforts to develop an
integrated, continuous process for the production of an important intermediate in the
synthetic procedure, 4-hydroxyacetophenone oxime (4HAPO).
Chapter 4 will present the development of a continuous process for the delivery of
pyrazinamide (PZA). The work was carried out as a collaboration between the Univer-
sity of Bath, Chick Wilson group and the University of Cambridge, Steven Ley group.
The aim of the work was to couple an established flow chemistry route to PZA with a
bespoke crystallisation platform, known as the kinetically regulated automated input
crystalliser (KRAIC). The KRAIC was developed at Bath by Dr. Karen Robertson.
The chapter will discuss the development and optimisation of a continuous synthesis
and crystallisation process for PZA.
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Chapter 5 will move towards the downstream process, concentrating on the devel-
opment of a cocrystallisation procedure for the delivery of thermochromic materials.
Previous work by the metastable materials group at Bath has produced crystalline
products with desirable colour-changing properties. However, efforts to scale-up pro-
duction in batch have been difficult. The main objective of the work is to develop a
suitable continuous crystallisation process for scale-up without changing the desired
properties. This in turn would allow for sufficient material to be produced for further
studies in device applications.
Chapter 6 will cover the investigation into a reactive crystallisation procedure for the
production of commercial API salt product. The work carried out was conducted dur-
ing a three month placement at the AstraZeneca (AZ) Research and Development site,
Macclesfield, UK. The overall aim was to investigate, develop and evaluate a continuous
crystallisation process for the API salt formation. In particular, the development pro-
cess was considered from an integrated manufacturing perspective. For confidentiality
reasons, the identity of the API cannot be disclosed. Instead, this chapter concentrates
on downstream process development and discusses the possible benefits of integration
within a wider continuous manufacturing framework.
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1.4 Continuous Chemistry Concepts
When considering continuous chemical reactions, it is important to identify a number
of fundamental differences between batch and flow processes. This section is concerned
with introducing some of the key concepts commonly encountered when considering
continuous chemical processing, a brief summary is outlined in Table 1.4.
Table 1.4: Comparison of the characteristics of batch and flow28
Batch Flow
Stoichiometry Defined by the concentra-
tion/molar ratio of the compo-
nents
Defined by concentration/ratio
of the flow rates
Reaction
time
Time spent under the reaction
conditions
Time spent in the reactor; depen-




Dependent on time spent in re-
action vessel
Dependent on distance travelled
along reactor length
Steady state Concentration of components
throughout the vessel at any
given time is uniform
Reactant concentration is steady
with time but different along the
reactor length
1.4.1 Residence Time (RT)
In traditional chemistry, the vast majority of reactions are carried out in batch pro-
cesses. In a batch reaction, the reaction time is determined by the time that the vessel
is held under the set reaction conditions. In continuous processes this is not the case,
instead the reaction is controlled by the residence time (RT). This is the time between
initiation and termination of a continuous transformation, or how long the reagents
spend inside the reactor conditions (Figure 1-4).28,29 RT is dependent on the reactor
volume and the flow rate (Figure 1-5). In a tubular reactor, RT can be calculated using
Equation 1.1. Where V is the volume (mL), Q is flow rate (mL min−1), l is length
(cm) and r is the radius (cm). By adjusting the reactor size or flow rate, precise control
can be exerted on the RT of a chemical process. This is important, as the RT has a
profound effect on the success of a process. Should the residence time be too short, then
the reagents are discharged from the reactor before the reaction is complete. If the RT
is too long, then the solution is occupying reactor space for no benefit.30 This not only
decreases the productivity of the process, but risks decomposition of the product(s) if
the reaction requires harsh conditions or the product is unstable.
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Figure 1-5: Residence time
If a reaction is run in a batch environment, then the concentration of the reagents and
products is uniform throughout the vessel at any given time. However in an optimal flow
process, the concentration of reagents and products changes along the reactor length.
Thus, the reaction time in a continuous process is related to the distance travelled
from the inlet of the reactor.30,32 The ideal situation to maximise productivity would
be to ensure that the residence time is equal to the reaction time.28 In other words, the
flow rate and reactor volume is set so that the chemical transformation is completed
at the point of reaction termination. However it is important to note that in the real
world, not all molecules that enter the reactor spend the same length of time within the
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reactor zone. In any flow system, there will exist a distribution of residence times that
is influenced by the fluid dynamics. This dispersion of the RT from the ideal is denoted
as the residence time distribution (RTD).29,33 In general, the tighter the RTD, the
more consistent the process will be.34 There are a number of methods to improve the
consistency of the RT including: enhancing mixing, segmentation of flow,35 changing
reactor geometry or decreasing solution viscosity.36
1.4.2 Steady State Conditions
Continuous reactors are preferably operated at steady state. At steady state, the
movement of chemical species into and out of the reactor is the same. At steady state,
the temperature and concentration at a specific spatial point does not change with
time.30 The yield and conversion at steady state is usually significantly different to the
overall process yield and conversion.29 This is because a continuous process will likely
undergo a period of unsteady state during operation start-up, shutdown, or after a
change in the process variables (Figure 1-6).33
Figure 1-6: Diagram of a flow process with steady state operation
It is possible to measure approximately when a system has reached steady state using
a tracer. The tracer can be monitored either offline or in situ but must be inert to
the reactor conditions.33 A typical example of a tracer would be a coloured dye, whose
concentration could be measured using a spectrometer. Once the dye concentration is
no longer changing with time, the system is said to have reached equilibrium.33,36,37
While steady state is a useful term, in reality most real continuous processes are prone
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to disturbances or fluctuations in temperature, pressure or chemical composition and
so never truly reach steady state. However, measuring experimentally does help to
determine when these disturbances in a process have reached a minimum, allowing
measurements to be made when the system is at its highest consistency. This is a
significant advantage in continuous processing over batch processing, as a batch reactor
operates under unsteady conditions. Hence it can be much easier to control critical
quality attributess (CQAs) in a continuous system if quality control focuses around
operation at steady state.14,38 Systems that operate close to steady state include plug
flow reactors (PFRs) and continuous stirred tank reactors (CSTRs).39
1.4.3 Mixing, Mass and Heat Transfer
One of the advantages observed in using continuous processes is the improved surface
area-to-volume ratio. This is mainly the case for tubular reactor platforms, such as in
microreactors or macro-scale coiled reactors, but it can be extended to include CST-
Rs if they are run in series (i.e. multiple small CSTRs in contrast to a single stirred
reactor of the same total volume). Since most processes require an outer heating jacket
in order to regulate temperature, in larger batch vessels where surface-to-volume ratio
is low, heat transfer is inefficient.29 This in turn can lead to thermal gradients which
increase the likelihood of unintentional side reactions occurring. In the case of flow
reactors, if the surface area-to-volume ratio is high this allows greater control over the
heating/cooling cycle resulting in a more consistent product. In the growing sector
of microwave-chemistry for example, a good surface-volume ratio is a key factor in
ensuring equal heating of the mixture.40
As with heat transfer, both mass transfer and mixing can be similarly improved in
flow. In large scale processes, these factors can have a significant influence in the
time required to establish homogeneity and this in turn can have a direct influence
on a processes efficiency. Generally, the higher surface-to-volume ratio of flow reactors
makes them superior to equivalent batch vessels in this regard. This is also true on
the bench-top scale, when comparing a flow reactor to a flask. For example Nagaki
et al. demonstrated how moving from a batch reactor to a microreactor significantly
improved synthesis of a series of biaryls.31,41 The improved surface-to-volume ratio led
to better heat and mass transfer in the system which was essential in facilitating the
conversion of the reactants to the products. Furthermore, by reducing the diameter
of the tubing and therefore increasing mass transfer and mixing, the conversion and
selectivity to the desired product was increased by 14 %.
In continuous processing, it can often be beneficial for a system to approach plug flow.
38
A plug flow reactor (PFR) consists of a vessel (or series of vessels) in which only radial
mixing occurs (Figure 1-7).42 This model assumes no back-mixing in the system and
demonstrates a tight RTD. Essentially, the flow moves through the reactor as a single
“plug” in the axial direction from inlet to outlet without any chemical dispersion.
Figure 1-7: Plug flow through a tubular reactor
Typically a single continuous stirred tank reactor (CSTR) is described as “perfectly”
mixed, that is, the vessel has a homogeneous composition.33 However, in practice a
single CSTR does not perform ideally and can suffer from a wide RTD, resulting in
poor reactor performance.43 This can be circumvented by running CSTRs in series. As
the number of CSTRs approaches infinite, plug flow is achieved.44 In reality, increasing
the number of CSTR stages has repercussions on the amount of equipment needed and
so is usually limited to less than ten. The benefits of a plug flow system are partic-
ularly pronounced in continuous crystallisation; where back-mixing leads to variation
in particle size distribution, impurity retention and crystal morphology.45–47 There are
three forms of mixing in a conventional tubular reactor, which can be categorised as
laminar, transitional and turbulent (Figure 1-8).29
Figure 1-8: Types of fluid flow
Mixing in these systems is described using the dimensionless Reynolds number (Re).
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Where is ρ is the fluid density (kg m−3), µ is the dynamic viscosity (kg m−1 s−1), u is
the net flow velocity (m s−1) and d is the tube diameter (m).37 Generally an Re < 2300
results in laminar flow, an Re between 2300 and 4000 is transitional and an Re above
4000 is turbulent.28 In laminar flow, fluid motion is mostly parallel to the tube axis.
In microreactors (where tubing diameter is less than 10−5 metres) laminar regimes can
provide efficient mixing.28 For larger reactors however, turbulence is needed to provide
intense, random motion to improve mass transfer and heat transfer.42 Most lab-based
batch mixing is either laminar or transitional.48 To achieve plug flow in a tubular
system requires a high velocity flow rate that generates turbulent mixing. However,
a secondary mechanism (such as segmentation) can be implemented to generate plug
flow, independent of flow rate.
The fundamental differences in continuous flow offer chemists greater control and ef-
ficiency that cannot be easily replicated under batch conditions. These advantages,
coupled with the drive for greener manufacturing has made CM increasingly attractive
to the fine chemical and pharmaceutical industries. As a result, this has spawned the
development of new technologies and applications in two distinct fields of research -
flow synthesis and continuous crystallisation.
1.5 Flow Synthesis
Flow synthesis is concerned with the continuous flow reaction of a chemical species to
a desired product.49 Generally flow synthesis has had much success in organic chem-
istry to produce pharmaceuticals and petrochemical products, but flow synthesis has
also been extended for the production of inorganic materials such as metal-organic
frameworks, quantum dots and nanoparticles. There are several advantages in flow
synthesis compared with batch synthesis. In particular, tubular flow reactors offer fast
mixing, excellent heat and pressure control, good mass transfer and heightened safety,
all factors that can influence the success of a synthetic reaction.50
1.5.1 Equipment and Technologies
In a simple flow synthesis set-up (Figure 1-9) there are a series of key equipment parts
required to carry out a reaction. This usually consists of a series of pumps, tubing,
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mixer pieces and a core reactor unit. The pumps are used to move solutions around the
system and the choice of pump is dependent on the application. Some typical examples
include peristaltic, gear and syringe pumps.29,51 Each have a number of advantages and
disadvantages and the choice of pump is dependent on the application. For instance, a
peristaltic pump is capable of handling small solid loadings, such as when transporting
a slurry. However a peristaltic pump can induce back-mixing, caused by the motion
of the moving parts. Aspects to consider in pump selection include: what range of
flow rates may be required? What reaction conditions (e.g. handling high pressure
reactions or pumping gas-liquid reactions mixtures) must be maintained? Is the pump
compatible with any corrosive or oxidising agents present?52 Mixing of two reagent
phases is facilitated by a mixer piece. In most cases a T-piece (as depicted in Figure
1-9) or Y-piece is used to combine two or more streams into a single channel. This
is sufficient for slow reactions or small reactors, but where faster mixing is required
the process can be intensified by in-line structures (such as static mixers) to ensure
completely homogeneous mixing.53 Other elements to consider are the need for elevated
temperatures or pressures; in this case a back pressure regulator (BPR) will be needed
for safe operation above a solvent’s boiling point. The benefits of high pressure or
high temperature are well documented, including increasing reaction rate, improving
selectivity and raising process intensification.54
Figure 1-9: Typical flow chemistry scheme
The reactor lies at the heart of the process and is where the chemical transformation
should take place. There are number of different types of reactors available. Some of
the common examples encountered are shown in Figure 1-10. Much like pumps, the
reactor type will largely be dependent on the nature of the reaction and the scale of the
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process. Chip reactors (Figure 1-10a) offer very high levels of heat and mass transfer due
to the large surface-to-volume ratios.50 This results in the reduction of side reactions
compared to batch where mixing and inefficient heat transfer can lead to unwanted
by-products. The internal volume of a chip reactor can range from below 1 µL and up
to and above 1 mL. This allows for optimisation of a synthesis using minimal amounts
of reagents.51 They can be machined from a range of materials including glass, stainless
steel, polymers and ceramics suitable for a range of chemistry.54 Chip based reactors
are an attractive flow technology for liquid-liquid or gas-liquid reactions but they suffer
from some disadvantages. In particular the system’s inherent small diameter increases
the likelihood of clogging and blockages occurring.17 Roberge et al. has shown that
statistically, over 50 % of all fine chemical and pharmaceutical reactions could benefit
from using micro or chip reactors for synthesis. However, their inability to handle solids
limits their application to less than half of these cases.55 Furthermore, scaling up chip
reactor technology can have high upfront costs, making it difficult for chip reactors to
compete with established batch processes at the kilogram scale.56
Figure 1-10: Typical reactors used in flow synthesis
Tubular coiled reactors (Figure 1-10b) are the simplest and most adaptable flow reactors
available. Coil reactors typically operate between 1 µL up to a few litres in volume, with
a wide range of internal diameters. Coil reactors are commercially available in a range
of inert materials but the most commonly used are fluoropolymer derivatives such as
polyether etherketone (PEEK), perfluoroalkoxy alkane (PFA), polytetrafluoroethylene
(PTFE) and fluorinated ethylene propylene (FEP).18 Where high temperatures (over
150 ◦C) or pressures (over 20 bar) are needed, stainless steel (or another suitable metal)
coils may be more suitable.29 The advantage of coil reactors is their versatility and
ease of use. The RT can be set by adjusting the length or internal diameter of the
coil, as well as the flow rate. They can be heated or cooled in a water bath or by a
programmable heater unit. Coil reactors can be connected in series and subjected to
different conditions making them suitable for multi-step reaction schemes. Much like
chip-based reactors, coiled reactors can also suffer from blockages from particulates
however, the larger diameter in coiled reactors makes it easier to clean and cheaper
42
to replace than chip reactors.51 However the larger diameter in coil reactors tends
to increase the RTD compared to those typically seen in chip reactors. This can be
overcome by introducing mixer pieces or segmentation to narrow the RTD in coils.
Chip reactors tend to offer better surface-to-volume ratio than coil reactors, making
them most suitable for very fast or highly exothermic reactions which benefit from the
superior mass and heat transfer rates.54 Slower processes benefit from the longer RTs
coil reactors offer as well as their higher productivity.
The third reactor type in Figure 1-10 is the packed bed unit. A packed bed unit is gen-
erally utilised when a heterogeneous reagent or catalyst is required. The unit consists
of a column or cartridge filled with solid material where each end is plugged with a filter
frit end-piece. A solution containing the reagents is pumped through the reactor to
begin the reaction. An effective packed bed reactor allows for heterogeneous reactions
to proceed without the need for a subsequent separation process. The performance of
a packed bed reactor is highly dependent on particle size, solid loading and RT.51 The
greater the surface-to-volume ratio of the solid particles, the better a reaction perfor-
mance is likely to be.29 However, if the particles are too small or partially soluble in
the feedstock, then leaching of the solid into the reaction stream can occur. This can
lead to blockage issues, or a reduction in catalytic activity over time. Such problems
can limit the run time of a flow process before a replacement cartridge is needed.57
Nevertheless reagents immobilised within a packed bed benefit from localised high mo-
larity, which can help drive a reaction to completion while simultaneously preventing
side reactions via continuous removal of the effluent.58
There is an extensive range of advanced reactor technologies available on the market,
most of which are designed to fit the chemistry. The range of applications include pho-
tochemistry,59,60 electrochemistry,61 microwave-assisted chemistry40,62 and gas-liquid
phase chemistry.63 Each sector is a ongoing area of study but these advanced reactors
are designed to take advantage of the inherent attributes of continuous flow processing.
Much of the equipment is modular and allows for combinations of pumps, mixers, pres-
sure regulators, reactors, heating and cooling zones to be assembled into versatile ‘plug
and play’ platforms. As such, the development of flow technologies gives additional
versatility compared to batch-based synthesis.
1.5.2 Pharmaceutical Synthesis
The use of flow technology can contribute towards improved sustainability, safety and
productivity making flow synthesis an attractive procedure for the manufacturing of
APIs or important intermediates. But the pharmaceutical industry still relies predom-
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inantly on batch or semi-batch reactors, despite the evident interest in continuous flow
manufacturing.64,65 In academia, the growth of flow technology for API generation can
be traced to the early 2000s. Examples of successful flow synthesis of drug products
include the production of ciprofloxacin, rimonabant and efaproxiral (Figure 1-11).
Figure 1-11: Chemical structure of a) ciproflaxin b) rimonabant and c) efaproxiral
In the case of ciprofloxacin, application of microreactor technology showed flow syn-
thesis could be applied sequentially to assemble the antibiotic and derivatives using
flow synthetic methods. In producing ciprofloxacin, the use of microreactor technology
offered greater control of the subsequent product formation compared to batch.66 For
rimonanbant and efaproxial, Gustafsson et al. demonstrated how a small coiled reactor
could be used to safely carry out an amide bond formation using the highly pyrophoric
reagent trimethylaluminium. Process intensification in flow meant lower volumes of
the hazardous reagent were needed and the process was much safer than the equiva-
lent batch system.67 More recently, the portfolio of high profile drugs that have been
successfully synthesised in a series of single or multi-step flow synthetic processes has
expanded rapidly, some notable examples include ibuprofen,68,69 artemisinin,70 ima-
tinib71,72 and nabumetone.73
A good example of a flow approach to pharmaceutical synthesis on an industrial scale
was published by Bristol-Myers Squibb. Here a batch process was developed for the
conversion of buspirone (an API for the treatment of anxiety disorders) to the metabo-
lite 6-hydroxybuspirone, a promising candidate under clinical study.74 While the batch
process was successful, several issues remained. Scaling up of the process to the pilot
plant significantly increased reaction time and raised concerns over the safety and po-
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tential for a run-away reaction. This was important as the reaction is exothermic and
required cryogenic temperatures to avoid unwanted side reactions. As such a consecu-
tive three-stage flow synthesis approach was implemented to overcome these challenges
(Figure 1-12).75
Figure 1-12: Schematic diagram for the flow synthesis of 6-hydroybuspirone
The process involved using a temperature controlled, jacketed reactor vessel for the
conversion of buspirone to its enolate derivative. Gaseous oxygen is then bubbled
through the enolate solution. The gas is fed counter to flow in a trickle-bed reactor
to yield 6-hydroxybuspirone.76 The process implemented the use of microstructures
(static mixers) to ensure good mixing of the starting materials before the enolisation
reactor. Using a flow reactor meant that temperature was easier to control compared
to the batch process, as the improved surface area-to-volume ratio enabled the efficient
removal of excess heat and easier maintenance of the cryogenic conditions. The static
mixer ensured homogeneity of the feed and shortened the reaction time. The system was
run for 50 hours under steady state operation producing over a 100 kg of the API with
a comparable quality to the batch product.75 Other examples of API flow chemistry
on an industrial scale include the synthesis of vildagliptin,77 2,2-dimethylchromenes
derivatives78 and production of intermediates towards etodolac synthesis.79
While production of pharmaceuticals using flow chemistry is beginning to grow, there
are some issues that have prevented widespread adoption. Issues include controlling
complex multi-step processes, integration of downstream processes, in-line purification
as well as an embedded culture and aversion to flow technologies. This is partly fu-
elled by the high up-front costs of flow equipment and a lack of trained personnel in
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flow practices.18,80 Despite this, the pharmaceutical sector is generally supportive of
continuous processing practices, while regulatory bodies like the Food and Drug Ad-
ministration (FDA) have begun accepting continuous manufacturing procedures.7,81–83
Furthermore, key practitioners in pharmaceutical development have highlighted flow
chemistry as a key enabling technologies in the adoption of green chemistry ideals.3
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1.6 Crystallisation
Crystallisation plays a critical role in the fine chemicals industry with the majority of
products requiring a precipitation or purification step at some point.84 In the phar-
maceutical sector, more than 90% of APIs are crystalline organic molecules.53 Crys-
tallisation is used to control important parameters in APIs such as purity, shape, size
distribution and polymorphism (Figure 1-13). Without proper control, poor crystal
performance can impact work-up, filtration, formulation and productivity.44,46 As such,
crystallisation has both a large effect on the performance of the final product and the
efficiency of the manufacturing process.
Figure 1-13: Important parameters in crystallisation control46
In order for crystallisation to occur, a system needs to be supersaturated. A system is
considered supersaturated when the amount of dissolved solute at a given temperature
and pressure exceeds the equilibrium solubility.85,86 This is can be described in terms








where S is the supersaturation, c is the solute concentration, c∗ is the equilibrium
solubility, ∆µ is the difference between the chemical potential of the solute and the
chemical potential at equilibrium, R is the gas constant and T is the temperature.38
For more practical uses, supersaturation is usually expressed as a ratio, or as the relative










So long as S > 1 (or σ > 0) the system can be considered supersaturated. Establishing
the equilibrium composition under a given set of conditions provides the basis for
a crystallisation process. Figure 1-14 shows a typical temperature vs concentration
solubility diagram.The solubility curve represents the solubility at equilibrium and the
dashed line represents the metastable zone limit. When the concentration of the solute
is below the solubility curve, the system is considered undersaturated and any crystals
will be dissolved in solution. The region between the solubility curve and the metastable
zone limit is termed the metastable zone width (MZW). Within this region, the system
is minimally supersaturated and thus only crystal growth and secondary nucleation
events will occur. Above the metastable zone limit is the supersaturated labile region,
where spontaneous primary nucleation occurs.
Figure 1-14: Solubility curve and the metastable zone width
When designing a crystallisation process, knowledge of the MZW is a useful tool in
ensuring controlled nucleation and crystal growth. However, the MZW is highly de-
pendent on many factors. In a cooling crystallisation for example the MZW can be
influenced by cooling rate, impurity levels, additive concentrations, stirring rate, flow
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rate, crystalliser scale and crystalliser geometry.38,44,85,86 As such, the MZW should be
considered a useful approximation rather than a fixed region.
1.6.1 Nucleation and Crystal Growth
Nucleation is the formation of a crystalline nucleus in a system. Nucleation can oc-
cur via several different pathways, the classical examples are primary and secondary
nucleation (illustrated in Figure 1-15). Primary nucleation occurs in the absence of
any crystalline solute. It has two distinct pathways, heterogeneous or homogeneous
nucleation. In homogeneous nucleation, the formation of crystals occurs without the
assistance of an interface or existing crystals. In primary heterogeneous nucleation,
nucleation is induced by a foreign particle or interface, such as a dust particle or the
crystalliser vessel walls.87 In comparison, secondary nucleation is the formation of new
crystals initiated by the presence of an existing crystal suspension. The source of
crystalline solute could be from ongoing primary nucleation, or can be induced by an
additive such as a seed crystal or template molecule.38,88
Figure 1-15: Nucleation pathways in crystallisation88
In primary nucleation, there are two nucleation pathways widely accepted within the
crystallisation community: classical nucleation theory (CNT) and two-step nucleation
theory (Figure 1-16). In CNT, fluctuations in the composition of a supersaturated
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solution lead to the formation of a small nucleus which acts as a focal point for crys-
tallisation.45 In this model, small molecules of the solute are added one after another
until it reaches a stable, critical size. The critical size of the cluster can be interpreted
as the activation energy barrier to the formation of a crystal. In the two-step model,
density fluctuations cause the formation of a highly disordered aggregate in the liq-
uid phase, which subsequently crystallises after long-range order has reached a critical
size.45,89 In this model, crystalline order occurs progressively over time. In comparison,
CNT builds one molecule at a time, with the cluster array having the same structure
as the resulting crystal.45
Figure 1-16: Nucleation models in crystallisation: classical nucleation (top) and two-
step nucleation (bottom)89
In order for a cluster to crystallise, a free energy barrier must be overcome. The relevant
phenomenon known as the critical cluster size (rc), can be explained using a free energy
diagram (Figure 1-17).87 The free energy required for a cluster formation (∆G) depends
on the competition between the free energy for the formation of a surface (∆Gs) and
the free energy for the phase transformation (∆Gv). The term ∆Gv favours growth, as
there is a decrease in free energy when a molecule in a supersaturated system moves
from the solution phase to the solid state. However, the ∆Gs term will increase as
the introduction of a liquid/solid interface results in a positive free energy. This is
proportional to the surface area of the cluster.89 Therefore, small clusters where the
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∆Gs term dominates tend towards dissolution, but as cluster size increases, ∆Gv begins
to exert greater influence. Once the total free energy passes through a maximum size
(rc), the total free energy will decrease continuously with growth becoming energetically
favourable, resulting in the formation of crystal nuclei.45 As supersaturation increases,
the height of the energy barrier and the value of the critical size decreases, once the
energy barrier is small enough, nucleation becomes spontaneous.87
Figure 1-17: Free energy diagram for nucleation a) at high supersaturation, b) at low
supersaturation87,89
In regards to heterogeneous nucleation (both primary and secondary), the presence of a
foreign body or surface allows for nucleation at lower levels of supersaturation compared
to homogeneous. This is due to the fact that adsorption onto a surface lowers the energy
barrier (∆Gcrit) for a crystallising material. The amount that ∆Gcrit is reduced by is
strongly dependent on the degree of similarity between the structure of the crystallising
material and the interface.87 Thus, it can be inferred that secondary nucleation (e.g.
by using seeding material) can be an effective strategy for controlling nucleation.38
Once a nucleation event has occurred, the cluster can continue to grow into a larger,
faceted crystal. The growth rate is dependent on a number of factors, such as the type
of impurities present, the local mixing environment, the amount of particle breakage,
agglomeration and the current supersaturation level.38 Both particle size distribution
and crystal morphology are influenced by the relative rates of nucleation and crystal
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growth amongst other factors.90
1.6.2 Crystal Morphology
The overall shape of the crystal, termed either as the crystal habit or morphology,
is an important parameter in crystallisation. In pharmaceuticals, the external shape
of a crystal can influence important physicochemical properties such as bulk density,
flowability, compressibility, melting point, solubility, stability, dissolution and bioavail-
ability. As such, the crystal shape can have a direct impact on a drugs performance
and processability.87,90 As an example, Beck et al. investigated the influence of the
size and morphology of calcium carbonate (CaCO3) crystals on pressure filtration.
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Crystals of CaCO3 could be crystallised in several different morphologies including
spherulites (polycyrstalline spherical particles), plates, cubic and needle shaped crys-
tals. The spherical particles of CaCO3 exhibited a similar polycrystalline behaviour
to that of an aromatic amine derivative product of industrial interest, which suffered
from filtration issues. Using calcium carbonate as a model compound, filtration exper-
iments were performed at a constant pressure. Results indicated that a large particle
size and narrow distribution improved the filtration of the spherical particles. The
work also confirmed that CaCO3 plate and needle-like crystals performed worse than
spherical and cube-like particles during pressure filtration. This was attributed to the
higher specific surface area, compressibility and tendency to break (leading to a larger
particle distribution) in plate-like and needle crystals, which results in a higher cake
resistance (Figure 1-18).
Figure 1-18: Effect of crystal morphology on filtration for spherulites and plate-like
crystals. Adapted from Davey et al. with reference to Beck et al.87,91
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1.6.3 Polymorphism
Polymorphism is defined as the ability of a chemical species to exist in two or more
crystalline forms with different structural arrangements. Polymorphism is a widespread
physicochemical characteristic and is observed in more than half of all APIs.92 The
strong interest in crystal polymorphism within the pharmaceutical sector can be at-
tributed to the fact that differences in chemical and physical characteristics can arise
with changes to the crystalline form.93 These characteristics can often increase an API’s
effectiveness, such as increasing solubility or rate of dissolution, which can influence a
drug’s bioavailability. Polymorphism can also improve an API’s mechanical properties
such as compactability or flowability which can reduce the intensity of downstream pro-
cessing steps like filtration or tableting.93 Of course, polymorphism can also negatively
alter such properties.
Control of the polymorphic form is of vital importance in drug development and is best
illustrated by the well known example of ritonavir. Ritonavir, (marketed as Norvir R©
in 1996) was distributed as an oral liquid and as a semi-solid capsule for treatment
of acquired immunodeficiency syndrome (AIDS).94 Ritonavir is not bioavailable in the
solid state and therefore a water/ethanol based solution was used to transport the API.
Since the drug was solution-based, polymorphic control was deemed unnecessary and
only one polymorph was identified (form I). However, an unknown but thermodynam-
ically more stable polymorph (form II) of Ritonavir began to regularly crystallise over
time. Form II was found to be more than 50% less soluble in the formulation than
form I.92 Ultimately, ritonavir had to be withdrawn from the market because the man-
ufacturing process could not reliably produce the desired polymorph. The product was
eventually relaunched, after an expensive and rigorous investigation was conducted to
control polymorphic behaviour in the manufacturing procedure.95
Generally, there are two kinds of polymorphic systems - either packing or conforma-
tional polymorphism. Packing polymorphism arises when molecules can arrange in dif-
ferent structures within a crystal lattice. Conformational polymorphism occurs when
different conformational isomers of a compound crystallise as distinct polymorphs.94 Ri-
tonavir is an example of conformational polymorphism, as the molecule can crystallise
in a trans (form I) or cis (form II) formation and exhibits different bulk properties as
a result.96
Under defined conditions, one polymorph is usually thermodynamically more stable.
Polymorphic forms that deviate from the thermodynamically favoured structure are
termed metastable. The metastable form will often undergo a phase transition to the
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stable form.93 The relative stability of polymorphs can be determined by calculating
the difference in free energy. The Gibbs free energy of transition (∆GT) at a constant
temperature and pressure is given by Equation 1.6:
∆GT = ∆HT − T∆ST (1.6)
where ∆HT represents the enthalpy difference between polymorphs, which reflects the
difference in the lattice or structural energy. ∆ST is the entropy difference, which relates
the difference in disorder and structural vibrations. When ∆GT < 0, a transformation
from the least stable polymorph can occur spontaneously. When ∆GT = 0 , the
two phases are in equilibrium while if ∆GT > 0, the transformation is not possible
under the specified conditions.92 ∆GT can be estimated from the solubility ratio of two
polymorphs (denoted form A and form B) in any given solvent from Equation 1.7:
∆GT = RT ln (
γBcB
γAcA




where R is the gas constant, T is the absolute temperature, cA and cB are the solubil-
ities of polymorph A and B respectively and γA and γB are the activity coefficients.
97
In dilute solutions, form A and B will be indistinguishable when dissolved. In this
case the ratio of activity coefficients (γB/γA) will be ≈ 1 and therefore the relative
thermodynamic stability of two polymorphs can be estimated from the ratio of their
solubilities.97,98 As the solubility is directly proportional to the free energy of a poly-
morph, determination of solubility is an effective method for comparing the stability
of polymorphic forms.87,92
The relationship between polymorphs can be enantiotropic or monotropic. Enan-
tiotropic polymorphs have a transition temperature (T transition) which is lower than
the melting point of the lowest melting polymorph. In this case, the relative stability
between two polymorphs changes before and after the transition point. In a monotropic
system, the transition point is above the melting point and therefore, one polymorph is
always the more stable over a given temperature range.97 In a monotropic system the
most stable polymorph will always be the least soluble, regardless of temperature. In
an enantiotropic system, the most soluble polymorph (and therefore most stable) will
be temperature dependent (Figure 1-19).87
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Figure 1-19: Solubility curves in a) monotropic and b) enantiotropic systems. Adapted
from Davey et al.87
The overriding factor in pharmaceutical drug development is usually stability. As was
demonstrated in the case of ritonavir, if the most stable form is not identified then this
can have serious repercussions on a product’s longevity. However, some metastable
polymorphic forms are stable for extended periods and undergo a phase transition over
extremely long time frames. In these cases, the choice of which polymorph to target will
depend on which form demonstrates the most important and desirable properties.88
1.6.4 Multi-component Crystals
Multi-component crystallisation is the formation of crystalline solids containing two
or more molecular species.99 The incorporation of a second component (coformer or
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solvate molecule) into a crystallisation can alter the crystal structure, providing a
route to modifying the properties of a solid. In pharmaceuticals, multi-component
crystallisation can be used to enhance solubility, dissolution rate, stability or increase
mechanical properties.92 Figure 1-20 depicts three common multi-component solid-
states.
Figure 1-20: Representations of multi-component crystal systems
Solvates
A solvate is a crystalline solid that incorporates a solvent molecule into a crystal lat-
tice.100 A solvate usually exhibits different physicochemical properties than the original
solid phase. In pharmaceutical development, hydrates (the incorporation of a water
molecule into the crystal structure) are the most important solvate. Water’s relatively
small size and ability to serve as both a hydrogen bond donor and acceptor, make
it likely to be incorporated within the lattice. As such, water can act as a stabilis-
ing force and prevent collapsing of a crystalline structure.93 This factor along with its
non-toxicity makes hydrates attractive targets for incorporating APIs.100
Salts
A salt consists of a crystalline solid that contains two or more components in which
proton transfer is complete.101 Salt formation is widely used with ionisable drugs. More
than half of APIs approved by the FDA are pharmaceutical salts.100 The most common
salt formation is between an acidic and basic molecule, but zwitterionic salts are also
prevalent. In the solid state, the pKa change during the reaction of an acid and a
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base is used as a predictor of salt formation. If the pKa change is three or more, then
the substance formed is predicted to be a salt.101 As with hydrates, forming a salt is
a simple, cost-effective method for improving low solubility and enhancing an API’s
bioavailability.102
Cocrystals
A cocrystal and a salt are relatively similar, however in a salt, a proton is transferred
from the acidic molecule to the base component, whereas in a cocrystal no hydrogen
transfer occurs; the components remain neutral.92 It is generally excepted that there
is a continuum that exists between cocrystals and salts. Cocrystals can be expected
where a pKa change of less than one is observed. However, this leaves some ambiguity in
defining a multi-component system with a ∆pKa between one and three.101 Cocrystal
formation is a viable alternative solid form when salt or polymorph formation does not
meet the required specifications. Cocrystals do not rely on the target molecule being
ionisable and bonding of the two components occurs through intermolecular forces
(hydrogen bonding, π − π interactions and van der Waals) in the crystal lattice. As
such, the number of potential targets with respect to cocrystallisation (such as non-
ionisable APIs) is greatly increased.102
As with single component crystals, solvates, salts and cocrystals are also capable of
displaying polymorphic behaviour. Polymorphs of multi-component crystals can have
significantly different properties. In pharmaceuticals this can influence bioavailability,
stability and dissolution, while in materials science properties such as photolumines-
cence, mechanical strength and colour can be tuned using cocrystallisation.103–105
1.6.5 Thermochromism
Building multi-component crystals offers the potential to tune bulk physicochemical
properties by changing intermolecular interactions within a crystal structure. Ther-
mochromism refers to the phenomenon where a material changes colour in response to
a temperature change. Materials which undergo a colour change in response to temper-
ature have the potential for applications in imaging, sensing and smart devices.106,107
Thermochromism is not exclusive to multi-component crystals nor to small organic
molecules.106,108 However a number of cocrystal systems investigated by Jones et al.
have been shown to afford a thermochromic change upon heating (Figure 1-21).109
Thermochromism in these systems is facilitated by a proton transfer mechanism in
the solid-state. While the isolation of these related crystal systems has been possi-
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ble, reproducible production of the thermochromic cocrystal is difficult in batch.110
This highlights that while cocrystallisation is an effective tool, it can still suffer from
difficulties encountered in single-component crystallisation like reproducibility and elu-
sive polymorphs.111 As such, the finer control that continuous manufacturing offers
could be an effective method for controlling the crystallisation of multi-component
systems.112,113
Figure 1-21: Thermochromism of the cocrystal 4-iodo-2-methylaniline:3,5-
dinitrobenzoic acid.109
1.6.6 Crystallisation Techniques
In order to initiate crystallisation, it is necessary to generate first a supersaturated
system. Figure 1-22 and Figure 1-23 depict common methods for generating supersat-
uration in solution mediated crystallisations. An overview of each method is outlined
below. It is important to note that crystallisation techniques are not mutually exclusive,
it is relatively common to employ more than one crystallisation technique in order exert
greater control or improve the yield of a crystallisation. Examples of combined crys-
tallisation methods include seeded-cooling114 or reactive-antisolvent crystallisation.115
Figure 1-22: Crystallisation techniques: A - evaporative (increasing concentration over
time), B - cooling (decreasing temperature over time).38
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Evaporative Crystallisation
Evaporative crystallisation involves dissolution of the target material into a chosen sol-
vent. The system is initially undersaturated, but as the solvent is left to evaporate over
time, saturation gradually increases. Eventually the solution becomes supersaturated
and nucleation occurs, the concentration will drop slightly and crystals begin to grow.
As the solution continues to evaporate, the solution again becomes supersaturated
and crystallisation proceeds further. This cycle is repeated until the crystallisation is
completed.
Evaporative crystallisation is a fast and effective screening method. It requires a min-
imum amount of material and preparation time, making it a technique of choice for
screening for desirable solid forms. However, it can be difficult to control as vari-
ations in temperature, solvent composition and encrustation results in difficulties in
reproducing results.88 Furthermore, evaporative crystallisation has limited scalability,
as evaporation of large quantities of solvent is both energy intensive and unsustain-
able.86 As such, once a desired crystal form has been identified from an evaporative
crystallisation, the process is often transferred to a more controllable method such as
cooling or antisolvent addition.
Cooling Crystallisation
Cooling crystallisation is an effective method in both batch and continuous crystallisa-
tion platforms. In cooling crystallisation, a solution is prepared where the target ma-
terial is undersaturated at a heightened temperature. The solution is then cooled until
the system becomes supersaturated and nucleation occurs. As the solution is cooled
further, the system becomes increasingly supersaturated and more crystal growth takes
place. Cooling crystallisation offers much greater control over a crystallisation process
than evaporative. For example, a crystallisation can be designed so as to promote crys-
tal growth and prevent encrustation issues by ensuring that the level of supersaturation
remains within the MZW.86 In controlled systems, one can also program a cooling pro-
file to reflect the desired level of supersaturation at each stage of the crystallisation.
As such, cooling crystallisation is often employed in API production where control of
the cooling process allows greater control over particle size, crystal shape and purity.88
Antisolvent Crystallisation
Antisolvent crystallisation induces crystallisation by reducing the solubility of the ma-
terial to trigger nucleation. The method requires identification of a solvent in which
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the substance has a very low solubility (i.e. the antisolvent). Addition of the anti-
solvent (sometimes termed drowning out) changes the solvent composition, reducing
the solubility of the substance and therefore generating supersaturation (Figure 1-23).
As the level of supersaturation is dependent on the solvent composition at a constant
temperature and pressure, one can use antisolvent addition rate to finely control crys-
tal growth. This method makes antisolvent crystallisation processes attractive where a
material’s solubility has a low dependence on temperature.116,117 However, antisolvent
crystallisation is also dependent on mixing and issues can arise with encrustation where
localised supersaturation occurs.45
Figure 1-23: Antisolvent crystallisation: arrow indicates increasing ratio of antisolvent
to solvent composition
Seeding Crystallisation
Seeding crystallisation can be an effective method for controlling a crystallisation pro-
cess. For instance, seeding with a desired polymorph can allow for the selective growth
of the desired crystalline form.114 While some systems do nucleate spontaneously, con-
trolling the nucleation rate, particularly on scale-up, can be subject to unanticipated
process variation.118 The addition of a seeding crystal allows for secondary nucleation
to dominate at lower supersaturation values. Seeding impacts all aspects of a crystalli-
sation process; including crystal morphology, particle size distribution, crystal growth,
nucleation rates and product purity.119 From a phase diagram perspective seeding elim-
inates the need for primary nucleation and so crystal growth can be contained to be
within the metastable zone (Figure 1-24).
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Figure 1-24: Schematic diagram for a seeded-cooling crystallisation, arrow tracking
decreasing concentration of solute in solution as seeding/cooling progresses.
Reactive Crystallisation
Reactive crystallisation is the formation of an insoluble crystalline solid from freely sol-
uble parent molecules.120 Like antisolvent crystallisation, reactive crystallisation does
not rely on temperature dependent solubility. However both antisolvent and reactive
crystallisation are dependent on solution homogeneity. Good mixing is needed to en-
sure crystal growth control. While this can be limiting in batch, both antisolvent and
reactive crystallisation techniques are particularly amenable to flow where they can
benefit from the improved mixing regimes.115 Often the driving force for supersatura-
tion in a reactive crystallisation is a change in pKa. Hence, reactive crystallisation is
usually limited to salt formation or cocrystallisation in organic molecules.121
1.7 Continuous Crystallisation
Crystallisation in fine chemical and pharmaceutical manufacturing is traditionally car-
ried out as a batch operation, but the current drive towards implementing continuous
manufacturing in pharmaceuticals has led to increased interest in developing and ap-
plying continuous crystallisation methods.18 Continuous crystallisation relies on many
of the same crystallisation techniques as batch (cooling, antisolvent, evaporation, seed-
ing etc). However, operation of the feed solution is constant and a slurry is steadily
withdrawn from the reactor (Figure 1-25), this is analogous to flow synthesis, where
reactants are fed into the reactor and product(s) continuously withdrawn.46
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Figure 1-25: Simple set-up for continuous crystallisation
There are two main categories of continuous crystallisers: continuous stirred tank re-
actors (CSTRs) and tubular crystallisers.
1.7.1 Continuous Stirred Tank Reactors (CSTRs)
The continuous stirred tank reactor or mixed suspension mixed product removal (M-
SMPR) is one of the most commonly employed continuous crystallisers. The CSTR
can be run as a single unit of operation or in series of cascading reactors (Figure 1-
26). Generally a single CSTR is used for crystallisation kinetics studies.122 However, as
outlined in Section 1.4.3, a single CSTR tends to have a wide residence time distribution
(RTD) and imperfect mixing. As such crystallisation processes typically use CST-
Rs in tandem, where the outlet of one stage is fed into another. In this way the
system begins to approach plug flow and reduces the batch-to-batch variability of a
process. A multi-stage CSTR system has a number of potential advantages. The
design of each stage is analogous to a batch reactor so implementing a CSTR system
is easier from pre-existing batch equipment. Careful design of the transfer method
for the solid suspensions between vessels ensures the system is effective at handling
high solid loadings. The addition of the feed and withdrawal of the product can be
controlled, allowing adjustment of the residence time. Furthermore, transfer between
vessels can be paused temporarily to extend the crystallisation operating cycle (periodic
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steady state) or operated continuously (steady state).123 Each individual vessel can
be heated or cooled as needed, allowing a step-wise cooling profile to control crystal
growth. Multi-stage CSTRs are relatively versatile, but the systems can suffer from
encrustation, impurity build-up and lower yields (in comparison to batch). Methods
have been devised to reduce these drawbacks, such as recycling the mother liquor,124
in situ process monitoring122 and in-line separation of impurities.125
Figure 1-26: Schematic diagram for a series of CSTRs, where n = the number of CSTR
operations
The potential benefits for using an CSTR are demonstrated by Agnew et al. Here
researchers demonstrated the scaling-up of batch production of paracetamol (PCM)
form II in a CSTR system. Form II is the metastable polymorph but displays enhanced
physical and mechanical properties compared to PCM form I. A structurally similar
molecule (metacetamol) was used as an additive in solution to preferentially crystallise
PCM form II. In both batch and continuous operation, high purity of the desired form II
polymorph was achieved. However continuous crystallisation in CSTRs showed superior
purity compared to batch, as no traces of PCM form I or metacetamol impurities
were found in the final product.126 The authors highlight the ease in which the batch
process could be transferred to the CSTR system, as well as indicating the improved
reproducibility exhibited by the continuous process.
1.7.2 Tubular Crystallisers
The other common reactor design for continuous crystallisation is the tubular crys-
talliser. In this system the feedstock is pumped through a tube where crystallisation is
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controlled by increasing supersaturation. The crystalline product is continuously with-
drawn from the reactor outlet. In theory, a cascade consisting of an infinite number
of CSTR crystallisers is equivalent to a plug flow tubular reactor, but the amount of
equipment required to reach this stage is practically unfeasible.46 Therefore plug flow
is generally far simpler to achieve and more cost-effective in a tubular reactor. Figure
1-27 outlines some common methods for achieving plug flow in tubular crystallisers.
Figure 1-27: Schematic diagram depicting methods for achieving plug flow in tubular
crystallisers via: a) high velocity flow, b) segmented flow or c) using an oscillatory
baffled reactor
The simplest method to achieve the desired plug flow dynamic is to pump the feedstock
at high velocity. As determined from Equation 1.2, generating a Reynolds number
around 4000 results in a turbulent system and plug flow. However in this case, the
required velocity is so high that an unfeasibly long tube is required, thus a high velocity
system is usually only ever useful for very fast crystallisation processes. To overcome
this drawback, a secondary mechanism is usually employed to achieve plug flow. One
possibility is the introduction of a series of static mixers. Static mixers promote the
mixing of fluids without using moving parts (Figure 1-28).127 The introduction of static
mixers has been demonstrated to enhance the mixing between feedlines, help suspend
particles in solution and to narrow the particle size distribution.53,128
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Figure 1-28: Photograph of a KenicsTM KM static mixer where helical structures direct
the flow of material129
Another method is to introduce an immiscible phase to segment the feedstock into dis-
crete slugs. The introduction of a secondary phase ensures no back-mixing can occur,
thereby achieving plug flow. The secondary phase can be an immiscible liquid or a gas.
The benefit of this design is that plug flow can be achieved while maintaining slow,
laminar pump regimes. As such, the residence time distribution in segmented flow
tends to be narrow.130 Furthermore, the introduction of a secondary phase can also
improve the mixing within each slug. The slugs circulate within the tubing, forming
eddies which ensures a homogeneous environment.131 The size and number of slugs can
be controlled by the frequency of the immiscible phase. The downside to this technique
is that separation of the phases is often required for collection of the crystalline prod-
uct. In most cases this can be relatively straightforward, but surface interactions can
sometimes lead to the two liquids forming an emulsion. Therefore, careful selection of
the immiscible phase is necessary. Some of the work in this thesis will be concerned
with the development and optimisation of the kinetically regulated automated input
crystalliser (KRAIC) which is categorised as a segmented flow crystalliser. Further
detail on the KRAIC design will be supplied in Chapter 2.
A continuous oscillatory baffled crystalliser (COBC) consists of a series of tubes with
baffles periodically arranged inside. A piston or bellow is used in combination with
pumps to generate a pulsating flow regime. As the flow moves through the tube the
baffles restrict the movement of the fluid. This leads to the generation of eddies within
each baffled segment, which provides turbulent mixing (Figure 1-29). As the mixing
regime is dissociated from the net flow rate and each baffled segment is homogeneous,
the system is essentially running at plug flow without the need for a high velocity
flow rate or the introduction of a immiscible phase.44 Additional advantages have been
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described, including good suspension of solids and slurries, enhanced heat and mass
transfer capabilities and easier scale-up. Limitations of the technology in crystallisation
has been encrustation issues, fluid viscosity and particle density limits as well solid
loading limit.37
Figure 1-29: Generation of eddies in a COBC system37
Several examples exist of successful API crystallisation in a COBC system includ-
ing; paracetamol (additive-cooling crystallisation),126β-l-glutamic acid (seeded-cooling
crystallisation),132 α-lipoic acid:nicotinamide (cocrystallisation) and salicylic acid (an-
tisolvent crystallisation).133 Of particular note, Brown et al. demonstrated the contin-
uous operation and production of salicylic acid (commonly used in aspirin) for more
than 100 residence times. During the work, operation under steady state conditions
produced over 800 g in 6 hours (a productivity of 3.2 kg day-1) with a narrow particle
size range 35.1± 3.2 µm.133
The attraction of operating under plug flow in a COBC or similar plug flow system,
is that under controlled steady state conditions, each particle in theory experiences
an identical environment during operation. This leads to a uniform and consistent
product. In addition, unlike a CSTR, tubular reactors do not have impellers, which
can cause particle breakage and uncontrolled secondary nucleation events. While it
is important to note that the current research scale crystallisers cannot compete with
established batch mass production methods, the potential to deliver consistent parti-
cle size, scalable processes and other critical attributes over an extended period could
prove attractive for delivering high value-low production chemicals. As these prac-
tices become more established, this may eventually lead to the adoption of continuous
crystallisers across a wider field of the fine chemical and pharmaceutical industry.
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1.8 Integration
One of the largest challenges facing continuous manufacturing (CM) is integration of
processing technologies. While great strides have been taken in the areas of flow synthe-
sis and continuous crystallisation, the amount of research dedicated towards integrating
these operations is relatively sparse. When considering the potential benefits of CM
it is important to consider the holistic viewpoint. Complex small molecule production
requires multiple stages of operation. For instance, API processes will likely require
several stages including synthesis, crystallisation, filtration and formulation of the drug
(Figure 1-30). If a process is only partly converted to continuous operation, then inad-
vertently, the batch steps could become a process bottleneck. In these cases, this can
add unnecessary complications to a system such as holding times, material transporta-
tion, chemical storage and safety issues. Ideally an integrated (end-to-end) approach
to CM will provide more benefits than a partially continuous (multi-stage) approach.
However, it is not always possible or indeed necessary to pursue an end-to-end CM
process. Ideally, the mode of operation should suit the chemistry and a continuous
multi-stage or semi-batch approach may be the most viable.
Figure 1-30: Typical workflow for API production134
Nonetheless, an integrated or partially-integrated process offers some key advantages
including increasing production speed, greater cost effectiveness, minimising environ-
mental impact, simplifying product supply chain, reducing materials inventory, in situ
processing of unstable intermediates, reduction in plant space requirements as well as
easier scale-up.27
1.8.1 Multi-step and Telescoped Processing
Multi-step processing or telescoped processes involve two or more continuous chemical
transformations that are carried out within the same unit of operation (i.e. multiple
synthetic steps in flow) or, where the output of one stage of operation is fed into
another continuously (e.g. flow synthesis followed by continuous crystallisation). In
both cases, the set-up can be considered a partially integrated mode of operation, but
not end-to-end continuous manufacturing.
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There are plenty of examples of telescoped reactions where two or more synthetic re-
actions are carried out in tandem, sometimes eliminating the need for intermediate
work-up or purification.135–137 However, most processes require a purification step at
some stage, which is often carried out in batch. In order to deliver integrated sys-
tems, the replacement of batch processes with continuous downstream technologies is
necessary for multi-stage and end-to-end continuous manufacturing.
There are examples of multi-step reactions which use in-line crystallisation or purifi-
cation techniques, but the sector is relatively underdeveloped compared to telescoped
flow synthesis. In-line work-up methods that have been used include liquid-liquid ex-
traction,138,139 scavenger columns,21,140 column chromatography,141,142 distillation143
and crystallisation.144 As a recent example, Loren et al. showed the synthesis and in-
line crystallisation of diphenhydramine (DPH).145 DPH is an antihistamine commonly
found in several medicinal products. In this work, researchers developed a novel, minia-
turised pharmaceutical purification platform (MiniPharm), which was integrated with
a microreactor and on-line monitoring system (Figure 1-31).
Figure 1-31: Simplified diagram of the flow synthesis and segmented flow crystallisation
of diphenhydramine
In this set-up, DPH was prepared from chlorodiphenylmethane (1) and dimethylamino-
ethanol (2). A chip reactor was used to rapidly mix the streams, and a back pressure
regulator (BPR) was used to maintain high pressure while operating above the solvent’s
boiling point. On-line monitoring and optimisation of the reaction was carried out
using mass spectrometry methods. The introduction of a segmented flow crystallisation
process reduced fouling issues encountered in the system, ensuring that 128 mg h−1 of
DPH could be processed without issues.145 While this work provides a good example
of integrating synthesis, crystallisation and on-line monitoring, the system is limited to
the microfluidic scale. In order to process high solid loadings or large crystal sizes, it
will be necessary for the integration of macro or meso-scale crystallisers into multi-step
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processes. Without the development of versatile, continuous work up and purification
technologies that can handle a range of solid-state parameters, the delivery of integrated
flow in the fine chemicals industry will remain challenging.146
1.8.2 End-to-End Integration
End-to-end integration of continuous manufacturing (CM) is the idea of delivering a
final product from raw materials without isolation or downtime. While end-to-end
manufacturing maximises the benefits of integrating units of operation, examples of
end-to-end manufacturing in pharmaceuticals and fine chemicals are relatively few.
End-to-end CM faces many challenges including complex control and feedback loops
for product quality control, in-line reaction monitoring, solid and slurry handling, ac-
cumulative dilution problems in multi-step processes and bridging gaps in units of
operation.25
An interesting example of bridging operational technologies was developed by Balogh
et al. In this work continuous production of a drug was developed by coupling flow syn-
thesis with formulation, via electrospinning (ES) (Figure 1-32).147 The work describes
a bench-top scale coupling of flow synthesis and drug formulation targeting acetylsali-
cylic acid as a model drug compound. In the work, ES is the key enabling technology
to turn the API-polymer solution into a fibrous solid product which was applied to a
water-soluble film. The work represents one of the few examples to incorporate formu-
lation in an integrated process and while the authors demonstrate formulation directly
after synthesis of the API-polymer solution, it is entirely possible that the ES unit
could also be applied after a purification step in a more complex workflow.
Figure 1-32: Schematic diagram of the end-to-end production of acetylsalicylic acid
fibres in flow (adapted from Balogh et al.)147
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Perhaps the biggest breakthrough in delivering pharmaceuticals end-to-end was car-
ried out by Mascia et al. Here researchers delivered a continuous integrated process
for the delivery of the API, aliskiren hemifumarate (AH). The chemical transformation
proceeds through 14 operation units including; two synthetic reactions, two crystalli-
sations, four separations, two washes and dilutions followed by an extrusion and mould
process. The result is a platform capable of producing AH from a stable precursor
through to formulation of the tablet in an unbroken, continuous process (Figure 1-33).
The total end-to-end residence time was 47 hours, which was more than six times faster
than the batch process. The process throughput was 41 g h−1 which corresponds to over
8500 tablets a day. Notably, researchers reported several advantages to running the
process end-to-end. For instance, the synthesis was shown to be much faster in flow
(3-4 hours vs 72 hours in batch). The reaction in batch usually needs to be cooled
before separation (due to reactor conditions being above the solvents boiling point)
however, in flow the separation can be carried out in-line at high pressure without is-
sue. Furthermore, the CSTR crystallisers acted as buffer units, as their long residence
times mean fluctuations in the upstream concentration can be mitigated and adjusted
for without interrupting the process. Finally, the melt extruder unit streamlined the
process, avoiding the need for milling, blending or granulation of the drug product.
The melt can be directly fed into the tablet moulding process. This significantly de-
creased the energy footprint and time required to go from drug substance to the final
tablet.27,38,144,148
Figure 1-33: Structure of the precursor (top) and tabulated product: aliskiren hemifu-
marate (bottom) in the integrated, continuous plant.
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Following on from this pioneering work, a continuous manufacturing platform that com-
bines both synthesis and final drug product formulation into a single, highly compact
unit was developed (Figure 1-34). The modular system uses a series of reconfigurable
tubular reactors, membrane separators, gravity separators, filtration units and CSTR
crystallisers.26,149 The platform has demonstrated continuous synthesis and crystalli-
sation of several drug compounds, including rufinamide, diphenhydramine, fluoxetine,
lidocaine and diazepam.
Figure 1-34: Photographs of the reconfigurable compact plant by Adamo et al. for
continuous production and formulation of APIs149
Finally, the first continuous process that delivers a drug product meeting good manufac-
turing practice (GMP) was developed by Eli Lilly for the synthesis of prexasertib. The
plant, consisting of eight continuous operations, resulted in the production of 3 kg day-1
of material for clinical trials. However, the process had to be separated into three-stages
due to size restraints, while the final crystallisation, filtration, and drying stages were
conducted in batch systems.11 As the authors note, because of time constraints, the
development of a continuous downstream process was not implemented. This reflects
the need for greater understanding and development of robust continuous crystallisa-
tion and other downstream processes that can be integrated with upstream systems
routinely.150,151 Despite this, the work does demonstrate how integrated process devel-







For specific experimental procedures, see the individual chapters. This chapter details
the general experimental and analytical methods commonly utilised throughout the
study.
2.2 Materials
Starting materials and solvents were sourced from commercial suppliers Sigma-Ald-
rich R© and VWR International with no further purification.
The carrier fluid used in segmented flow crystallisation experiments was a fluorinated
perfluoropolyether (PFPE), commercially known as Galden SV110, which was sourced
from Solvay.
In Chapter 4, the manganese dioxide catalyst and the starting material pyrazinecar-
bonitrile were provided by the Steven Ley group, University of Cambridge.
In Chapter 6 all raw materials were supplied by AstraZeneca for the duration of the
project. The reference succinate salt of the target active pharmaceutical ingredient
(API) was sourced from the current commercial process after isolation.
2.3 Gravimetric Solubility
Gravimetric solubility studies were carried using the Cambridge Reactor Design (CRD)
Polar Bear Plus reactor. The Polar Bear Plus is a platform for programmable heating
and cooling cycles over a temperature range of −40 to 150 ◦C. It has interchangeable
inserts that allow scaling up of systems from 1.5 to 250 mL (Figure 2-1). Solubility
measurements were carried out in 20 mL, screw cap glass vials. A known volume of
solvent was decanted into each vial and heated or cooled to the desired temperature.
The vials were stirred continuously at a controlled stirring rate of 500 rpm. Excess solid
matter was added until a persistent slurry was achieved. The slurry was left for at least
4 hours to equilibrate before filtering using a disposable syringe into a pre-weighed vial.
The vial was sealed and weighed before being allowed to evaporate and dry in an oven
at 50 ◦C overnight. The change in the mass of solution vs the dry solute allowed the
concentration to be determined. Using this data, a solubility vs temperature graph was
constructed to give a solubility curve. Each run was repeated in triplicate. The same
procedure was used to determine the solubility of 4-hydroxyacetophenone (4HAP) and
4-hydroxyacetophenone oxime (4HAPO) in ethanol/water mixtures at 20 ◦C.
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Figure 2-1: Photographs of a) the Polar Bear Plus reactor b) the interchangeable inserts
2.4 Synthesis
2.4.1 One-pot Amidation of 4-Hydroxyacetophenone
The batch method in the direct amidation of 4HAP for production of paracetamol
(PCM) was based on the work by Rancan et al.152
Stoichiometric amounts of 4HAP and hydroxylamine hydrochloride (HOA) were weighed
out and transferred to a vial in a 1:3 ratio. A stirrer bar and 5 mL of solvent were added
to each vial. The vial was then placed on a hotplate and stirred vigorously at 90 ◦C for
one hour. The solvent was then reduced on a rotary evaporator. The resulting solid
was then taken for sample analysis.
In later experiments, the screw cap vial was replaced with a biotage reaction vial and
sealable cap. To each vial, stoichiometric amounts of 4HAP and HOA were added with
5 mL of solvent. In these experiments, the vials were heated to 120 ◦C for one hour in
a sand-bath with constant stirring. The samples were allowed to cool before analysis.
2.4.2 Preparation of 4-Hydroxyacetophenone Oxime
4-hydroxyacetophenone oxime (4HAPO) was prepared using a combination of the batch
methodologies outlined by Tokmadzhyan et al. and Quartarone et al.153,154
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A glass three-necked round bottom flask of 250 mL volume was placed in a oil bath
with a reflux condenser attached (Figure 2-2). To a mixture of water and ethanol,
stoichiometric amounts of 4HAP and sodium acetate (NaAc) were added. The system
was heated to 90 ◦C before adding HOA. Regular samples were taken and diluted with
deuterated DMSO before analysis by nuclear magnetic resonance (NMR). Once the
reaction had reached completion, rotary evaporation was used to remove excess solvent
to leave a crude solid. The solid was washed with a saturated aqueous solution of NaCl
and NaHCO3 at 0
◦C. The solid was recrystallised using diethyl ether and hexane to
leave a pure white solid.
Figure 2-2: Diagram depicting the configuration in batch synthetic experiments for
4HAPO production
2.4.3 Beckmann Rearrangement of 4-Hydroxyacetophenone Oxime
Batch methodologies were investigated for the the Beckmann rearrangement of 4HAPO
to PCM using trifluoroacetic acid (TFA). The procedure used was developed by Quar-
tarone et al.154
The apparatus set-up is the same as outlined in Figure 2-2. To a 250 mL glass round
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bottom flask under nitrogen gas, 9.8 mL of acetonitrile (ACN) and 1.0 mL (13 mmol)
of TFA was added. The solution was stirred at 250 rpm and heated to 70 ◦C. Stoichio-
metric amounts of 4HAPO (1.3 mmol, 0.2 g) was added to the solution and the reaction
was allowed to proceed for 1 hour. Regular 0.1 mL samples were removed and diluted
with 0.3 mL of DMSO-d6 for reaction monitoring using NMR. The resulting solution
was rotary evaporated to remove excess solvent to leave a crude brown oil. The viscous
oil was diluted with diethyl ether and washed with water at 0 ◦C. The final product
was recrystallised from the diethyl ether layer using hexane. The off-white solid was
then separated from the solution using filtration and allowed to dry overnight before
analysis.
2.5 Flow Synthesis
Flow synthesis experiments were carried out using the commercially available Vapourtec
R-series Flow Unit (Figure 2-3).
Figure 2-3: Photograph of the Vapourtec R-Series
The system is a reconfigurable, modular device that allows for a range of flow chemistry
reactions to be carried out. The system consists of an R2+ pumping module which is
equipped with two high performance liquid chromatography (HPLC) pumps. Each
HPLC pump has a chamber volume of 10 mL, with accurate flow rate range of 0.01 to
10 mL min−1. A built-in manifold controls the pressure. The pumps are primed manu-
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ally using a syringe to remove any air bubbles in the pump chamber before pumping at
the set flow rate. The second module is the R4 heater unit. The R4 unit consists of four
independent heated zones which allow for variable temperature control. Depending on
the exact experimental set-up, a reactor coil or column is plugged into a heating zone
and the temperature is monitored via a temperature probe. Each modular unit can
be controlled via the in-built controls, but the system can also be connected to and
controlled via a laptop, using the Flow CommanderTM software.
Specific reactor set-ups will be illustrated and discussed in the relevant Chapters 3 and
4 of this thesis. The range of reactors used throughout this work is however, outlined
below:
• A perfluoroalkoxy alkane (PFA) tubular coil reactor of volume 10, 12 or 27 mL
(1 mm inner diameter (ID))
• A static mixer coil with a volume of 20 mL (3.2 mm ID)
• A static mixer coil with a volume of 65 mL (5.6 mm ID)
• An adjustable omnifit packed bed column (100 mm length, 6.6 mm ID) of variable
volume (0.1 to 2.4 mL)
All reactor equipment is commercially available from Vapourtec Ltd.
2.5.1 Steady State Measurements
For steady state measurements, a calibration curve was constructed using Eosin Y dye
in ethanol (EtOH) at various concentrations (Appendix Figure 9-1 ). The extinction
coefficient of the dye in EtOH at 478 nm was determined using the Beer-Lambert law
(Equation 2.1):
A = εcl (2.1)
Where A is absorbance, ε is the molar extinction coefficient, c is the concentration
and l is the optical path length. A plot of absorbance vs concentration was used to
determine the molar extinction coefficient of the dye in EtOH.
Steady state measurements were carried out on the flow process by pumping a stock
solution of the dye through the reactor and sampling the effluent at periodic intervals.
Measuring the absorbance of the dye in solution using offline UV/Vis spectroscopy on
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a Jenway 6305 spectrometer allowed the concentration change to be plotted against
time. The time taken to reach steady state was then be determined from the graph.
2.6 Crystallisation
2.6.1 Evaporative Crystallisation
Evaporative crystallisation was employed in the pursuit of multi-component molecular
complexes. The work was carried out in order to replicate the thermochromic cocrystal
complexes developed by Jones et al.155 In each case, stoichiometric molar quantities
of the target components were weighed into a clean 7 mL glass vial (approximately
10 - 50 mg). The solids were dissolved using the minimum amount of solvent to form
a saturated solution (1 - 5 mL). In some cases, it was necessary to gently heat the
solutions or use a sonicator bath to ensure complete dissolution. Once dissolved, the
vials were sealed with a plastic lid. The lid was then punctured five times to allow the
solvent to evaporate. Sample solutions were then left to evaporate free from agitation
either at room temperature or at fixed temperatures of -4, 30 or 40 ◦C.
2.6.2 Antisolvent Crystallisation
Antisolvents were identified by screening the solubility of the target materials in a
number of different solvents. Candidates where no visible or only partial dissolution
occurred were identified as potential antisolvents. The choice of antisolvent was then
limited to those that were miscible with the saturated solution of the coformers.
The antisolvent crystallisation was scaled up to 20 mL vials and temperature was con-
trolled using the Polar Bear Plus reactor. In these studies, stoichiometric amounts
of the starting materials (around 50 mg) were added to the chosen solvent with gen-
tle stirring. Samples were transferred to the Polar Bear Plus stage and held at the
desired temperature for at least 1 hour to ensure complete dissolution. The antisol-
vent was prepared as a stock solution in a separate 20 mL vial and subjected to the
same conditions. A known volume of antisolvent was then transferred quickly using
an Eppendorf pipette, from the antisolvent stock to the saturated solution to induce
nucleation. Crystallisation was then monitored over the next hour. The solid was sep-
arated using gravity-assisted or vacuum filtration. In later attempts to understand the
role of solvent on stability and thermochromic behaviour for multi-component com-
plexes containing halo-anilines, the samples were left undisturbed in the vials at room
temperature until the solvent/antisolvent had fully evaporated.
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2.7 Continuous Crystallisation
2.7.1 Kinetically Regulated Automated Input Crystalliser (KRAIC)
2.7.2 Theory
The kinetically regulated automated input crystalliser (KRAIC) is a modular flow crys-
tallisation platform (Figure 2-4) designed by Dr. Karen Robertson at the University
of Bath. It is an open tubular crystalliser that uses segmentation to achieve a plug
flow without the need for high velocity flow rates. Feed solution, a carrier fluid and air
are pumped independently into a mixer piece resulting in a tri-segmented flow regime
which is then propelled through three coils, each of which can be independently heated
or cooled before a filtration step (Figure 2-5).131 The residence time is controlled by
adjusting the pump velocity or by changing the reactor length. The main body of the
KRAIC consists of a 15 metre length of fluorinated ethylene propylene (FEP) tubing
(3.2 mm inner diameter) through which the segmented flow will proceed. Segmenta-
tion and mixing can be controlled by adjusting the independent flow rates of the air,
feedstock or carrier fluid. As the KRAIC is a modular unit, additional mixer pieces,
tubing lengths and feed inlets can be added. In this thesis, several variations on the
design of the KRAIC will be outlined and the merits discussed.
Figure 2-4: Photograph of the KRAIC crystalliser housing unit
The main driver for crystallisation in the KRAIC is cooling, however other configura-
tions are possible. The carrier fluid is liquid fluorinated PFPE, known commercially
as Galden SV110. The Galden and FEP are both hydrophobic in nature and thus, the
carrier fluid preferentially wets the surface of the tubing over the solution phase. This
isolates the segmented solution from the walls of the tubing, ensuring that nucleation
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Figure 2-5: Schematic representation of the KRAIC configuration
in the KRAIC is generally driven by primary homogeneous crystallisation. The air
provides an effective barrier between the solution slugs and helps to prevent unwanted
back-mixing or coalescence of individual slugs, thereby ensuring the desired plug flow.
Furthermore, air can be used to adjust slug size, the smaller the slugs, the more in-
tense the mixing regime due to the generation of eddies. This helps to ensure the slugs
remain homogeneous and promotes controlled crystal growth. In order to separate the
carrier fluid from the solution phase before filtration, an end-piece is employed (Figure
2-6) .
Figure 2-6: Diagram of tri-segmentation and carrier fluid recovery in the KRAIC during
a cooling crystallisation
The end-piece is a small piece of FEP tubing that consists of an inlet (for a neutral
solvent), followed by several small pores and an wider bore outlet. The neutral solvent
is a miscible solvent which does not alter the solubility of the solution; it is used to
increase the velocity of the net flow, reducing the chances of fouling around the outlet
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by reducing contact time of the crystals with the reactor walls. The small pores in
the end-piece allow separation of the carrier fluid. Galden easily passes through the
pores as it displays a low contact angle and surface tension with the FEP tubing. In
this way, the carrier fluid can be recovered and recycled, while the more hydrophobic
properties displayed by the solution phase will pass over the pores without falling
through. However, there is loss in flow velocity with the absence of the Galden as well
as a change in the diameter of the end-piece as it reaches the outlet, this is made up
for by the additional velocity of the neutral solvent phase. Crystals are then separated
from the effluent by standard vacuum filtration in most cases.
2.7.3 Experimental
For specific reactor designs and experimental set-ups for the KRAIC and related seg-
mented flow crystallisers, please refer to Chapters 3, 4 and 5. Here, a generic outline
will be given for setting up a standard KRAIC crystallisation experiment.
A saturated solution of the target system is prepared to the desired concentration
and volume. In a cooling crystallisation, the solution is heated and stirred until fully
dissolved using Asynt hot plates equipped with an Asynt DrySyn basin and temperature
probe. Carrier fluid, air and pure solvent are pumped through a 15 metre coiled tubing
of FEP with inner diameter (ID) of 3.2 mm to prime the system. Flow rates of the
carrier fluid, air and solution are adjusted to provide uniform slugs. The system is
allowed to equilibrate for at least 1 to 3 residence times before swapping to the solution
feed. The crystalline product is collected at the end of the tubular reactor and extracted
using Büchner filtration. The filtered samples were allowed to dry before weighing the
product and conducting analysis.
2.8 Single Crystal X-ray Diffraction (SCXRD)
2.8.1 Theory
To determine a crystal structure it is necessary to probe the positions of individual
atoms within the crystal’s molecular framework. In order to do this an incident beam
of light is needed to “see” the structure of molecules. Visible light has too long a
wavelength to probe these small distances, so a wavelength close to typical atomic
distances is required. X-rays posses a wavelength in the nanometre range (0.01 to
10 nm), which lies close to the typical atomic spacing in a crystal structure.156 As X-
rays pass through a sample, interactions with the atoms will cause a scattering of the
transmitted light. The strength of scattering is dependent on the number of electrons in
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the atom and can thus be used to identify the atom type. Furthermore, the scattering
of the light can be recorded and the resultant pattern can be recombined to determine
the crystal structure.
While a single molecule is unlikely to give a strong scattering pattern, a perfect crys-
talline solid material is made up of a large number of identical molecules which are
arranged in a precise pattern. The pattern is repeated in all directions, to give a highly
ordered structure. This regular arrangement of many atoms or molecules not only en-
hances the scattering, but gives the scattering in turn a regularity that can be used in
structural analysis. Each molecule can be represented as a single point, the result is
a regular array of dots. This two-dimensional repeating unit of molecules is known as
the the crystal lattice. Lattice points that are extended into three dimensions form a
unit cell. The unit cell is defined as the smallest repeating volume of lattice points that
are representative of the crystal structure. There are four types of unit cells depending
on the positioning of the lattice points (Figure 2-7).
Figure 2-7: The four types of unit cell derived from lattice points
Based on the reflection and rotation symmetry elements present in the unit cell, con-
straints on the geometry of the unit cell gives rise to seven possible crystal systems
summarised in Table 2.1. The combination of the seven crystal systems and four unit
cells gives rise to the fourteen Bravais lattices. Furthermore, a crystal has symme-
try elements that are regularly arranged in space and relate to the inherent lattice
symmetry within its unit cell. The combination of all allowed symmetry translations
distributed across the Bravais lattices gives raise to 230 possible arrangements. These
arrangements, known as the 230 space groups, define all the ways a crystal structure
can be arranged according to their symmetry.156
Having defined the regular, long range order present in a crystal structure, it is possible
to predict when X-rays will interact with molecules in such a way as to provide a
detectable scattering of light. Unless the radiation scattered by the lattice points are
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Table 2.1: Table of the seven crystal systems and their symmetry restrictions
Crystal System Unit Cell Restrictions Lattice Types
Triclinic None P, I ,F
Monoclinic α = γ = 90◦ P
Orthorhombic α = β = γ = 90◦ P
Tetragonal a = b; α = γ = 90◦ P, I
Rhombohedral a = b = c; α = β = γ 6= 90◦ P, I, F, C
Hexagonal a = b; α = β = 90◦; γ = 120◦ P, C
Cubic a = b = c; α = β = γ = 90◦ P
Where a, b and c are the unit cell axis and their associated angles α, β and γ
all in the same phase, then destructive interference will lead to zero intensity overall
and no detectable diffraction. Bragg et al. described how constructive interference
can be modelled from a set of parallel lattice planes (where a plane consists of a series
of regular lattice points). Each set of parallel planes is represented by a set of Miller
indices (denoted using the integers h, k, l). As shown in Figure 2-8, Bragg indicated
that constructive interference between waves requires the X-ray beam and scattered
radiation to have an angle of incidence and angle of reflection that is equal to each
other. In this way, the lattice plane acts like mirror and the diffracted beam is reflected
off the surface. Rays reflected from adjacent planes will interfere constructively when
Bragg’s law is satisfied. Bragg’s law is defined in Equation 2.2, where d represents the
spacing between lattice planes, λ is the wavelength, n is an integer and θ is the angle
of incidence.
Figure 2-8: The Bragg model depicting the diffraction of X-rays by sets of parallel
lattice planes
Path difference = 2dsinθ = nλ (2.2)
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The Bragg equation forms the basis for all methods of obtaining the lattice geometry
from the diffraction pattern. A single crystal will give a discrete set of diffraction
patterns based on the orientation of the crystal in reference to the incident X-ray.
However, Bragg’s law describes only the necessary geometric constraints required to
observe diffraction, it cannot predict the intensity of the reflection. The intensity
of diffraction relates to the scattering of the incident ray by the atoms present and
therefore contains all the information on the spatial positions of the molecules within
the structure. In order to determine the intensity of the reflection, experimental data is
required. The variation in intensities within an X-ray diffraction pattern is an indication
of the distribution of electron density. The intensity of the scattering by the electrons
around an atom is known as the the atomic scattering factor (fj), which is proportional
to an atom’s atomic number at low Bragg angles.
An X-ray diffraction experiment measures the intensity of a series of reflections at
different positions. Each reflection corresponds to diffraction from a set of lattice planes.
Rearrangement of Bragg’s law shows that there is an inversely proportional relationship
between sin θ and d-spacing (Equation 2.3). A diffraction pattern is constructed in units
of 1d . The diffraction pattern describes the reciprocal lattice, which is inversely related
to the direct lattice. The distance of each individual spot from the central point in the







The structure factor (Fhkl) describes the dependence of the intensity for each reflection
on the crystal structure. It consists of the sum of the individual atomic scattering




fjexp2πi(hxj + kyj + lzj) (2.4)
Where fj is the atomic scattering factor of the j
th atom and x,y,z are the direct coor-
dinates of the jth atom in the lattice. Each set of reflections with indices h, k and l,
are represented by a specific structure factor. Fourier transformation of the sum of the








Fhklexp[−2πi(hx+ ky + lz)] (2.5)
Where ρxyz is the electron density in position x, y, z and V is the volume of the
unit cell. Experimentally the observed structure factor magnitudes are obtained, but
the phase information is lost.157 In order to solve the structure, the phases must be
determined; for small organic molecules, the direct method is the norm. This process
relies on using an approximation to determine the phases of the structure factor through
statistical relationships between reflections. Successful use of the direct method yields
the location of most non-hydrogen atoms in the structure.
Refinement is carried out using the least squares method. This procedure relies on
approximating some of the atomic identities and positions within the crystal structure.
From this, a series of calculated structure factors (Fobs) can be obtained which can
be compared with the experimental structure factors (Fcalc). A least squares process
then cycles the atomic positions and vibrations to minimise the difference between
observed and calculated structure factors. An R factor is then calculated to measure the
agreement between the calculated and observed structure factors (Equation 2.6). The
R factor value should decrease throughout the refinement process. A good refinement
is typically indicated by an R factor of less than 5 %.
R =




Single crystal X-ray diffraction (SCXRD) experiments were carried out using the Rigaku
Oxford Diffraction Supernova diffractometer. The Supernova platform is able to op-
erate with either a Mo-Kα and Cu-Kα radiation. All single crystals were first coated
in fomblin (a non-diffracting fluid) before being mounted onto the looped filament
attached to the goniometer. The mounted crystal was then subjected to X-ray diffrac-
tion experiments using the monochromatic Cu-Kα radiation source at 150 K where the
temperature was controlled using Oxford Diffraction Cryostream 700 series.
Data collection and processing were carried out using the CrysAlisPro 171.37.33 soft-
ware. Diffraction data was refined with the help of Dr. Lauren Hatcher using SHELX-
213 software by applying direct methods in the WinGX interface and applying the least
square refinement method in SHELXL, before visualising the structure in the Mercury
software.
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2.9 Powder X-ray Diffraction (PXRD)
2.9.1 Theory
Powder X-ray diffraction (PXRD) is used in the determination of the crystal struc-
ture for a bulk, crystalline material. The technique has a variety of uses including
determining polymorphic forms, confirming cocrystal or salt formation and identifying
impurities in a material.156 In a powder sample, multiple crystals with different orien-
tations will be present. A beam of X-rays is fired at a powdered sample, some of the
randomly orientated crystals will be in the correct position to give raise to a diffraction
pattern. This will result in diffraction from multiple crystals and lattice planes. These
collections of diffraction spots become superimposed on one another, forming a cone of
diffraction (Figure 2-9). Each set of planes will give off its own cone of radiation.
Figure 2-9: Cones of diffracted X-rays produced from a crystalline powder sample
If a detector is placed perpendicular to the X-ray beam, these cones will appear as
a series of complete rings. The sample is rotated in relation to the X-ray source to
collect a complete data set. The PXRD pattern is produced by plotting the integrated
intensity of the rings against the 2θ angle.158 PXRD patterns are characteristic of the
crystal and notably the 2d positions of the PXRD peaks reflect the underlying unit cell.
PXRD can therefore act as fingerprinting technique for identification of the molecule.
Furthermore, a simulated powder pattern can be constructed from SCXRD data. The
simulated PXRD pattern can be an effective method for confirming polymorphic form
or identifying the bulk material.
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2.9.2 Experimental
Bruker D8 Advance Diffractometer
PXRD data was collected using a Bruker D8 Advance diffractometer equipped with
a monochromatic Cu-Kα radiation (λ = 1.540 56 Å) source. Unless otherwise stated,
crystalline samples were ground to a powder using a mortar and pestle before PXRD
collection. The sample was mounted onto a glass slide and attached to a zero back-
ground sample holder using a non-diffracting adhesive plasticine. Samples were sub-
jected to X-rays at room temperature (298 K) during analysis. Collection was carried
out from 5 to 40◦ 2θ angles. Rotation of the sample holder was necessary to remove
preferred orientation effects.
STADI P Diffractometer
Later analytical measurements were taken using a STOE STADI P diffractometer in
transmission mode, equipped with a Cu-Kα radiation (λ = 1.540 56 Å) source. Powder
samples were placed between two non-diffractive transparent films and mounted onto
the equipment via sample holder discs. The samples were subjected to X-rays at room
temperature and collection was carried out between 2◦ and 75◦ 2θ angles. The samples
were rotated throughout the measurements.
In both cases, comparisons were drawn between experimental data and simulated pow-
der patterns produced from single crystal X-ray diffraction data in literature; this
allowed determination of the polymorphic forms present.
2.10 Differential Scanning Calorimetry (DSC)
2.10.1 Theory
Differential scanning calorimetry (DSC) is a thermal analysis technique that allows the
measurement of phase changes or solid-state transitions. The technique compares the
heat flow of a sealed pan containing a sample with that of a reference pan (usually
an empty, sealed pan). As the two pans are heated or cooled during a programmed
temperature cycle, there should be no noticeable difference in the amount of heat flow
required to maintain the same temperature in both pans until a thermal event occurs
in the sample. As a phase change or transition occurs, a reduction or increase in heat
flow will be required depending on the change. For instance, melting is an endothermic
process and so the sample absorbs heat. In order for the temperature to remain the
same, more heat flow will need to be supplied to the sample pan in comparison to
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the reference pan. This data is recorded against temperature in a DSC trace and any
exothermic or endothermic events can be detected (Figure 2-10).159 The technique is
useful as thermal events such as the melting point, glass and polymorphic transitions
can be detected in the trace and used for identification or characterisation of a material.
The techniques can also be effective for screening potential cocrystals, as the cocrystal
will likely display a different melting point to the individual components.
Figure 2-10: DSC trace depicting a) glass transition, b) an endothermic phase transi-
tion, c) solidification/recrystallisation and d) a melting point
2.10.2 Experimental
Thermal events were investigated using a Thermal Advantage Q20 DSC instrument
equipped with a Thermal Advantage Cooling System and operated under a dry nitrogen
gas purge of 18 mL min−1.
Between 1.0 and 8.0 mg of sample was weighed into a Tzero aluminium pan. Samples
were sealed by crimping an aluminium lid onto the pan before being transferred to
the heating chamber. The heating and cooling profile was programmed using the
Advantage for Qseries software c© (ver. 5.40, 2001-2011, TA Instruments-Waters LLC)
and the resulting trace was interpreted with TA Universal Analysis software.
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2.11 Nuclear Magnetic Resonance (NMR)
2.11.1 Theory
A nucleus possesses a spin angular momentum, whose spin state is determined by
the number of unpaired protons and neutrons. The magnitude of the spin angular
momentum is given by Equation 2.7:
Magnitude of spin angular momentum =
√
I(I + 1)~ (2.7)
Where I is the spin quantum number and ~ is the reduced Planck’s constant. Elec-
trons, neutrons, and protons have a spin quantum number of a 12 . A nucleus with an
even number of protons and neutrons (e.g. C12) generally has an a total spin angular
momentum of zero, as all nucleons are paired up. For nuclei with an odd number of
proton or neutrons, a non-zero quantum number is encountered because each unpaired
nucleon contributes 12 to I. Based on this, it is possible to predict the spin quantum
numbers of various isotopes as shown in Table 2.2.
Table 2.2: Possible nuclear spin quantum numbers (I ) from the numbers of protons
and neutrons in a nucleus





Even Even 0 C12, O16
Odd Odd 1, 2, 3... B10, N14












Because angular momentum is a vector, it has both a magnitude and direction (+ or
-). A nucleus with an angular momentum of I will have 2I + 1 possible orientations
in the z axis (Equation 2.8):
Iz = m~ (2.8)
Where m is the magnetic quantum number with values between (Equation 2.9):
m = −I ,−I + 1,−I + 2, .....+ I (2.9)
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The nuclear magnetic moment (µ) of an atomic nucleus arises from the spin of the
protons and neutrons. The magnetic moment of a nucleus is related to I by Equation
2.10.
µ = γI (2.10)
Where γ is the gyromagnetic ratio of a nucleus. In the absence of a magnetic field,
the energy levels of a spin active nucleus are degenerate. However, when a magnetic
nucleus is placed within a magnetic field, the spin energy levels are split into allowed
magnetic quantum number (m) orientations. For example, the nucleus of the hydrogen
atom has two permitted orientations. In general terms, it can point either in the same
direction as the field or in the opposite orientation (Figure 2-11).
Figure 2-11: Splitting of hydrogen energy levels in a magnetic field
These energy levels are separated by an energy barrier, the size of which can be in-
creased by the strength of the magnetic field. The selection rule for NMR spectroscopy
is ∆m = ±1, the allowed transitions therefore occur between adjacent energy levels.160
By applying an external radio frequency (RF) equivalent to the spacing between the
non-degenerate energy levels (∆E), the spin state of a nucleus can be flipped so that
it’s magnetic moment now opposes the applied field (Figure 2-12). The RF absorbed
is referred to as the resonance frequency.
The resonance frequency of the nucleus will vary slightly depending on the local chem-
ical environment and therefore, a slightly different external RF is required to cause
different nuclei to resonate. This is the result of local shielding effects which reduce
the effectiveness of the external magnetic field felt by the nucleus, this is observed as a
chemical shift. In order to generate a detectable signal, the nuclei are allowed to relax
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Figure 2-12: Absorption of the radio frequency (RF) causes the magnetic moment of a
nuclei to flip and oppose the magnetic field (B0).
back to the preferred orientation state before pulsing another dosage of RF radiation.
This is cycled several times to generate an averaged signal. From the RF pulse, any
radiation that is absorbed correlates to a resonance frequency. As the sample relaxes,
a decaying, oscillating signal is generated which can be converted to a NMR spectrum
using Fourier transformation (Figure 2-13).161
Figure 2-13: NMR spectrum obtained from the Fourier transformation of the signal
decay generated after an RF pulse
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2.11.2 Experimental
Routine NMR analysis was carried out using a Bruker Avance 300 MHz spectrometer.
A small amount of sample was dissolved into 0.3 ml of deuterated dimethyl sulfoxide
(DMSO) and transferred to a 5mm NMR tube for analysis. A proton spectrum was
collected using TopSpin (3.6.1.). All spectra and corresponding peaks were analysed
with MesResNova Software.
The relative conversion and selectivity for synthetic reactions was measured from the
integral of the NMR peaks. As the limiting reactant will produce an equivalent amount









Where RA/B is the molar ratio of A to B, integralA is the integral of peak A, Na is
the number of protons corresponding to peak A, integralB is the integral of the peak
B, Na is the number of protons corresponding to peak B.
2.12 Hot Stage Microscopy
2.12.1 Experimental
Real-time analysis of phase transitions was conducted using a Mettler Toledo FP82
hot stage equipped with a Leica DM1000 microscope. A small amount of sample was
placed onto a glass slide and transferred to the hot stage chamber. The sample was
then subjected to a temperature program using the FP90 Central Processor. The
microscope was equipped with an Infinity 2 camera to record any changes in real time.
The Studio86Designs software was used capture the video. Playback of the videos was
carried out using Studio Player.
In a typical experiment, a sample is heated at 5 ◦C min−1 from a start temperature of
35 ◦C until the sample has visibly melted. The video would be logged and played back
to observe any visible changes in colour; a loss of crystallinity; solvent precipitation or




An optical microscope with a Nikon Coolpix P5100 camera attached was used to eval-
uate crystal size, morphology and colour. Samples were placed on a glass slide under
the microscope and the Nikon Coolpix camera was used to take digital images of the
crystalline material.
Where particle size measurements were taken; a microscope calibration slide equipped
with a grid net with divisions of 0.01 mm was placed under the sample slide. Pictures
of the crystalline samples were taken using the Nikon Coolpix digital camera. By
calibrating the number of pixels equivalent to 0.01 mm, the scale of the picture could
be determined. Using this, the particle size could be determined by measuring the
length and width of individual crystals by converting the number of pixels into the
equivalent length in millimetres using the imageJTM software.
2.14 Scanning Electron Microscopy
2.14.1 Theory
Scanning electron microscopy (SEM) is a tool used for materials characterisation and
provides information about the surface, shape, composition and defects in solid mate-
rials. It is used to produce high resolution images in the micron and nanometre range.
SEM is used to overcome the limits of resolution in optical microscopy, which makes
it possible to discern details which would otherwise be indistinguishable to the human
eye. SEM uses electrons fired from an electron gun to probe the surface of a material.
A typical SEM consists of three parts; an electron column, the specimen chamber and
a computer interface system.162 The electron gun is held within the electron column,
which generates an electron beam. A series of electromagnetic lenses located within the
column focuses the beam into nanometre-sized probe. The gun, the column, and the
specimen chamber are kept under vacuum to prevent particulates from interfering with
the electron beam generation. The electrons in the beam are directed at the sample
and penetrate a few microns into the surface. Interaction with the atoms results in the
emission of a variety of detectable signals.
Some of the electrons in the incident beam undergo elastic and inelastic scattering upon
colliding with the sample. The elastically scattered electrons are eventually deflected
out of the specimen without any kinetic energy loss. These electrons are backscattered,
originally belonging to the incident electron beam that struck the samples surface. Once
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out in the vacuum, these electrons can be captured by a detector and used to form a
backscattered electron image. A backscattered electron image gives compositional con-
trast information of the surface. In addition to backscattered electrons, some electrons
belonging to the target material are ejected from the specimen. These electrons are
generally loosely bound, outer shell electrons residing close to the specimen surface.
They are struck by the electrons of the incident beam and if enough energy is imparted
to them, they are ejected from the atom. If they escape from the specimen (due to
their close proximity to the surface), these electrons can be detected. As these electrons
originally belonged to the specimen, they are known as secondary electrons and can be
used to form a secondary electron image, which provides topographic contrast infor-
mation. Both forms of contrast are detected and processed to obtain high resolution
images of a samples surface.
Elemental dispersion information is obtained from X-rays generated when the primary
electron beam interacts with inner shell electrons of an atom.163 The inner shell elec-
trons are knocked from their orbits and ejected from the atom (much like in secondary
electron generation). The loss of an inner electron results in a vacancy in the orbital
and the atom enters an unfavourable, energised state. The vacancy is immediately
filled using an outer shell electron, which is transferred to the inner shell. This brings
the atom back to its ground state, with an accompanying release of energy equal to the
difference in the binding energy of the two shells. This excessive energy is released in
the form of an X-ray photon, whose value will be characteristic of the atom’s molecular
weight.
2.14.2 Experimental
SEM was carried out using a JEOL SEM6480LV at the University of Bath and a JSM-
6610LV at the Research Complex at Harwell (RCaH). In both cases, the samples were
coated beforehand using gold (Au) with a Sputter Coater Quorum Q150T ES depositing
a 4 to 10 nm coat on the samples. After coating, the samples were transferred to the
SEM vacuum chamber and mounted onto a motorised stage to be analysed.
2.15 Laser Diffraction
2.15.1 Theory
The Malvern Mastersizer uses laser diffraction to calculate the size of the particles in a
sample. In this technique, the scattering pattern of laser light by a sample of dispersed
particles is measured on a series of detectors positioned at different angles (Figure
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2-14).164 As the particles are fed past the laser, the angle of the emerging scattered
light will be dependent on the particle size. The scattering angle will be larger the
smaller the particles. The detected light intensities at various angles are processed by
a computer. The measured signals are converted to a particle size distribution (PSD)
using a mathematical model. Several theoretical models are currently used to extract
particle size data from laser diffraction including: Fraunhofer, anomalous diffraction
and Mie theory. Mie theory requires knowledge of the the refractive index of a particle
and dispersion media, but is the most robust method for studying small particles.165
In all cases the particles are assumed to be spherical. For non-spherical particles,
particle orientation will affect the distribution of light scattering observed and this is
a current limitation of the technique. Regardless of the model used, processing of the
light scattering is used to determine the volume density of particles within a defined
set of size classes. The data is then compiled into a distribution based on those size
classes.
Figure 2-14: Simple laser diffraction set-up for particle analysis
2.15.2 Experimental
Measurements made using the Malvern Mastersizer 3000 were carried out with the
help of Dr. Martin Depardieu. The Malvern Mastersizer 3000 (software version 3.36)
was used to measure the distribution of controlled nucleation crystals produced during
pyrazinamide (PZA) production. The particles were suspended in a saturated solution
of pyrazinamide (PZA) in isopropanol to avoid particle dissolution. The refractive index
of the dispersion solvent was supplied to the software and incorporated into the data
analysis. A manual Malvern Hydro SM dispersion cell with a stirring rate of 2000 rpm
was used to disperse the sample to avoid the formation of aggregates. After 30 minutes,
the majority of these aggregates had dispersed without damaging the particles. The
suspended sample was then fed past the laser, where the in-built software measured the
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scattering of the particles and converted the raw data to a volume density vs particle







The work in this chapter outlines the development of a continuous process for the
production of paracetamol (PCM) and forms part of research effort to generate a route
to PCM from renewable feedstocks. This research presented concerns the final synthetic
step in this procedure and aimed to develop and evaluate a suitable flow synthetic
process for coupling with continuous crystallisation.
3.1.1 Background and Aims
Paracetamol (PCM) or acetaminophen, is an important medicinal compound and com-
mon active pharmaceutical ingredient (API) in many over-the-counter pain relief med-
ications. In 2014, the UK population was prescribed 42 million paracetamol-containing
medicines while annual production worldwide exceeds 100000 tons.166,167 Considering
the high demand for PCM, pharmaceutical companies have developed a number of pro-
duction methods to provide a cheaper and more efficient means of synthesis in order
to maximise net profit. The most common industrial methods for PCM production in-
volve the acetylation of 4-aminophenol to PCM. However, this method of production is
not without its difficulties. The commercial routes to the 4-aminophenol intermediate
suffer from moderate selectivity and produce large quantities of salt by-products that
reduce the atom efficiency.167 Strong acids such as sulphuric acid are used as a catalyst
in most of these reactions but it is both strongly corrosive and large quantities are
polluting. Therefore research has attempted to replace sulfuric acid with alternative
catalysts with moderate success.168,169
In pursuit of the need for greater sustainability and efficiency, the development of alter-
native routes to medicinal compounds such as PCM have been developed using green
chemistry principles. One particular route known as the Hoechst–Celanese procedure
is used for the production of PCM from phenol (Figure 3-1).170 This route involves the
direct acetylation of phenol to the stable intermediate 4-hydroxyacetophenone (4HAP).
This is followed by an oximation reaction using hydroxylamine hydrochloride (HOA)
and an acid catalysed Beckmann rearrangement to deliver the final product.
Figure 3-1: Hoechst−Celanese green synthesis of paracetamol from phenol
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The Hoechst−Celanese process has been successfully scaled to industrial production,
but a number of challenges remain. For instance, the stages employ mineral acids and
inorganic bases each requiring significant work-up between operations. Furthermore,
the starting reagents are derived from finite fossil fuels, which should be replaced with
renewable feedstocks. Production of PCM could potentially benefit from an alternative
synthetic approach within a holistic, continuous manufacturing framework. This could
lead to improvements in the sustainability and efficiency of the process.
As such, the aim of this work is to develop and couple a flow synthetic method for the
production of PCM with a continuous crystallisation work-flow for purification. The
work forms part of a wider effort to produce medicinal products from green feedstocks.
The proposed synthetic route developed by the Centre for Sustainable Chemical Tech-
nologies (CSCT) to produce PCM from limonene (which can be naturally sourced from
citrus fruit) is shown in Figure 3-2.171
Figure 3-2: The proposed synthetic route from limonene to paracetamol171
The final step in this process was targeted for integration with continuous crystallisa-
tion. In pursuit of integration, the work aimed to develop an effective flow chemistry
method compatible with downstream continuous processing technologies. While the
primary target of this work was PCM, which is a well understood model compound
for synthetic and crystallisation research, later research also investigated the integra-
tion and continuous production of the intermediate compound 4-hydroxyacetophenone
oxime (4HAPO). 4HAPO represents a stable intermediate in the production of PCM.
In this case, the research aimed to showcase how a holistic approach, incorporating
flow synthesis and continuous crystallisation might benefit design of continuous manu-
facturing platforms.
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3.2 Investigation into the One-Pot Synthesis of Paraceta-
mol
In the Hoechst-Celanese process for the production of PCM, the ketone is first subjected
to an oximation, followed by a Beckmann rearrangement in a multi-stage process. In
general, the oximation step favours basic conditions, as the hydroxylamine reactant
is stored as salt for stability, but in the presence of a base becomes a nucleophile. In
contrast, a Beckmann rearrangement favours strongly acidic conditions.172 As such, the
process is generally a two-step reaction and requires significant work-up between steps,
usually facilitated by ammonia to neutralise the base. To avoid this, initial attempts for
the production of PCM concentrated on the investigation of a one-pot synthetic route
to paracetamol from 4HAP. The synthetic procedure is outlined in Figure 3-3. The
synthesis was developed by Rancan et al. for the self-catalysed amidation of ketones.152
Figure 3-3: Direct amidation of 4-hydroxyacetophenone
In the self-catalysed mechanism demonstrated by Rancan et al. 4HAP readily converts
to 4HAPO and subsequently to PCM without the need for additional acids or bases.
At high temperature, the oximaton reaction between 4HAP and HOA occurs readily
and subsequently releases a hydrochloric acid molecule, which catalyses the Beckmann
rearrangement of 4HAPO to PCM. The process was shown to work well under solvent-
less conditions or in the presence of a small amount of acetonitrile (ACN). A maximum
conversion of 98% and selectivity to PCM of 97% was reached when heating between
90 and 110 ◦C for 1 hour. The reaction was further investigated by University of Bath
Master’s student Adam Steele, who replicated the reaction under solventless condi-
tions. In subsequent kinetic studies under stoichiometric conditions, the production of
paracetamol was shown to be completed within the first fifteen minutes at 120 ◦C.
Based on these initial findings the one-pot synthesis of PCM was targeted as a poten-
tially attractive process for integrated continuous manufacturing. The almost quanti-
tative conversion and high selectivity suggested the reaction could be linked directly
to a developed crystallisation platform. Furthermore, the reaction proceeds well in less
than an hour and could easily be improved by the higher mass and heat transfer ratios
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typical in flow. While the use of ACN is not ideal as a solvent medium, it is recognised
as the ‘greener’ alternative when considering dipolar aprotics as a reaction medium.173
If the reaction can be translated into flow, this procedure could avoid the need for
strongly corrosive acids typically required in the amidation of 4HAP.
Based on these observations, the work in this section aimed to replicate the work
reported by Rancan et al. and transfer the solvent-based process to a flow chemistry
platform. Particular attention was paid to the primary goal of integrated manufacturing
and the flow chemistry route was therefore designed with the specific goal of integration
with continuous crystallisation.
3.2.1 Batch One-pot Synthesis of Paracetamol
3.2.1.1 Experimental
The experimental parameters investigated in batch experiments for the direct amidation
of 4HAP are outlined in Table 3.1. The experimental method was based on the work
carried out by Rancan et al.152









(4HAP:HOA) (mL) (ACN:4HAP) (◦C) (min)
PCM1 1:3 5 10 90 60
PCM2 1:1 5 90 90 60
PCM3 1:3 5 38 120 60
PCM4 1:3 10 60 80 165
PCM5 1:1 100 250 70 1080
PCM6 1:1 100 250 90 1380
In PCM 1 and 2, stoichiometric amounts of 4HAP and HOA were added along with
a specified volume of solvent to a 7 mL vial. A magnetic stirrer was added and the
solution was heated on a hotplate to a temperature between 70 and 120 ◦C. The solution
was allowed to react for one hour. Where the solid was extracted, the reaction was
worked-up using rotary evaporation to leave a crude off-white solid. Routine nuclear
magnetic resonance (NMR) analysis was carried out on the crude product and the
conversion and selectivity were determined using the method described in Section 2.11.
In PCM3, the screw cap vial was replaced with a biotage reaction vial and sealable cap.
Stoichiometric amounts of 4HAP and HOA were added with 5 mL of solvent. The vial
103
was heated to 120 ◦C for one hour in a sand-bath with constant stirring. The sample
was allowed to cool before analysis.
In PCM4 to PCM6, the vial was scaled up to a 150 mL round bottom flask and stoi-
chiometric amounts of 4HAP and HOA were added to the specified volume of solvent.
The reaction was heated in an oil bath with constant stirring at 200 rpm. Samples were
taken periodically to monitor reaction progress using routine NMR analysis.
PCM7 investigated the effect of water on the one-pot reaction and followed the same
method as PCM3 to allow comparison. The parameters are summarised in Table 3.2.
Table 3.2: Influence of water on one-pot PCM reaction
Experiment ACN Volume Water Volume Water Content
(mL) (mL) (v/v%)
PCM7.1 4.5 0.5 10
PCM7.2 3.5 1.5 30
PCM7.3 2.5 2.5 50
PCM7.4 0 5.0 100
Reaction conditions: 2.5 mmol 4HAP, 7.5 mmol HOA, 120 ◦C, 1 hour
3.2.1.2 Results and Discussion
The isolated products from initial replications of the work carried out by Rancan et
al. are shown Table 3.3. In this case, PCM1 and PCM2 underwent rotary evaporation
after reaction completion to remove any remaining solvent, resulting in a crude solid.
The crude was then recrystallised from hot deionised water. The isolated crystalline
product was then subjected to analysis.




PCM1 99 5 87
PCM2 96 5 88
Interestingly the addition of three molar equivalents of HOA in PCM1 as opposed to
PCM2 did not change the selectivity to PCM, but did promote a higher conversion.
Observations during the run however, indicated that a solid suspension was present
during the reaction procedure. This was later determined to be undissolved HOA,
which was not readily soluble in ACN. Nonetheless, the reaction proceeded well within
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1 hour, producing PCM which was effectively isolated using recrystallisation. The
products from each reaction were also tested using differential scanning calorimetry
(DSC); the melting point was then compared to an experimental reference of PCM.
The results are shown in Figure 3-4.
Figure 3-4: Comparison of DSC traces for PCM1, PCM2 and a experimental reference,
note that values are offset in the Y-direction for clarity
As can be seen, the peak maximum for the endothermic melting peak matches well
with the experimental reference of PCM. While the results are in good agreement with
the reactivity described in literature, a better understanding of the reaction in situ was
needed to develop a flow synthetic method. For instance, it was important to determine
a suitable residence time (RT) to use in the flow set-up. Ideally the RT should allow
for high conversion and selectivity to PCM without degradation of the product. As
the reaction is a two-step process, the process would also need to balance and optimise
both the oximation step and Beckmann rearrangement for maximum yield. Another
issue was the poor solubility of HOA in ACN, which could lead to clogging in-line either
due to precipitation or poor solid suspension depending on the set-up.
As such, experiments PCM3 to PCM6 tried to determine whether adjusting the reaction
conditions could help facilitate the transfer of the one-pot process into flow. The results
of the reactivity of the one-pot method in batch are shown in Table 3.4.
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Table 3.4: Reactivity of PCM batch investigations according to NMR
Experiment Conversion Selectivity Reaction Time
(%) (%) (%) (min)
4HAPO PCM
PCM3 96 3 88 60
PCM4 74 9 88 165
PCM5 83 Traces 88 1080
PCM6 83 8 91 1380
From the data and parameters in Tables 3.4 and 3.1, a few trends emerge. As the
amount of solvent increases, the time taken for the reaction to proceed increases.
PCM3, PCM4 and PCM5 all showed little conversion to PCM after 1 hour. As stated
earlier, increasing the stoichiometric ratio of HOA:4HAP improves conversion but has
only a marginal effect on selectivity; in the literature, supplementary work showed
the same trend. Increasing the temperature promotes a faster reaction but also leads
to side-products forming. These were not actively identified, but have been noted in
the literature as decomposition products.152 The conversion has been calculated on
the assumption that these impurities contribute to the conversion while the selectiv-
ity assumes that the decomposition products share the same signal-to-proton ratio as
4HAPO and PCM. This method does not produce quantifiable results, but does pro-
vide a quick method for screening and comparing the reaction progress using NMR
spectroscopy. Identification and separation of these impurities is beyond the scope of
this thesis. Despite the addition of solvent, reduction in molar ratio or increase in
temperature, the solid suspension of HOA remained problematic. While some reactors
are capable of handling solids in-line, equipment limitations in terms of pump capabil-
ities meant that a high solid loading requirement would not allow the reaction to be
transferred to flow easily. In order to overcome this, a solvent screen was carried out
on the HOA salt to determine if this component could be effectively dissolved instead.
From the solvent screen, HOA salt was found to be readily soluble in water. Thus,
batch reactions were conducted using a mixture of acetonitrile and water ranging from
10 to 100% water content (PCM7). These were compared to PCM3, run under the same
conditions without water content. In this way, the effect of water on the reaction could
be determined. The results are summarised in Figure 3-5. As can be seen from the
graph, even the addition of 10 v/v% of water will reduce selectivity towards PCM by
more than half. As water content increases, the preference for 4HAPO also increases.
Furthermore, an unknown aromatic side product became more prevalent. A reduction
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in conversion is also visible, with the exception of a small increase at 50 v/v% water.
The increase may indicate a localised maximum for conversion, but selectivity to PCM
is not improved. Regardless, the results do show that solvent choice has a clear role
in the reaction progress. Care must therefore be taken to minimise the water content
while maintaining dissolution of the reactants.
Figure 3-5: Effect of water on the one-pot synthesis of PCM. Reaction conditions:
2.5 mmol 4HAP, 7.5 mmol HOA, 5 mL solvent, 120 ◦C, 1 hour
Further attempts to find suitable conditions indicated that the reaction could be best
run in a 95:5 v/v% ACN:H2O mixture. This was found to be the lowest volume of
water content that could effectively dissolve stoichiometric amounts of HOA at 80 ◦C.
Here, the temperature was lowered to avoid thermal decomposition of the products.
The results are shown in Figure 3-6. As can be seen, the selectivity to PCM is still
very low after one hour. This gradually increases as the reaction progresses, but is
significantly slower than the pure ACN process. In terms of dissolution of reactants,
HOA did remain in solution at reaction temperature, but a biphasic solvent mixture
and solid particulates were noted at room temperature. This indicates the dissolved salt
reduces the miscibility of ACN and water at high concentrations. While the reaction
had not fully completed after 22 hours, the selectivity to PCM had only reached 72%
with an increasing amount of by-products noted in the spectra. The long reaction
times and reduced conversion compared to the pure ACN process makes its application
in bench-top flow equipment limited, particularly where integration with downstream
technology is the aim.
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Figure 3-6: Effect of water on the one-pot synthesis of PCM. Reaction conditions:
2.5 mmol 4HAP, 2.45 mmol HOA, 10.5 mL solvent, 80 ◦C, 22 hours
Based on these results, the effectiveness of using a cosolvent to facilitate dissolution of
the starting materials did not appear to be a viable approach. While it is possible that
a balance could be found between a low water content, long RT and high temperature
to optimise the reaction, the results show that the solvent may have the biggest impact
on the reaction rate. A possible reason for the loss in rate could be related to pH.152
Typically the oximation of 4HAP to 4HAPO uses a base as a buffer, while the Beck-
mann rearrangement is favoured by strongly acidic conditions.172 The addition of water
will neutralise the HCl component of the HOA salt, potentially stunting the reaction
rate. With high solvent content, the reaction rate is reduced due to dilution. Hence,
the reaction is most favourable under solventless conditions because a localised high
concentration of hydrochloric acid is maintained as the oximation take place, which
subsequently facilitates the Beckmann rearrangement.
3.2.2 One-pot Synthesis of Paracetamol in Flow
Since a cosolvent approach using water was not a suitable candidate for effective trans-
ference to a flow process, an alternative method was investigated. Instead of attempting
to dissolve HOA, a packed bed column was used to support the reagent. Packed bed
reactors have been previously used for in-line work up, scavengers, solid catalyst sup-
port or solid reagents in flow synthesis.140,174,175 For the one-pot amidation reaction,




In flow, the one-pot amidation process was carried out using the Vapourtec R-series
flow reactor. For full details of the Vapourtec apparatus, see Section 2.5. The packed
bed reaction set-up is outlined in Figure 3-7.
Figure 3-7: Experimental set-up for one-pot, flow synthesis of PCM
An adjustable omnifit fixed bed reactor of variable length was fitted to a heater zone
on the Vapourtec R-series heater module. The column was packed with approximately
3.8 g of HOA. Celite was packed into both ends of the column to fill the void volume.
Each end of the column was sealed with a frit and the length of the column was adjusted
to pack the solid. The column was primed with pure ACN at the set flow rate for 1.5
RTs at 120 ◦C. A back pressure regulator (BPR) was fitted downstream (7 to 8 bar)
to prevent solvent boiling in-line. After priming, the line was switched to the stock
solution of 4HAP dissolved in ACN. Aliquots were collected at periodic intervals and
reaction monitoring was conducted using NMR spectroscopy. The parameters used in
one-pot packed bed flow synthesis experiments are outlined in Table 3.5.
Table 3.5: Parameters for the packed-bed flow synthesis of PCM
Experiment 4HAP HOA Solid Volume 4HAP
Flow Rate
RT
(mol dm−3) (mmol) (cm3) (mL min−1) (min:sec)
PCM8.1 0.28 27.9 2.1 0.50 4:10
PCM8.2 0.28 27.9 2.1 0.25 8:20
PCM9 0.27 26.7 1.8 0.22 8:10
Reaction conditions: Solvent = ACN (100 mL), Temperature = 120 ◦C, Column volume = 2.4 mL,
BPR = 7 - 8 bar
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3.2.2.2 Results and Discussion
PCM8
In PCM8, the solution of 4HAP was initially pumped at 0.5 mL min−1 (PCM8.1). This
was later lowered mid-run to 0.25 mL min−1 (PCM8.2). The reaction was monitored
with off-line NMR and the results are shown in Figure 3-8. As can be seen from the
graph, conversion of 4HAP remained low, reaching a maximum of 33% after running the
reaction for 50 min. However, selectivity towards PCM was high, reaching 75%. While
the selectivity towards PCM was not as high as delivered in batch, the total time spent
within the column was only approximately 4 to 5 min. The presence of localised excess
HOA readily promotes the Beckmann rearrangement. However, the lower conversion
suggests that conditions were unfavourable for the oximation step. To improve this,
the flow rate was halved mid-run to increase the residence time to 8 minutes. The
effect was a noted increase in both the conversion and selectivity towards the desired
product, with conversion reaching 72% at 70 minutes. Selectivity to PCM also reached
a value of 97%. The remaining 3% was assigned to thermal decomposition products,
as no peaks for 4HAPO were visible in the spectrum.
Figure 3-8: Conversion and selectivity to PCM using off-line NMR monitoring in
PCM7. Flow rate changed to 0.25 mL min-1 after 50 min
Results suggest that the majority of the oxime intermediate can be converted to
paracetamol within 8 minutes. While the oxime intermediate was detected again at
80 minutes the high selectivity towards PCM remained. The run was ended at 85 minutes,
as the BPR became blocked with solid particles. Based on earlier observations in batch
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regarding the poor solubility of HOA in ACN, the HOA salt was determined to be
leaching from the column into the solution stream at the reaction temperature but as
the effluent cooled, precipitation of HOA occurred and the BPR became a choke point
for solid particles.
PCM9
Based on the good conversion and selectivity evident in PCM8.2, PCM9 aimed to
replicate the work carried out over a longer period. The results are depicted in Figure 3-
9. The flow rate was adjusted to give an equivalent RT to PCM8.2. However, in PCM9
the reaction was less productive. Here the reaction reaches a conversion between 60 to
70 %. Furthermore the selectivity towards PCM was reduced, with an average of 78%.
It is difficult to discern the exact cause for the reduced reaction progress. A possible
reason may be that the active surface area of the column was reduced compared to
PCM8.2, as the exact column conditions and length (and therefore the column RT) are
difficult to reproduce accurately. As a consequence the volume-to-surface area ratio
may have been lower, which can affect the reaction rate of flow processes using packed
beds.29,58
Figure 3-9: Conversion and selectivity to PCM using off-line NMR monitoring in PCM9
As was the case with PCM8, difficulties still remained in PCM9, which suffered from
large pressure oscillations during the process. Eventually a blockage formed 37 minutes
into the run, this was alleviated by raising the flow rate briefly, however the spike in
conversion and yield at 50 minutes is likely a consequence of the blockage increasing
the RT in the column. The upside of this is that the reaction yield and conversion
to PCM could likely be increased by lowering the flow rate. The major difficulty in
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doing this is that a BPR relies on a regular flow rate to maintain pressure. As the
flow rate is lowered, it becomes more difficult to maintain safe operating pressures that
prevent ACN from boiling in-line. This would in turn lead to precipitation and further
blockage issues. Several attempts were made to apply temperature control to the BPR
unit. These included insulating the tubing and actively heating the BPR in a water
bath. However, neither approach was sufficient to prevent blockages or severe pressure
oscillations in the process.
3.2.2.3 Summary
From the results discussed, the one-pot reaction showed promise in translation of 4HAP
to PCM production into flow, some of the problems encountered could be mitigated by
careful optimisation of the reaction and subsequent temperature and pressure control.
In particular, PCM8.2 and PCM9 display the closest conversion and selectivity to the
batch approach, with appreciable conversion to PCM in less than 10 minutes. However,
oscillations in the column pressure caused issues with maintaining the high tempera-
tures safely, while particulates leaching from the column caused blockages during the
operating period.
In terms of integration, the process developed is currently not suitable for coupling with
continuous crystallisation. While translation of the amidation was partially successful,
the significant blockages and pressure oscillations in the packed column cause issues.
One possible solution to this might be to introduce a quenching agent to the reaction
after the column and before the BPR. This could redissolve any particulates and prevent
blockages, however this would also dilute the product, making crystallisation more
difficult. Scaling up would remain an issue, as the pressure oscillations may become
worse even with quenching and this could have a knock-on effect on the crystalliser
flow rate. A further problem would be the reactivity, which would decrease slowly
as the HOA in the column is used up. This would lead to a build-up of starting
material impurities during crystallisation. To compensate, the column would require
periodic replacement or two columns would need to be run alternatively, along with
in situ monitoring to determine when the columns needed swapping. While this is
still a potential route for continuous manufacturing (CM), most of these additions add
significant complexity to the process before even the integration with a crystallisation
process can be evaluated. A possible viable approach to scale-up and integration of the
one-pot method might be to use continuous stirred tank reactors (CSTRs). Individual
CSTRs are more analogous to batch reactors and thus better capable to handle solid
suspensions; in this case the HOA would not need to be fully dissolved and therefore
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leaching would be less of a problem. However the reaction rate and purity might
decrease, as mass and heat transfer would be less effective. To compensate for this,
the CSTR set-up would need to be run with a longer RT. Alternatively a solventless
approach could be most effective. The reaction has been previously shown to work best
under these conditions and this could be facilitated in flow by the use of a twin screw
extruder process. Literature precedent has already shown that multi-step telescoped
synthesis can be effectively implemented in extrusion processes.176
3.3 Two-Step Synthesis of Paracetamol
In continuing to pursue applications of integration of flow synthesis and continuous
crystallisation, an alternative approach was investigated for PCM. In this case, the
one-pot process was separated into two distinct steps, which could potentially be later
linked. This section will discuss the development of flow synthetic approaches to the
production of 4HAPO from 4HAP and the subsequent Beckmann rearrangement of
4HAPO to PCM as separate processes.
3.3.1 Oximation of 4-Hydroxyacetopheone Using Acetic Acid
Since the poor solubility of HOA salt in ACN made it difficult to translate the one-
pot amidation process into a continuous tubular reactor, an alternative approach was
investigated in early trials. HOA is usually supplied as a salt, as free hydroxylamine
slowly decomposes in solution. However despite the reduced shelf life, hydroxylamine
is readily available commercially in a 50 wt% aqueous solution. By replacing the salt
form with the aqueous form, it was hoped that a solution based method could be
developed. In pursuit of a green process, acetic acid was used to facilitate the reaction
in the absence of the hydrochloric acid component.
3.3.1.1 Experimental
The Vapourtec R-series modular unit was used in all flow synthesis experiments. For
a fuller description of the Vapourtec R-series unit, refer to Section 2.5. Stock concen-
trations of 4HAP and hydroxylamine solution were prepared in ACN and acetic acid
(AcOH) respectively. Each pump was primed with the required pure solvent respec-
tively. The feed streams were combined at a polyether etherketone (PEEK) T-piece
mixer (1 mm inner diameter (ID)) before the reactors. A BPR with a pressure of 7
to 8 bar was used to avoid solvent boiling in line. The system was primeed at tem-
perature for at least 1.5 RTs before switching to feed solution. Regular aliquots were
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taken to monitor reaction progress and analysed using NMR spectroscopy. In initial
experiments (PCM10) a perfluoroalkoxy alkane (PFA) tubular coil reactor with a vol-
ume of 27 mL (1 mm ID) was used. This was later replaced with a single or series of
static mixer coils (PCM11 and PCM12). In PCM11, the reaction was carried out at
the Innovative Technology Centre (ITC), University of Cambridge while visiting the
Steven Ley research group. The set-up consisted of three 20 mL (3.2 mm ID) static
mixer coil reactors placed in series and heated individually to 120 ◦C (Figure 3-10).
Figure 3-10: Schematic diagram for the flow oximation of 4HAP in acetic acid using
three static mixers in series.
In experiments at the University of Bath, the three static mixers were replaced with a
single, 65 mL (5.6 mm ID) static mixer coil. The single coil was wrapped around a glass
water bath which was actively heated on a hotplate to 60 - 70 ◦C. All other features of
the reaction set-up remained the same (Figure 3-11).
Figure 3-11: Schematic diagram for the flow oximation of 4HAP in acetic acid using a
single 65 mL static mixer coil.







































































































































































































































































3.3.1.2 Results and Discussion
PCM10
In PCM10, the reaction was carried out in a standard PFA coil. During the run, it
was noted that the acetic acid and HOA solution did not mix well with the 4HAP
solution in ACN. Off-line testing revealed that the high HOA/Acetic acid content
made AcOH solution immiscible with ACN. After leaving the reactor, the solution
remained biphasic and formed two layers in the collection vessel. Reaction monitoring
was carried out using off-line NMR (peaks can be seen in Appendix Figure 9-2). A
clear consistency is maintained throughout the run, with a mixture of the starting
material (peak at 7.8 ppm, 4HAP) and the product (7.5 ppm, 4HAPO) detected at
the time of extraction. While the reaction went selectively to the oxime product,
the conversion remained steady throughout the run at 70 to 80 % (Figure 3-12). At
80 minutes the feed was switched to pure solvent, which is reflected in the NMR spectra
at 90 minutes where a lack of NMR peaks is observed. While the conversion was not
complete within 10 minutes, the reaction was unproblematic and simple to run; showing
steady production of 4HAPO was achieved over nine RTs without issues.
Figure 3-12: Conversion of 4HAPO using off-line NMR monitoring in PCM10
The reaction was worked up after completion and the solvent removed under vacuum.
However, the resulting product remained as a viscous brown oil. This was unexpected,
as 4HAPO is usually an off-white solid at room temperature. Further washing with
water and subsequent extraction using ethyl acetate resulted in a crude solid product.
The product was then recrystallised from hot water to leave an off-white solid. The
isolated yield was 41 %, with trace amounts of 4HAP present.
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While initial results were promising, an improved isolated yield and conversion were
required for further integration with downstream technologies. The closely related
molecular structures of 4HAP and 4HAPO meant that separation using crystallisation
techniques would be difficult as their solubility behaviour could be similar. While they
could be separated using in-line chromatography, this would slow and complicate the
production process. On the other hand, if the conversion and selectivity to 4HAPO
was sufficiently high, then separation in-line could be avoided. Therefore to improve
conversion, the reaction was transferred into a series of static mixer coils at heightened
temperatures. This would encourage mixing of the biphasic solutions and increase
reaction rate.
PCM11
In PCM11.1, PCM10 was transferred to a series of static mixer reactors in tandem,
which were heated to 120 ◦C. In PCM11.2 the reaction was repeated in the absence of
acetic acid. The results are summarised in Figure 3-13.
Figure 3-13: Conversion to 4HAPO using off-line NMR monitoring in PCM11.1 and
11.2
As can be seen from the graph, the reaction proceeded to produce almost quantitatively
the 4HAPO product in PCM11.1. Comparison of the NMR spectra at different time
stamps showed that almost no trace of 4HAP remained in PCM11.1 (See Appendix
Figure 9-3 for stacked spectra). A minor intermediate was seen to form, but was
not visible in the isolated product. During the run, the reaction mixed well in the
static mixer coils and the biphasic nature of the solution was lost within the first coil.
Separation of the phases occurs gradually upon collection and cooling. In PCM11.2,
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the reaction was run without the high concentration of acetic acid to check whether
the acetic acid played a purpose in the oximation. Based on the results in PCM11.2,
the acetic acid is needed to initiate the oximation process. Without its presence, the
conversion remains less than 5 %. This was a clear indication that the presence of acetic
acid catalyses the reaction. This behaviour was also seen by Ren et al. when preparing
ketoximes using aqueous hydroxylamine in ionic liquids.[177]
PCM12
Having established that selective production of 4HAPO was possible in a ten minute
flow reaction, PCM12 attempted to improve the process further by reducing the temper-
ature to avoid thermal decomposition of the product while increasing the concentration
of aqueous hydroxylamine and AcOH to promote 4HAPO formation. To replicate the
set-up from PCM11 (carried out at the University of Cambridge), a single, large 65 mL
static mixer coil wrapped around a water bath was used. This was close to the equiva-
lent volume of the three 20 mL static mixers used in Cambridge. The water bath was
heated to 80 ◦C. The reaction was monitored using quantitative NMR where maleic
acid was used as a reference standard. The reaction was run for 9 RTs and the results
from reaction monitoring in PCM12 are shown in Figure 3-14.
Figure 3-14: Quantitative NMR measurements for 4HAPO production from 4HAP
using acetic acid as a cosolvent
As was the case with PCM11.1, PCM12 produced 4HAPO in quantitative yields. The
expected yield per aliquot was calculated to be 3.1 mg and was based on the flow rate
and collection period. As can be seen from Figure 3-14, the mass of product per sample
is close to the expected value, with an average of 3.3 mg at steady state. Analysis of
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the individual NMR spectra showed the small shoulder peak from PCM11.1, which
is believed to be a solution-based intermediate, as the peak was lost after removal
of the solvent. Further investigation is required to confirm this. However literature
precedent has indicated that an intermediate complex can form between 4HAPO and
trifluoroacetic acid (TFA).154 It is possible that a similar intermediate may form in the
presence of high amounts of AcOH and an analogous behaviour may be being observed.
The reaction was worked up using a more robust method than PCM10. The isolated
yield was 63%, but significant improvement was still required. The high amounts of
acetic acid encouraged the product to form a viscous oil before recrystallisation. In
order to effectively crystallise, large amounts of sodium bicarbonate were required to
neutralise the acid. The reaction then had to be separated from the solution using
liquid-liquid extraction facilitated by ethyl acetate and water. The isolated product
was tested using DSC and NMR to confirm the major product was 4HAPO. The results
can be seen in Figure 3-15 and Table 3.7.
Figure 3-15: DSC of trace PCM12
Comparison of the melting point from the DSC trace and NMR peak shift with values
taken from literature gives firm indication that the isolated compound from PCM12 is
4HAPO. It is also worth noting that 4HAPO undergoes exothermic decomposition at
temperatures above the melting point (visible as a large exothermic peak centred on
175.7 ◦C). This is confirmed by the lack of a recrystallisation peak in the DSC trace on
cooling the sample. Oxime products can be unstable and this thermal behaviour has
been observed in other analogous organic oximes, such as benzaldehyde oxime.180
While the reaction was successful in producing 4HAPO with a high throughput, the
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Table 3.7: Proton NMR chemical shifts of PCM12 and melting point from the DSC
trace
Experiment Chemical Shift (ppm) Melting Point (◦C)
PCM12 (300 MHz, DMSO-d6) 2.08 (3 H, s),
7.12 - 6.32 (2 H, m), 7.47 (1 H, d, J
7.3 Hz), 9.63 (1 H, br, s), 10.87 (1 H,
br, s)
144.8
4HAPO154 (200 MHz, DMSO-d6) 2.09 (3 H, s),
6.73 - 6.78 (2 H, d), 7.45 - 7.49 (2 H,
d), 9.60 (1 H, br, s), 10.84 (1 H, br, s)
140 - 145
4HAP178,179 (500 MHz, DMSO-d6) 2.47 (3 H, s),
6.84 (2 H, d, J = 8.5 Hz), 7.83 (2 H,
d, J = 8.5 Hz), 10.32 (1 H, br, s)
108 - 110
See Appendix Figure 9-4 for the experimental spectra
need for intensive extraction and purification does not lend itself well to coupling with
crystallisation procedures. However, the reaction could potentially prove useful as a
telescoped oximation process for other applicable compounds such as the precursor to
nylon-6, ε-caprolactam, which is typically made from cyclohexanone oxime.181
3.3.2 Oximation of 4-Hydroxyacetophenone Using Sodium Acetate
While the production of 4HAPO using acetic acid was successful, the procedure is not
currently well-suited for coupling with continuous crystallisation processes without a
offline work-up procedure. Another approach was therefore investigated. The reaction
scheme is shown in Figure 3-16. Here 4HAPO is readily prepared using the salt form
of HOA in the presence of sodium acetate dissolved in an aqueous/alcohol solvent
mixture.182
Figure 3-16: Reaction scheme for the production of 4HAPO
The batch synthesis is described in the experimental Section 3.3.1.1 and is based on the
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preparation procedure for 4HAPO described by Mo et al.182 This work was replicated
in PCM13 for evaluation as a flow synthetic route to 4HAPO.
3.3.2.1 Experimental
For PCM13, the apparatus set-up is the same as depicted in Figure 2-2. To a 100 mL
glass round bottom flask under nitrogen gas, 4 mL of ethanol and 12 mL of water were
added with stirring to HOA (0.52 g, 7.5 mmol) and sodium acetate (NaAc) (1.03 g,
12.5 mmol). The solution was stirred at 250 rpm and heated to 85 ◦C. A stoichiometric
amount of 4HAP (0.68 g, 5.0 mmol) was added to the solution once the set temperature
had been reached. The reaction was allowed to proceed for 90 minutes. Regular 0.1 mL
samples were removed and diluted with 0.3 mL of DMSO-d6 for reaction monitoring
using NMR.
In flow synthesis experiments, the flow rates and the concentrations were set to provide
an analogous reaction mixture to the batch process within the reactor. Flow rates were
set to give a total RT of 15 minutes in a polytetrafluoroethylene (PTFE) tubular coil
(ID = 1 mm) heated to 85 ◦C. The output from the reactor was pumped directly into a
round bottom flask held in an ice bath. The set-up is shown in Figure 3-17. Reaction
monitoring was carried out using NMR spectroscopy.
Figure 3-17: Schematic diagram for the flow oximation of 4HAP in ethanol/water















































































































































































































































































































3.3.2.2 Results and Discussion
PCM13
The results of the reaction monitoring vs time are summarised in Figure 3-18.
Figure 3-18: Production of 4HAPO from 4HAP using the method outlined by Mo et
al.
As can be seen from the results, 4HAP was readily converted to 4HAPO within 10
minutes and the reaction was completed in 20 minutes. The product was then isolated
using an ice bath, where 4HAPO was allowed to crystallise for 3 hours. The isolated
yield was 57%.
Like the acetic acid experiments, the method was effective for production of 4HAPO in
a short reaction time. However, isolation and crystallisation of the product was much
more straightforward, not requiring solvent neutralisation and removal. In addition, an
ethanol/water solvent is preferable to ACN and acetic acid in terms of crystallisation
medium and green solvent selectivity. As the product could be readily isolated using
an ice bath, a cooling crystallisation profile might be an effective method for integrated
continuous crystallisation. Based on the initial batch test, the reaction was determined
to be potentially applicable for direct integration with continuous crystallisation.
PCM14
While the reaction proceeded well in batch, the synthetic process had to be tested in a
continuous system. In PCM14, PCM13 was translated into a flow synthesis platform,
as shown in Figure 3-17.
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In all runs, NMR reaction monitoring showed the reaction proceeded to 4HAPO selec-
tively and with high conversion (Appendix Figures 9-5 and 9-6). PCM14.3 in particular,
indicated that the molar ratio of HOA and NaAc with respect to 4HAPO could be de-
creased without compromising the selectivity and conversion. However care must be
taken with high concentrations, as PCM14.2 and PCM14.3 both showed signs of en-
crustation around the T-piece and BPR. To compensate, the reactor temperature was
increased to 95 ◦C and potential choke points were insulated where possible to prevent
precipitation and encrustation. In each case, the effluent from the reactor was fed di-
rectly into a round bottom flask, where crystallisation began to occur after 30 minutes
of operation. The crystallisation was allowed to proceed undisturbed in an ice bath
overnight before extraction via Büchner filtration. In the case of PCM14.1 and 14.2,
the effluent was worked-up using rotary evaporation to determine loss to the liquor.
The results are shown in Table 3.9.
Table 3.9: Isolated yields of 4HAPO in ethanol/water flow reactions
Experiment Crystallisation (%) Work-Up (%) Total Yield (%)
PCM14.1 13.5 56.3 69.8
PCM14.2 41.1 28.7 69.8
PCM14.3 29.7 Not worked up 29.7
As can be seen from the results, the crystallisation yield increases as the concentration
of the reactant increases. There is however, a large loss of product to the mother
liquor, though this is decreased at higher supersaturation levels. The loss to liquor
compared to batch is likely a consequence of dilution during the collection period. This
happens primarily during start-up and shutdown, as the pump flow is laminar, the
concentration of reactants is lower than at steady state. The crystallisation recovery
would likely be improved by collecting only once steady state is achieved. However,
the mother liquor can also be easily worked up to improve total product recovery. The
crystalline product was tested using powder X-ray diffraction (PXRD) and DSC. The
corresponding melting and decomposition peak from the DSC trace are summarised in
Table 3.10. The values are compared to PCM13 and show good similarity.
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Table 3.10: Melting point and decomposition peaks in DSC traces for PCM13 and
PCM14






4HAPO154 140 - 145 -
The PXRD pattern matched well with the simulated pattern of 4HAPO generated
from the reported single crystal X-ray diffraction (SCXRD) structure (Figure 3-19).183
In conjunction with the DSC melting points obtained from the isolated crystalline
product, this confirmed the production of 4HAPO.
Figure 3-19: PXRD patterns for PCM14 vs simulated 4HAPO powder pattern from
the SCXRD structure183
Some minor issues remained, however. The yield obtained from the crystallisation was
relatively low and required a long induction time. Furthermore, close analysis of the
PXRD pattern suggests that NaAc may be a trace impurity in the isolated product.
Ideally, this should be reduced where possible, while raising the supersaturation level of
4HAPO. To achieve this, a better understanding of the solubility was needed to create
an optimised crystallisation procedure. Development of the crystallisation process is
described in Section 3.4.
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3.3.3 Beckmann Rearrangement of 4-Hydroxyacetophenone Oxime
While the production of PCM via direct one-pot amidation of 4HAP was not trans-
ferable to flow within the scope of this project, isolation of 4HAPO product within
the oximation flow process allowed the opportunity for the development of a second
step-wise flow method. Investigations thus moved towards subjecting the 4HAPO in-
termediate to a Beckmann rearrangement. While the two-step process does not benefit
from direct integration, partial translation into flow may still have beneficial produc-
tivity and efficiency advantages compared to batch and also represents a useful proof
of concept within the integrated CM research scope. Work carried out by Quartarone
et al. had previously shown that the Beckmann rearrangement of 4HAPO could be
realised using TFA as an organocatalyst.154 The reaction scheme is shown in Figure
3-20 and formed the start point for the current investigation.
Figure 3-20: Reaction scheme for the production of PCM using TFA
3.3.3.1 Experimental
The experimental set-up in the batch methodology is described in Section 2.4.3. The
experimental conditions for batch experiments are summarised in Table 3.11.
Table 3.11: Parameters for batch organocatalysed Beckmann rearrangements experi-
ments
Experiment 4HAPO TFA ACN Reaction Time
(mmol) (mmol) (mL) (min)
PCM15.1 1.3 13.1 10.8 120
PCM15.2 1.3 13.1 10.8 120
PCM15.3 1.3 13.1 10.8 120
Reaction conditions: 70 ◦C, 250 rpm
126
3.3.3.2 Results and Discussion
PCM15
PCM15 aimed to repeat the procedure carried out by Quatarone et al. and determine if
the reaction would be applicable in a flow system. In all PCM15 experiments, 4HAPO
readily dissolved in the TFA/ACN solution at 70 ◦C. The reaction was run for 2 hours
as described in the literature. NMR analysis in PCM15.2 indicated that the reactant
4HAPO was depleted within the two hour period (Figure 3-21) with the majority of
the reaction already proceeding within 1 hour. A high selectivity towards PCM was
achieved, though a small amount of what appeared to be 4HAP was detected (Appendix
Figure 9-7). The formation of ketones has been shown to be possible via hydrolysis of
the ketoxime.154 This may have been facilitated in the present case by trace amounts
of water in the solvent mixture. However, only a small amount of 4HAP is detected,
as such the formation of PCM is more favourable under the current conditions.
Figure 3-21: Conversion and selectivity to PCM using off-line NMR monitoring in
PCM15.2
Once the reaction had reached completion, the product was isolated by removal of
the solvent, leaving a viscous oil. Addition of ice cold diethyl ether, ethyl acetate or
water caused precipitation of a pink solid which was extracted. The crude product
was purified by recrystallisation using hot water. The results for the isolated yield
are shown in Table 3.12. As was the case with acetic acid experiments, the strongly
acidic environment favours the formation of a viscous oil during rotary evaporation.
However, precipitation of the solid can be induced by the addition of a small amount
of antisolvent and subsequent recrystallisation gave PCM as the desired product.
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Table 3.12: Isolated yield of the batch organocatalysed Beckmann rearrangements
experiments
Experiment Extraction Solvent Mass Yield
(Antisolvent) (g) (%)
PCM15.1 Diethyl Ether 0.054 27
PCM15.2 Water 0.081 40
PCM15.3 Ethyl Acetate 0.042 21
The isolated yield was variable, but this was due to experimental differences in work-up
and extraction. While the extraction method needed further improvement to increase
the isolated yield, the relatively fast and simple synthetic reaction showed high potential
for translation into a continuous environment. The isolated product was tested using
NMR and DSC. The peak positions and subsequent melting points of the product are
shown in Table 3.13. The results clearly indicated that the isolated product matched
well with the expected chemical shifts of PCM and the melting point also showed good
agreement with literature. Therefore, the extracted product showed a high selectivity
towards PCM, even if the isolated yield was lower than anticipated.
Table 3.13: Analysis of PCM15 after isolation
Experiment Chemical Shift (ppm) Melting Point
(◦C)
PCM15.1 (300 MHz, DMSO-d6) 1.97 (3 H, s), 6.62 - 6.71
(2 H, m), 7.28 - 7.38 (1 H, m), 9.14 (1 H, br, s),
9.65 (1 H, br, s)
168.8
PCM15.2 (300 MHz, DMSO-d6) 1.97 (3 H, s), 6.60 - 6.72
(2 H, m), 7.27 - 7.39 (2 H, m), 9.15 (1 H, br, s),
9.66 (1 H, br, s)
168.2
PCM15.3 (300 MHz, DMSO-d6) 1.97 (3 H, s), 6.66 (2 H,
d, J = 8.9 Hz), 7.33 (2 H, d, J = 8.9 Hz), 9.15
(1 H, br, s), 9.66 (1 H, br, s)
169.0
4HAPO154 (200 MHz, DMSO-d6) 2.09 (3 H, s), 6.73 - 6.78
(2 H, d), 7.45 - 7.49 (2 H, d), 9.60 (1 H, br, s),
10.84 (1 H, br, s)
140 - 145
PCM184 (400 MHz, DMSO-d6) 1.98 (3 H, s), 6.68 (2 H,
d, J = 8.8 Hz), 7.34 (2 H, d, J = 9.2 Hz), 9.14
(1 H, br, s), 9.65 (1 H, br, s)
170.2 - 170.6
See Appendix Figure 9-8 for the experimental spectra
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Platform Development
For flow chemistry experiments using TFA as an organocatalyst, the schematic diagram
of the reactor set-up is shown in Figure 3-22. The set-up used the Vapourtec R series
pump and heater modules (as described in Section 2.5) to control the flow rates and
reactor temperature respectively. The flow was transported from the feedstock to the
reactor using PTFE tubing (1 mm ID) and the streams were pre-mixed using a PEEK
T-piece (1 mm ID) at room temperature before entering the reactor. Pressure was
maintained using a BPR (4 to 7 bar). Two PEEK valves were installed either side of
the reactor in order to allow the system to be isolated while maintaining the pressure,
should a safety issue arise. The PTFE reactor (27 mL, 1 mm ID) was heated to 70 ◦C.
Regular aliquots were taken to monitor the reaction progress using NMR. The effluent
was collected in a round bottom flask and reduced under vacuum to isolate the product.
Figure 3-22: Set-up for the flow synthesis of paracetamol using 4HAPO and TFA
In terms of extraction, the process used in the batch system was refined further. In
this case, the formation of the viscous oil was avoided. The majority of the solvent
was reduced under vacuum to leave a small amount of pink oil. To the pink oil, a
small amount of ethyl acetate or water was added. Rotary evaporation of the sol-
vent/cosolvent mixture left a pink solid. The pink solid is extracted using ice cold
water and left to dry overnight; no further purification was required. The experimental












































































































































































































Translation of the batch methodology to a flow environment was relatively straight-
forward in this case. The concentration of 4HAPO in the feedstock was adjusted to
ensure that after mixing, the conditions in the coil reactor reflected those used in the
batch process. Despite the increased concentration of 4HAPO in the feedstock, the
solute remained in solution. The reaction was run over 2 to 3 hours. As the mass and
heat transfer in a coil reactor tends to be superior to batch vessels, the residence time
was reduced to 1 hour in PCM16.1 and 30 minutes in PCM16.2. As the reaction was
shown in literature to be sensitive to the TFA/substrate molar ratio, the flow rate and
therefore mixing ratio was kept the same.
The results from the NMR monitoring of PCM16.1 are shown in Figure 3-23. As can be
seen, despite the reduced reaction period, the process is still highly selective to PCM
with conversion that matches the batch procedure. The improved productivity and
reaction efficiency is not surprising, as the use of TFA in Beckmann rearrangements
has been demonstrated for the production of caprolactam from cyclohexanone oxime in
a microchemical flow system.185 For caprolactam, the reaction time was decreased from
100 min to 40 sec, though this does not necessarily translate to higher productivity due
to the difference in reactor scale.
Figure 3-23: Conversion and selectivity to PCM using off-line NMR monitoring in
PCM16.1
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For PCM16.2, the RT was decreased further to boost efficiency, however the reaction
does not go to completion (Figure 3-24). Instead, the conversion averages 83% over 4
RTs, though the selectivity towards PCM remains high.
Figure 3-24: Conversion and selectivity to PCM using off-line NMR monitoring in
PCM16.2
Based on these results, a 60 minute RT is effective under the current conditions, however
it is possible that a 30 minute RT could still be facilitated by adding a static mixer
reactor or by increasing reactor temperature. The latter however, may lead to thermal
decomposition under extreme conditions. While the batch process contained a small
amount of 4HAP and an unknown side product, the flow reactor appears to reduce this
complication. While traces of both impurities are still visible in the raw NMR spectra
above the baseline, both appear significantly reduced relative the PCM peak integral
(See Appendix Figure 9-9).
Analysis of the isolated product is shown in Table 3.15. The experimentally determined
melting point was similar to the values found in the batch experiments. The NMR peak
shift was also close to the value found in batch experiments and literature. The isolated
yield was also improved, the addition of a small amount of water and ethyl acetate to
the rotary evaporation process helped to avoid the formation of the viscous brown oil
previously encountered. Of note however, was the higher than anticipated isolated
yield of PCM16.2. This was unexpected as conversion was monitored as lower than
PCM16.1 while the product showed a similar purity after isolation. The likely cause
was that the reaction continued in the collection vessel, or during rotary evaporation.
In further work, this could be avoided by the addition of a quenching stream after the
reactor. Earlier work in this thesis during the one-pot amidation procedure, along with
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results shown by Zhang et al., indicate that water would be effective at preventing
further reactivity in the presence of TFA.186




Chemical Shift (ppm) Melting
Point (◦C)
PCM16.1 71 (300 MHz, DMSO-d6) 1.97 (3 H, s), 6.66
(2 H, d, J = 8.8 Hz), 7.33 (2 H, d, J =
9.0 Hz), 9.15 (1 H, br, s), 9.66 (1 H, br, s)
168.5
PCM16.2 83 (300 MHz, DMSO-d6) 1.97 (3 H, s), 6.66
(2 H, d, J = 8.9 Hz), 7.33 (2 H, d, J =
8.9 Hz), 9.15 (1 H, br, s), 9.66 (1 H, br, s)
169.2
Raw spectra in Appendix Figure 9-10
While the methodology discussed here is effective as a single flow synthesis reaction,
it is not well suited for integrated continuous crystallisation. In order to initiate crys-
tallisation, supersaturation must be induced. TFA is a strong acid and potentially
hazardous, thus it would make a poor crystallisation solvent medium. Currently, 9 mo-
lar equivalents are needed to facilitate the reaction. As well as safety concerns, addition
of TFA has the effect of diluting the reaction medium, which makes it more difficult to
induce crystallisation. Therefore TFA would likely need to be removed prior to crys-
tallisation. Ideally a solvent swap would be used, however current available methods
are limited in dealing with complex solvent mixtures such as ACN/TFA. However, the
work does show that the conversion from 4HAP to PCM can be achieved using a series
of stepwise, flow synthetic reactions with off-line workup.
3.4 Integrated Crystallisation of 4-Hydroxyacetophenone
Oxime
While the amidation procedure from 4HAP to produce PCM in the work presented
was unsuitable for integrated crystallisation investigations in its current state, during
the course of these studies, the oximation synthesis in ethanol/water solutions for pro-
duction of 4HAPO was identified as a possible alternative target. As has been demon-
strated in this work and literature, 4HAPO is useful intermediate in the preparation
of PCM. A fast and clean route has been designed to deliver 4HAPO in quantitative
yields using a flow synthesis platform. In this section, investigations aimed to optimise
the flow synthesis process for integration with a continuous crystallisation platform.
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3.4.1 Gravimetric Solubility Studies
In order to best determine the suitable conditions for crystallisation, a gravimetric
solubility study was carried out to measure the solubility of 4HAP and 4HAPO in
ethanol/water solvent mixtures. The experimental procedure is outlined in Section 2.3.
The solubility dependence of 4HAP and 4HAPO in different ethanol/water mixtures is
shown in Figure 3-25 and the average solubility for each composition is shown in Table
3.16.
Figure 3-25: Solubility curves for 4HAP and 4HAPO in ethanol/water solvent mixtures
at 20 ◦C
Table 3.16: Average solubility of 4HAPO and 4HAP in ethanol/water mixtures at 20 ◦C
EtOH 4HAP 4HAPO








From the results, 4HAP and 4HAPO both have low solubility in pure water. As
the amount of ethanol increases, the solubility of both components increases. The
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solubility of 4HAP reaches a maximum at 75 v/v% EtOH. The degree of change is
different between the two components; 4HAP is more strongly influenced by ethanol
(EtOH) than 4HAPO. The largest solubility difference is at 50% EtOH where 4HAP
is almost four times more soluble than 4HAPO. While this solvent ratio would be best
to eliminate any remaining organic impurities, the high overall solubility would result
in a significant loss of product to the liquor. Furthermore, the conversion of 4HAP
to 4HAPO is high in the flow synthetic process, so there is a low probability that
4HAP impurities will exceed the solubility threshold, providing the reaction reaches
completion.
The most ideal solvent ratios from the data for integration, would be 12.5 and 25 v/v%
EtOH. 25 v/v% shows a larger difference in the solubility ratio of 4HAP and 4HAPO,
while maintaining relatively low solubility at ambient conditions. This is also the set-
up that has been tested in the flow synthesis reaction successfully. Reducing EtOH
content to 12.5 v/v% would reduce the amount of product lost to the liquor, but may
promote precipitation of unreacted 4HAP or by-products. While pure water offers the
highest potential solid recovery, the synthetic reaction requires a degree of EtOH in the
feedstock to achieve dissolution of 4HAP at ambient temperatures.
The temperature dependent solubility of 4HAP and 4HAPO in 25% and 12.5% EtOH
is shown in Figure 3-26.
(a) 4HAP (b) 4HAPO
Figure 3-26: Temperature dependant solubility of a) 4HAP and b) 4HAPO in 25% and
12.5% ethanol/water solutions
From the data, the solubility of 4HAP and 4HAPO was found to be similar at 5 ◦C
in both EtOH compositions. However, as the temperature increases 4HAP becomes
more soluble than 4HAPO. The difference in solubility with temperature is larger for
25 v/v% EtOH solutions. For 4HAPO, both solvent compositions generated solubility
curves from the data with a good exponential fit. For 4HAP, the solubility curve
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generated was less accurate, particularly at high temperatures. This is due to the fact
that the supersaturated solution of 4HAP became biphasic at high saturations (due to
preferential dissolution in EtOH over water). This made it difficult to determine by eye
when saturation had been reached and led to higher variation in repeat measurements.
Another complication is that 4HAP forms a hydrate at high water content and low
temperatures. This leads to a switch in the most thermodynamically stable polymorph,
where form I is preferred above 29 ◦C and the hydrate form is more stable below 29 ◦C.
Literature has shown that form I and the hydrate have different solubilities. Hence form
I and the hydrate are enantiotropic and a change in the solubility curve is expected
above and below 29 ◦C.187 This could be corrected in Figure 3-26 by taking more
solubility measurements above and below the transition temperature. However, it was
deemed unnecessary for this work, as the important aspect was to ensure the solubility
of 4HAP was low in relation to 4HAPO.
What is established clearly from the data is that a change in the solubility behaviour
will occur after conversion of 4HAP to 4HAPO. Therefore, the system can optimised to
be undersaturated with respect to 4HAP but supersaturated with respect to 4HAPO.
Hence, it was potentially possible to crystallise directly from the reaction effluent. The
work therefore, concentrated on developing a reaction procedure and cooling crystalli-
sation process that would work within this framework.
3.4.2 Platform Development
Having established parameters within which to conduct continuous crystallisation ex-
periments, the next aspect was to establish a suitable crystalliser. A number of condi-
tions needed to be met for successful integration:
1. The synthesis and crystalliser needed to be similar in scale;
2. The flow rates between synthesis and crystallisation needed to be complementary;
3. The system needed to be safe and easy to operate;
4. The platform design needed to be versatile and modular for optimisation.
Based on these criteria, the kinetically regulated automated input crystalliser (KRAIC)
described in Section 2.7.1 would meet most of the essentials. However, concern regard-
ing safety prevented integration. The KRAIC is a large platform and requires significant
lab space. The flow chemical reaction uses HOA, which is a suspected carcinogenic and
while the current flow synthetic process reduced potential contact, precautions needed
to be taken to ensure that the effluent from the crystallisation was safely housed in
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a fume cabinet after exiting the reactor. To overcome this shortcoming, a compact
miniature KRAIC, known as the mini-KRAIC (m-KRAIC) was built (Figure 3-27).
The m-KRAIC uses the same concepts as the KRAIC and is a segmented flow crys-
talliser. In order to save space however, the main body of the KRAIC consisting of
a 15 m fluorinated ethylene propylene (FEP) tubular coil (3.2 mm ID), is compacted
onto a single custom size DrySyn basin.
(a) m-KRAIC set-up (b) m-KRAIC coiled reactor
Figure 3-27: Photographs of the m-KRAIC
For comparison, the volume and length of the KRAIC is 121 mL and 150 cm respec-
tively. The m-KRAIC has a volume of 115 mL and length of 143 cm. The compact
design of the m-KRAIC could have a minor effect on the mixing regime within the
reactor but it will not change the overall plug flow regime and therefore is not detri-
mental to the crystallisation process. The design is as versatile and modular as the
KRAIC and so the crystalliser can be adjusted to the system. The m-KRAIC will
also be easier to transport for off-site experiments and can fit into a conventional fume
cabinet, which allows crystallisation experiments to be safely run where solvent vapour
is a concern. For the purposes of this work, the more compact design meant that the
additional space could be used to accommodate the synthetic reaction, allowing inte-
gration experiments to be tested within a smaller space, emphasising the potential for
reducing future plant footprint.
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3.4.3 Experimental
A schematic of the integrated, flow synthesis and m-KRAIC platform set-up is shown
in Figure 3-28 and a photograph is shown in Figure 3-29. In decoupled runs, the flow
synthesis output was collected in a round bottom flask and allowed to crystallise at
room temperature unless otherwise stated.
Figure 3-28: Schematic diagram of the integrated synthesis and crystallisation process
for 4HAPO production.
Figure 3-29: Photograph of the integrated synthesis and crystallisation process for
4HAPO production
Synthesis
The synthetic reaction was carried out in a 27 mL reactor coil consisting of PFA tubing
(1 mm ID) housed in a glass reactor and equipped with a temperature probe. The coil
is attached to an R-series heater unit which controls and monitors the temperature.
Pumping of the reagent streams was facilitated by the Vapourtec R-series pump module
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and heating the synthesis reactor was facilitated by the Vapourtec R-series heater
unit. A BPR (2 to 4 bar) was used to maintain pressure in the reactor. The outlet
from the flow synthesis was transported to the segmentation point using temperature-
controlled jacketed tubing which was actively heated to avoid crystallisation before
segmentation. In later experiments where supersaturation was particularly high, the
BPR and feed-lines 1 and 2 were actively heated to avoid precipitation. The BPR was
heated using a glass column with a temperature probe attached to the R-series heater
unit. Temperature of the jacketed tubing was controlled using a Grant R3 TX150
circulator unit.
In investigations for decoupled synthetic reactions, the segmented flow crystalliser was
not used and the effluent from the reactor was transported using jacketed tubing 3 (J3)
to a round bottom flask stirred at 500 rpm.
Steady state operation was verified as follows. A 1.0 mmol dm−3 concentration of Eosin
Y dye was prepared in EtOH. The Eosin Y solution was run at 0.45 mL min−1 in
Feed 1 into the reactor and a corresponding feed of pure EtOH (Feed 2) was run at
1.35 mL min−1. Aliquots from the reactor were taken at regular intervals and the ab-
sorption of the sample was recorded at a fixed wavelength of 478 nm using a Jenway
bench-top Spectrometer. The same cuvette with a 1 cm length was used for all mea-
surements and the absorption was calibrated against a reference containing pure EtOH.
The cuvette was cleaned with EtOH and dried before the next measurement. The con-
centration was determined from the absorption using the Beer-Lambert law (Equation
2.1) and the corresponding values were then used to construct a concentration vs time
plot to determine steady state in the flow reaction. The results from this calibration are
assumed to be analogous with the flow synthetic reactions using the same flow rates.
Segmentation
Segmentation is achieved by introducing an immiscible fluid (i.e. a carrier fluid) and
air to the feed line using a glass cross piece (3.2 mm ID). The air and carrier fluid
were supplied using Ismatec (Reglo-Z series) gear pumps. The cross piece was kept
submerged under a water bath which was actively heated. The carrier fluid used is a
liquid perfluoropolyether (PFPE), known commercially as Galden SV110.
Crystallisation
Crystallisation was facilitated by the m-KRAIC. The temperature of the coil was not
actively controlled and is left at room temperature. In some runs, an additional active
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cooling step was added. This consisted of a 1.2 m (3.2 mm ID) section of FEP tubing
jacketed with silicone tubing (J4). This cooling step was controlled using a designated
circulatory bath. The cooling step was installed after segmentation but before the m-
KRAIC coil. A zero volume FEP union was used to connect the jacketed tubing to the
main crystalliser. Galden recovery, as well as filtration of the crystalline product, was
achieved using an end-piece as described in Section 2.7.1.
The experimental parameters for synthesis and crystallisation of experiments in 25 v/v%
EtOH are shown in Table 3.17 and 3.18 respectively. The experimental parameters for

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.4.4 Results and Discussion
25 v/v% EtOH
The isolated yield and residence times for flow synthesis and crystallisation experiments
in 25 v/v% EtOH are shown in Table 3.21.
Table 3.21: Residence times and isolated yield for 4HAPO continuous synthesis and
crystallisation for 25 v/v% EtOH









HAPO1 57:00 11.4 n/a 39:40 55:50
HAPO2 60:00 15.1 01:30 20:40 38:20
HAPO3 71:00 16.7 01:30 20:40 38:20
a: Including synthesis and transfer stage (RT = 16:10 min)
As can be seen from the results, the isolated yield was relatively low. Even with the
addition of a cooling step only a small increase was observed in the crystallisation yield.
The concentration was also increased in HAPO3 with no major improvement in the
isolated yield. The reason that no major change was observed was that the majority
of crystallisation only occurred on contact with the filter paper. No crystallisation was
visible to the naked eye within the m-KRAIC during the operation period. The relative
supersaturation for HAPO1-3 at two key points are shown in Table 3.22.
Table 3.22: Relative supersaturation in 25 v/v% EtOH
Experiment Cooling Step m-KRAIC Outlet
Set Tempera-
ture
Rel. Supersat. Temperaturea Rel. Supersat.
HAPO1 n/a - 23.9 0.86
HAPO2 5 4.6 23.2 0.9
HAPO3 5 8.6 23.0 2.2
a: Measured using an external temperature probe at the m-KRAIC outlet. The relative
supersaturation was calculated, using Equation 1.5. The equation from Figure 3-26 b) was used to
calculate equilibrium solubility
As can be seen from the Table 3.22, all runs showed a degree of supersaturation in
the system. However, as no visible crystallisation occurred within the m-KRAIC it is
possible that the system remained within the metastable region throughout. As the
m-KRAIC uses a segmented flow environment analogous to the KRAIC, the slugs are
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suspended away from the walls of the tubing due to a capillary effect.131 As such, het-
erogeneous nucleation via the crystalliser walls is removed. This environment favours
primary homogeneous nucleation. This may have had a knock-on effect of extend-
ing the induction time compared to the batch process. As the filter paper acts as a
surface, this lowers the energy barrier to crystallisation and hence induces nucleation.
One method that would help in better crystallisation process design would be to use
turbidity experiments to find an approximate metastable zone width (MZW). How-
ever, the MZW is dependent on both cooling rate and the crystalliser environment.
Therefore, batch tests may not inherently reflect the m-KRAIC vessel, while internal
measurements are difficult in the m-KRAIC due to equipment limitations. If it became
possible to measure the MZW routinely in flow crystallisers such as the KRAIC, then
this could help in the adoption of continuous crystallisation technology.
Another issue was that the flow rates from the air and carrier fluid were not always
consistent; this was particularly the case for HAPO1. This was rectified by removal
and cleaning of the pumps but RT could not be predicted from the combined set flow
rates values, so the RT was measured experimentally. The pumping in the synthetic
reaction feed was tested and found to be consistent. As a result only the downstream
processing was affected. The reaction was monitored using offline NMR, carried out
by taking aliquots from the m-KRAIC outlet. The reaction was tracked before, during
and after the collection period, by observing the aromatic peak region between 6 to
10 ppm. The results for HAPO3 are shown in Figure 3-30.
Figure 3-30: NMR spectra between 6 and 10 ppm at different time stamps during
HAPO3
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As the results show, the lack of peaks at 7.8 ppm and 6.8 ppm between 40 to 100 minutes
indicates that 4HAP has converted to 4HAPO. The conversion is similar to the results
observed the uncoupled flow synthesis processes. The resurgence of the 4HAP peak
at 115 min occurs during the shutdown period, at which point the feed lines had been
switched to pure solvent. HAPO1 and HAPO2 showed the same spectra trends to
HAPO3 (See Appendix Figures 9-11 and 9-12).
Samples were taken from the isolated product and subjected to DSC. Traces from each
run (HAPO1 to HAPO3) are shown in Figure 3-31, the corresponding values for the
melting peak and exothermic peak are given in Table 3.23.
Figure 3-31: Comparison of DSC traces for HAPO1, HAPO2 and HAPO3, note that
values are offset in the Y-direction for clarity
Table 3.23: Melting point and decomposition peaks in DSC traces for HAPO1 to
HAPO3





As can be seen from the traces, there is a good overlap between the melting points, but
the exothermic peak corresponding to decomposition of 4HAPO is more variable. This
is reflected in the values in Table 3.23. Nonetheless, DSC results match those from flow
synthesis experiments in Section 3.3.1. This confirms that the addition of a continuous
crystallisation platform and filtration step have not affected product stability.
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Samples from HAPO1 to HAPO3 were also subjected to PXRD analysis and the diffrac-
tion patterns are shown in Figure 3-32. These are compared to a simulated pattern
derived from the SCXRD structure of 4HAPO.183
Figure 3-32: Comparison of PXRD patterns for HAPO1 to HAPO3 with the simulated
pattern reported from SCXRD
A quick comparison reveals that the patterns show a good match with the simulated
pattern, which confirms the presence of the known 4HAPO crystal form. As 4HAPO
only has one reported polymorph, no other forms are expected to be isolated during
crystallisation. Some differences in relative peak heights are observed, but this is likely
a consequence of preferred orientation.
While the coupling of the compact m-KRAIC and flow synthetic method was effective
in producing a small, self-contained integrated reactor space, issues remained with crys-
tallisation. Previous work in direct batch crystallisation from flow synthesis had shown
that crystallisation occurred within 30 minutes, but in the m-KRAIC process, no visible
crystallisation occurred in-line during operation. Supersaturation appeared insufficient
to induce primary nucleation as crystallisation mostly occurred during filtration. This
in turn led to clogging of the filter which needed frequent changing. To induce crys-
tallisation, the supersaturation level needed to be raised. As already noted during
gravimetric measurements, reducing EtOH composition will increase supersaturation
in the crystalliser. This would provide a simple method to increase supersaturation
without changing the process equipment or flow rates.
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12.5 v/v% EtOH
To ensure 4HAP and 4HAPO remained in solution during flow synthesis in 12.5 v/v%
EtOH, the uncoupled 4HAPO reaction was tested. The synthesis was carried out as
described in the experimental, Section 3.4.3, however the effluent from the reactor was
decoupled from the segmentation bath and collected in a round bottom flask. The
parameters for the synthesis-only (HAPO4) and all coupled flow experiments (HAPO5
to HAPO7) are outlined in Table 3.19 and 3.20.
HAPO4
In first attempts at running the reaction at the reduced EtOH composition, blockages
occurred in the set-up. This was generally around the BPR, T-piece and reactor outlet.
To mitigate this the glass column (pictured in Figure 3-28 in the experimental) was
added and the BPR was actively heated to 65 ◦C. Up to this point, the BPR had not
needed to be actively heated. The T-piece could not be actively heated, but the distance
from the jacketed feed lines, T-piece and reactor were adjusted so as to minimise the
portion of tubing without an active heat source. The reaction proceeded well after these
changes and the resulting effluent crystallised at room temperature during collection.
The samples were left overnight to crystallise and the isolated yield was 56.5% from a
75 minute collection period. NMR monitoring was carried out under the new conditions
to determine if solvent composition affected the reaction rate. The peaks between 6 to
10 ppm were tracked and the results are shown in Figure 3-33.
Figure 3-33: NMR spectra between 6 and 10 ppm at different time stamps during
HAPO4
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As can be seen, 4HAP was converted to 4HAPO readily and any residual peaks are
below the baseline. 4HAPO is the major product, but a secondary peak is noted to
overlap with the 4HAPO aromatic proton peaks. These shoulder peaks are most visible
at 64 min. However, they are not seen in the isolated product, indicating they are likely
the solution based-intermediate previously observed.
HAPO5 to HAPO7
After verifying that the synthetic reaction rate was unaffected by the reduced EtOH
content, experiments HAPO5 to HAPO7 were reconnected to the segmented crys-
talliser. HAPO5 was run without the cooling step and HAPO6 and HAPO7 were run
with the additional active cooling step. The isolated yield and residence times for cou-
pled flow synthesis and crystallisation experiments are shown in Table 3.24, HAPO4
has been included for comparison.
Table 3.24: Residence times and isolated yield for 4HAPO continuous synthesis and
crystallisation in 12.5 v/v% EtOH
Experiment Yield (%) Residence Time (min)
Cooling Step m-KRAIC Totala
HAPO4 56.5 n/a n/a 16:10
HAPO5 61.6 n/a 23:30 39:40
HAPO6 Blocked 01:50 25:00 43:00
HAPO7 Blocked 01:20 15:40 33:10
a: Including synthesis and transfer stage (RT = 16:10 min)
In HAPO5 no blockages occurred during the run, however no visible (by eye) crys-
tallisation occurred within m-KRAIC during the run. Crystallisation did occur readily
around the m-KRAIC end-piece and on the filter paper. The crystallised product was
collected and left to dry before weighing. The yield was 61.6%. The result does indicate
that while no visible crystal growth is occurring within the m-KRAIC, work-up of the
extracted product will result in similar solid recovery to batch crystallisation. To try
to induce nucleation, the cooling step was added for HAPO6 and HAPO7 to increase
supersaturation. In HAPO6 the cooling step was run at 5 ◦C initially but the system
blocked within 30 minutes. After resetting, the cooling step was raised to 20 ◦C, but no
crystallisation occurred after 28 minutes. The cooling step was then dropped to 15 ◦C
but a major blockage formed at 40 minutes, 10 minutes after lowering the cooling step.
As a result of the blockages in the m-KRAIC, the system had to be shutdown and reset
without accurate yield collection.
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In HAPO7 the cooling step was set to 10 ◦C. The air and carrier fluid pumps were also
increased by one increment (equivalent to an increase of 2.1 mL min−1). The additional
velocity to the net flow during crystallisation was intended to reduce blockage formation
and help better suspend any crystals in the slugs. A cooling step of 10 ◦C was used as
a median between 20 ◦C which did promote nucleation and 5 ◦C which blocked readily.
Despite these changes, the system blocked 40 minutes into operation.
The relative supersaturation of 4HAPO at the m-KRAIC outlet and during the cooling
step in 12.5 v/v% EtOH is shown in Table 3.25.
Table 3.25: Relative supersaturation in 12.5 v/v% EtOH






HAPO5 n/a - 26.0 6.0
HAPO6 5/20/15 19.1/8.4/11.1 23.2 7.0
HAPO7 10 14.6 24.5 6.5
a: Measured using an external temperature probe at the m-KRAIC outlet. The relative
supersaturation (σ) was calculated using Equation 1.5. The equation from Figure 3-26 b) was used to
calculate equilibrium solubility
As can be seen, the relative supersaturation is much higher than compared with HAPO1
to HAPO3. As a result, the driving force towards nucleation is much higher. Im-
portantly the higher supersaturation is maintained at ambient temperatures. This is
confirmed by looking at the temperature profiles for HAPO5 and HAPO6 (at 5 ◦C) as
shown in Figure 3-34.
(a) No active cooling step (b) Active cooling to 5 ◦C
Figure 3-34: Temperature profiles for a) HAPO5 with no cooling step and b) HAPO6
at 5 ◦C cooling step, as measured using an external temperature probe
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As the feed proceeds into the m-KRAIC there is rapid heat loss after the water bath.
In the case of HAPO6, the temperature decreases below room temperature for a short
period during the cooling step before stabilising. Each data point of the m-KRAIC
represents a different coil. The feed rapidly reaches ambient conditions in both HAPO5
and HAPO6 and this is maintained throughout the 20 to 25 min RT of the m-KRAIC.
In combination with the examples given in Table 3.25, it is safe to assume that the
supersaturation level is high and relatively constant in the m-KRAIC. However this
did not lead to spontaneous nucleation, as a consequence of the wide MZW.
While the additional cooling in HAPO6 and HAPO7 may have caused some crystalli-
sation, the major cause for blockages occurred around the join between the cooling
step and the m-KRAIC. Despite attempts to form a flush connection, observed crystals
appeared to snag on the join. This then became a point for secondary nucleation that
caused rapid growth. In future, a more effective design may be to directly attach the
cooling stage to the m-KRAIC tubing, thereby removing the uneven surface and avoid
uncontrolled nucleation.
Analysis of the solid form of HAPO4 and HAPO5 using DSC and PXRD is shown in
Figure 3-35. HAPO6 and HAPO7 could not be analysed as the blockages were not
recovered.
(a) (b)
Figure 3-35: Analysis of HAPO4 and HAPO5 a) DSC traces and b) PXRD patterns
with simulated PXRD pattern of 4HAPO for comparison.
As was the case with HAPO1 to HAPO3, the solid form matches the expected PXRD
pattern for 4HAPO. The DSC trace also shows the typical melting point between 140 ◦C
and 145 ◦C followed by a decomposition peak. No major changes were observed in the
polymorphic behaviour of the product extracted from the m-KRAIC compared to the
batch crystallisation in HAPO4.
In summary, cooling crystallisation in the m-KRAIC for 4HAPO was not particularly
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effective. The set-up in itself showed high versatility within a compact plant space,
allowed control over the cooling profile, synthetic flow rate, crystallisation net flow and
demonstrated direct coupling between flow platforms, but the cooling crystallisation
did not initiate nucleation in a controlled manner. The apparent wide MZW of 4-
HAPO in the m-KRAIC along with high solid loading (when nucleation did occur)
within the tubular environment led to major blockages in the system. The system
could be potentially optimised further by introduction of an antisolvent or seeding step
for example, to drive controlled nucleation but this does add another layer of complexity
to the process.
For instance, in seed addition, the delivery system would need to be carefully controlled
to ensure that the same quantity of seeds were delivered to each slug to ensure controlled
crystal growth. In the case of the antisolvent, increasing water content has been shown
to decrease the solubility of 4HAPO and 4HAP ethanol:water mixtures. The effect of
adding water on the solubility would be most pronounced in 50 v/v% ethanol or higher
compositions. While this could be readily taken advantage of in a single, continuous
crystallisation process, coupling with flow synthesis meant that HOA and NaAc were
also present in the effluent. The coupled process needs to ensure that these reactants
do not crash out of solution, which becomes more likely as the EtOH composition
increases. This highlights the major difficulty of integration in this work, whereby the
overall process needs to balance the requirements of both the synthetic reaction and
crystallisation step without compromising the other.
HAPO8
While a high solid loading can be prone to blockages in the KRAIC and m-KRAIC.
Alternative approaches may be more suitable. For example, CSTRs in series tend to
be capable of handling high solid loadings. As a proof of concept, the reaction was
repeated as described in HAPO4, where J3 was disconnected from the m-KRAIC and
the effluent transferred to a round bottom flask. The reaction was run for a total of nine
RTs to show that the system could be operated over a prolonged period. Collection was
carried out during start-up, steady state and shutdown periods which were determined
by UV-Vis measurements as described in the experimental Section 3.4.3 and the results
are shown in Figure 3-36.
Based on Figure 3-36, the reaction reaches steady state by the second RT; this was used
to infer when steady state was reached in HAPO8. During the HAPO8 run, no initial
crystallisation occurred during the start-up procedure, but crystal growth did occur
upon cooling to ambient temperatures. Once the system had reached steady state,
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Figure 3-36: Change in concentration of the dye Eosin Y in the flow reactor during
steady state measurements
collection was switched to a separate flask where immediate crystallisation occurred
without the need for temperature control. Some encrustation formed over time at the
tubing outlet, but this did not impede the flow over the three hour operation period.
The collection was then switched to another flask during shutdown. The crystalline
product was isolated after stirring under ambient conditions for three to four hours.
The solid recovery is summarised in Table 3.26.




(h:min:sec) (%) (g h−1)
Start-up 00:16:00 1 46.0 7.05
Steady State 01:52:00 7 62.3 9.54
Shutdown 00:32:00 2 42.4 6.49
Overall 02:40:00 10 57.7 8.68
The average solid recovery is slightly lower than HAPO4, but a higher solid recovery
is achieved at steady state. HAPO4 has an overall higher yield as the system had
more time to crystallise. The differnce in overall recovery suggests the recovery could
be improved by using a temperature controlled holding vessel. The productivity of
the synthetic reaction was found to be 8.68 g h−1, but this excludes the time taken
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for the crystallisation period. Even so, this would potentially be an improvement over
the batch process since once the system reaches steady state, crystallisation readily
occurs. Ideally, the collection vial could be replaced with a CSTR system. In this
case, a temperature control profile could be applied to a series of vessels to induce
nucleation and control crystal growth. However, the scale and number of vessels would
be important as the net flow rate of the CSTRs would be dependent on the flow rate
of the synthesis, unlike the m-KRAIC set-up in which air/carrier fluid can be used to
adjust the crystalliser net flow without impacting the upstream synthesis. A pseudo-
continuous CSTR system may be the most beneficial in this case. Although other issues
could arise such as the build-up of impurities or encrustation in the CSTR vessels.
In terms of solid analysis, the NMR, PXRD and DSC of all three samples were remi-
niscent of previous runs and matched well the expected physical properties of 4HAPO
(Figures in Appendix 9-13, 9-14 and 9-15 respectively). Hot stage microscopy (HSM)
was also carried at 5 ◦C min−1 from 32 to 175 ◦C. The results are shown in Figure 3-37.
Figure 3-37: HSM images of HAPO8 at a) 32 ◦C b) 142 ◦C c) 145 ◦C and d) 175 ◦C
As can be seen, no changes are observed in the product until the melting point at 142
to 145 ◦C. This is followed by a darkening of the solution as 4HAPO decomposes up to
175 ◦C. The trend matches what has been observed in the DSC traces up to this point.
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3.5 Chapter Conclusions
In this research, attempts were made to transfer the synthesis of paracetamol (PCM)
from 4-hydroxyacetophenone (4HAP) into a integrated continuous synthesis and crys-
tallisation process. In pursuit of this, a one-pot synthetic method was replicated in
batch and investigated for transfer into a flow environment. Direct transfer was prob-
lematic as issues were encountered by the inability of traditional small-scale tubular
reactors and pumps to handle solid suspensions of the reactant hydroxylamine hy-
drochloride (HOA). Attempts to fully dissolve the starting reagents in a mixture of
ACN and water showed minimal success, as the addition of water generally stopped
the reaction at the intermediate 4-hydroxyacetophenone oxime (4HAPO) or slowed
the reaction progress significantly. To overcome this, a different approach was used
involving packing excess HOA in an adjustable column. The attractiveness of this
process was the high selectivity to the desired product, fast reaction time and the
mild reaction conditions. However, issues occurred with precipitation and clogging.
The best results were obtained using low flow rates, where PCM was produced as the
major product within a 10 minute residence time (RT). However, the hydroxylamine
hydrochloride reactant proved problematic, often leaching into the reaction stream and
causing blockages. While further development might optimise the process to combat
this, integration with downstream crystallisation technology appeared difficult without
in-line work-up of the product, which would add complexities to the process procedure
that ideally, could be avoided.
Instead, the reaction was separated into distinct steps; oximation of 4HAP to 4HAPO
and a subsequent Beckmann rearrangement of 4HAPO to PCM. Oximation of 4HAP
was successfully implemented in a tubular flow reactor using acetic acid and aqueous
hydroxylamine. However, the reaction required neutralisation and liquid-liquid sepa-
ration to extract the product, which interrupted the continuous framework. This flow
reaction was later replaced with a simpler process using hydroxylamine hydrochloride
and sodium acetate (NaAc) which had previously been demonstrated in batch. While
both methods produced high conversion and selectivity to the 4-hydroxyacetophenone
oxime intermediate, the second approach showed potential for integration, as the prod-
uct could be crystallised directly from the reactor output.
In striving to achieve production of PCM from 4HAP, this work has also demonstrated
that the Beckmann rearrangement of 4HAPO isolated from the oximation flow process
could be redissolved in ACN and combined with the homogeneous organocatalyst triflu-
oroacetic acid (TFA) in flow to produce PCM with high selectivity. While the product
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required offline work-up for isolation, the reaction showed a higher productivity and
purity than the batch process due to the improved heat transfer and avoidance of ther-
mal decomposition. In effect, a possible route to PCM from 4HAP has been developed
which translates the important chemical steps into a continuous environment. This
could be potentially integrated to form a telescoped continuous method with sufficient
development of in situ separation and extraction technologies.
In order to demonstrate an integrated flwo chemistry and crystallisation continuous
process, the synthesis and crystallisation of 4HAPO was taken forward as an alterna-
tive candidate. Here, a batch method for the production of 4HAPO was successfully
transferred to a flow synthesis platform. Furthermore, a crystallisation profile was de-
signed from the solubility of 4HAPO in ethanol/water mixtures. From this data, a
continuous crystallisation process was investigated in a compact KRAIC design. The
m-KRAIC used less reactor space than the KRAIC but displayed a similar reactor vol-
ume; allowing easier integration between the crystallisation and synthetic procedures.
The m-KRAIC allows for safe operation and crystallisation using potentially hazardous
materials or solvents. A cooling crystallisation profile was tested in 4HAPO produc-
tion with partial success. In particular, 4HAPO showed a large MZW which resulted
in little in situ crystallisation during the cooling crystallisation, but nucleation readily
occurred during filtration. While beyond the scope of this work, an alternative route
would be to introduce seeds to the system. If the seeding dosage in each slug could be
regulated within the cooling profile, this could lead to the desired controlled nucleation.
While a purely cooling crystallisation process could not be demonstrated for 4HAPO
in the m-KRAIC, a semi-batch model did indicate that coupling the flow process with
a series of CSTRs could be demonstrated as successful integration of flow synthesis
and crystallisation for 4HAPO. The direct crystallisation of high purity 4HAPO from
the flow synthetic oximation of 4HAP opens the door to continuous crystallisation. A
CSTR system would allow design of a cooling profile that could initiate nucleation and
increase solid recovery. CSTRs are generally better at handling the high solid loading
encountered during crystallisation of 4HAPO and could be particularly effective for
integration between the flow synthesis step and continuous crystallisation process in
this case. While the m-KRAIC may not be effective for crystallisation of 4HAPO
under the current conditions, it has potential applications as a compact, segmented
flow crystalliser that can be used in conjunction with other flow technologies to deliver
small scale integrated processes on a lab scale. It could therefore be considered for wider
applications in pursuing other pharmaceutical products or chemical commodities that







The work presented in this chapter has been published as a communication in Reaction
Chemistry and Engineering under the heading:
‘Integrated plug flow synthesis and crystallisation of pyrazinamide’ C. Daniel Scott,
Ricardo Labes, Martin Depardieu, Claudio Battilocchio, Matthew G. Davidson, Steven
V. Ley, Chick C. Wilson and Karen Robertson, React. Chem. Eng. 3, 631-634, 2018.
Flow chemistry and continuous crystallisation techniques offer high levels of control
over the resultant products and opens opportunities for leaner and more sustainable
manufacturing. However, integration of the the two techniques is relatively novel. Most
examples of integrated continuous manufacturing use continuous stirred tank reactors
(CSTRs) to achieve the desired crystallisation.27 Examples of integrated tubular crys-
tallisation processes are uncommon.
The work in this chapter outlines the development of an integrated, telescoped synthesis
and crystallisation process to deliver the pharmaceutical drug pyrazinamide (PZA).
The approach involved the direct coupling of the flow synthesis method developed
by the Steven Ley group (University of Cambridge) with the kinetically regulated
automated input crystalliser (KRAIC) platform at the University of Bath.131 The work
formed a collaborative project between researchers at the University of Bath and the
University of Cambridge. Support for the project on the synthetic reaction procedure
was provided by Dr. Ricardo Labes (Cambridge) and crystallisation experiments were
carried out with the help of Dr. Karen Robertson (Bath). Mastersizer particle size
analysis was carried out with the help of Dr. Martin Depardieu (Bath). In this chapter,
the development of the process along with analysis of the resultant product is described.
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4.2 Background and Aims
Previous work carried out by Battilocchio et al. had shown that an effective method
for the synthetic production of pyrazinamide could be achieved through hydration of
pyrazinecarbonitrile (PyCN).188 Pyrazinamide is an attractive target material as the
relatively simple molecule is a common pharmaceutical drug used in the treatment of
tuberculosis and is recognised as an essential medicine by the World Health Organisa-
tion (WHO).189 The reaction proceeds quantitatively in the presence of a manganese
(IV) dioxide (MnO2) catalyst when heated to 80
◦C. While MnO2 is a cheap, reliable
catalyst for hydration of nitriles, it can be difficult to use in batch.190,191 The heteroge-
neous catalyst tends to adhere to surfaces and can become clumped together, reducing
reaction efficiency and making the resulting product difficult to work-up and separate
from the catalyst. However in a flow environment, the catalyst can be packed into a
column. Here, the reactants can be pumped through the column to perform the reac-
tion. This inherently separates the catalyst from the products as the effluent leaves the
reactor column and therefore avoids a complex work-up and separation process (Figure
4-1).
Figure 4-1: Hydration of PyCN under catalytic conditions
This reaction is attractive for the development of a flow synthetic method due to its
mild reaction conditions and high atom efficiency, leading selectively to the desired
product with few impurities. In order to determine if the synthesis of PZA would
be applicable for integrated flow synthesis and crystallisation, preliminary work was
undertaken to reproduce the results achieved by Battilocchio et al. Reproduction of
the flow synthetic method would allow for evaluation of the crystallisation process and
suitability of PZA flow synthesis for coupling with continuous crystallisation.
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4.3 Investigation into the Flow Synthesis of Pyrazinamide
4.3.1 Experimental
Flow synthesis experiments were carried out using the Vapourtec modular flow reactor
equipped with a R2+ pump module and R4 flow heater system. For a full description
of the Vapourtec unit see Section 2.5. An adjustable omnitfit column (100 mm, 6.6 mm
inner diameter (ID)) of variable volume (0.1 to 2.4 mL) was attached to the heater
unit and packed with between 0.7 g and 1 g of MnO2 powder, mixed with 0.2 g of celite
to prevent the build-up of back pressure. Each end of the column was capped with
a small amount of celite to help prevent MnO2 powder from exiting the column. A
12 bar back pressure regulator (BPR) was connected to the outlet of the omnifit column.
Fluorinated ethylene propylene (FEP) tubing (1.0 mm ID) was used to connect the feed
solution to the pump, the pump to the inlet of the reactor column and the outlet of
the column to the BPR. Wider bore FEP tubing (1.50 mm ID) was used to connect
the outlet of the BPR to the collection vessel. The column was heated to 80 ◦C under
12 bar pressure (Figure 4-2).
Figure 4-2: Schematic diagram of the uncoupled flow synthesis process
A feed solution of PyCN was prepared to a concentration of 0.28 mol dm−3 in water.
The reactor column was equilibrated and primed with H2O at 1 mL min
−1 for 10 min-
utes before being switched to the feed solution. A 20 mL aliquot was collected for each
PZA1 experiment, over a total collection period of sixty minutes. After collection, the
resultant solution was evaporated on a rotary evaporator, leaving a white, crystalline
solid. The solid was extracted using diethyl ether and allowed to dry before determin-
ing the synthetic yield. Collection was performed in triplicate and the average yield
was calculated from the individual solid recoveries.
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For comparison, nuclear magnetic resonance (NMR) spectroscopy measurements were
taken of the starting material and the product on a Bruker Avance 300 MHz spectrom-
eter and the resultant spectra were compared to known chemical shift values of PyCN
and PZA from literature. Evaluation of the solid form was carried out using differential
scanning calorimetry (DSC) and powder X-ray diffraction (PXRD) and comparisons
were made with literature values.
4.3.2 Results and Discussion
PZA1
Using the experimental set-up in Figure 4-2, the production of PZA from PyCN in
flow was successfully replicated in PZA1. The approximate residence time from inlet
to outlet of the reactor was experimentally derived as 4 minutes. In Table 4.1 the
isolated yields for the hydration of PZA are summarised.
Table 4.1: Flow synthesis of Pyrazinamide
Experiment Flow Rate Residence
Time
Run Time Isolated Yield
(mL min−1) (min) (min) (%)
PZA1.1 1.00 2 20 81.5
PZA1.2 1.00 2 20 63.1
PZA1.3 1.00 2 20 64.7
Average 1.00 2 60 69.8 ± 10.2
In the synthesis-only run (PZA1), PZA was found to be isolated in an average yield of
69.8 % over the total collection period of 60 minutes. While the values for the isolated
yield were lower than anticipated, for the purposes of coupling the synthetic reaction
with the continuous crystallisation these values were deemed sufficient. This was be-
cause PZA remained in solution at reaction temperature (80 ◦C), but was observed
to begin to crystallise at room temperature. This was important, as a prerequisite
to translation into the flow crystalliser under consideration for integration, was that
the feedstock needed to be supersaturated at ambient temperatures. The spontaneous
growth observed of crystals in the collection flask was a good indicator that this is the
case and that cooling crystallisation may be a suitable approach for initiating precipi-
tation.
Proton NMR analysis was carried out on the product of PZA1, to identify PZA and
determine if any unreacted PyCN was present. The chemical shifts detected are out-
lined in Table 4.2, along with values taken from literature. There is only a small change
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in the NMR spectra between the two compounds PyCN and PZA. However, the clear
growth of two additional peaks at 7.89 ppm and 8.29 ppm indicates the formation of
the amide. There is also a slight down-field shift of the aromatic protons compared
to PyCN. The combination of these two factors confirms the conversion of PyCN to
PZA. The peak shift values taken from PZA1 are close to those quoted in literature,
although some residual solvent (H2O) is still present when looking at the raw spec-
trum (Appendix Figure 9-17). Analysis of the NMR data would therefore suggest that
the discrepancy in yield is due to difference in extraction and work-up, rather than
reactivity.
Table 4.2: Proton NMR chemicals shift of isolated product in PZA1
Experiment Chemical Shift (ppm)
PZA1.1 (300 MHz, DMSO-d6) 3.35 (H2O), 7.88 (1 H, br. s), 8.28 (1
H, br. s), 8.72 (1 H, dd, J = 2.5, 1.5 Hz), 8.86 (1 H, d, J =
2.5 Hz), 9.18 (1 H, d, J = 1.5 Hz)
PZA1.2 (300 MHz, DMSO-d6) 3.35 (H2O), 7.88 (1 H, br. s), 8.28 (1
H, br. s), 8.71 (1 H, dd, J = 2.5, 1.5 Hz), 8.85 (1 H, d, J =
2.3 Hz), 9.18 (1 H, d, J = 1.5 Hz)
PZA1.3 (300 MHz, DMSO-d6) 3.36 (H2O), 7.89 (1 H, br. s), 8.29 (1
H, br. s), 8.72 (1 H, dd, J = 2.5, 1.5 Hz), 8.85 (1 H, d, J =
2.5 Hz), 9.18 (1 H, d, J = 1.5 Hz)
Starting Material,
PyCN
(300 MHz, DMSO-d6) 8.83 (dd, 1H), 8.94 (d, 1H), 9.21 - 9.13
(1H, m)
Pyrazinamide192 (400 MHz, d6-DMSO) 7.84 (1 H, br. s), 8.24 (1 H, br. s),
8.70 (1 H, dd, J = 2.5 Hz, J 1.5 Hz), 8.85 (1 H, d, J = 2.5 Hz),
9.17 (1 H, d, J = 1.5 Hz)
Pyrazinecarbonitrile193 (300 MHz, d6-DMSO) 8.85 (1 H, dd, J = 2.5 Hz, J = 1.5
Hz), 8.95 (1 H, d, J = 2.5 Hz), 9.20 (1 H, d, J = 1.5 Hz)
The PXRD data for PZA1 was compared to the three most accessible polymorphs of
pyrazinamide. The patterns were generated from the available single crystal X-ray
diffraction (SCXRD) structures (Figure 4-3).194–196 The powder patterns for PZA1
clearly indicate that the crystalline product corresponds closely to the α polymorph.
Work by Cherukuvada et al. suggests that this is the most thermodynamically stable
polymorph of PZA at room temperature.197 However, PZA has enantiotropically related
polymorphs, with the δ form being the most stable below 25 ◦C, α the most stable
between 25 and 155 ◦C and the γ being the most stable from 155 to 191 ◦C. This
highlights the need for careful crystallisation control to ensure polymorphic purity as
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the crystallisation process may drive the formation of a kinetic polymorph product, or
mixture of polymorphs.
Figure 4-3: PXRD analysis for PZA1. Comparison with the simulated pattern for three
PZA polymorphic forms
To confirm the results in the NMR and PXRD analysis; DSC was carried out on
PZA1.1, the results are summarised in Figure 4-4. From the DSC trace, a clear melting
point at 190.3 ◦C can be seen. This fits with the expected value between 190 and
194 ◦C.197 Furthermore, a phase transition is visible above the baseline in PZA1.1,
with a peak maximum at 151.6 ◦C. This is close to the expected phase transition from
polymorph α to γ (140 to 155 ◦C) typically seen when heating a sample of α-PZA.
Figure 4-4: DSC of the Flow Synthesis of PZA1.1
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Given the decreased yield, the reaction was retested using the same synthetic method
but with a more efficiently packed column, where celite was mixed with MnO2. The
renewed column was run under the same conditions. The results for the yield are shown
in Table 4.3.
Table 4.3: Second attempt at the flow synthesis of PyCN
Experiment Flow Rate RT Run Time Isolated Yield
(mL min−1) (min) (min) (%)
PZA1.4 1 2 20 88.4
PZA1.5 1 2 20 94.1
PZA1.6 1 2 20 92.7
Average 1 2 60 91.7 ± 3.0
As can be seen, the yield is 20 % higher than the first attempt, which was on average
around 69.8 %. Since the reaction was run under the same conditions, the discrepancy
was put down to poor packing of the column in the first attempt as well as greater care
taken during work up and isolation of the product in PZA1.4 to PZA1.6.
In summary, the hydration of PyCN to pyrazinamide was replicated in a flow envi-
ronment successfully. The desired product was produced in a high yield under the
similar conditions to those outlined by Battilocchio et al. Analysis by NMR of the
product showed no residual starting material (notable loss of the peak at 8.94 ppm).
The polymorphic form isolated matched the α-PZA form, which was identified as the
expected form under the aqueous cooling crystallisation conditions. Crystallisation oc-
curred during collection, but in order to determine the most accurate solid recovery,
work-up on a rotary evaporator was used to remove the solvent.
The system thus provides a good framework for an integrated continuous crystallisation
approach. There are a number of factors that support this. The reaction set-up was
straightforward and easy to control, making it simple to replicate. This ensures that
during optimisation of the downstream process, performance of the upstream synthesis
is reliable and non-variable. The reaction is well understood, atom efficient and per-
formed in water. The synthetic process was found to be highly selective to the desired
product, with no side products detected in NMR spectroscopy. Furthermore, water
acts as a green solvent, making it attractive from a sustainability perspective. The
resulting high selectivity ensures that the system becomes supersaturated as it cools
to ambient temperatures. Under these conditions, it was deemed possible to directly
couple the flow synthetic reaction to the continuous crystallisation platform without
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the need for in-line work-up.
4.4 Coupling Synthesis and Crystallisation
4.4.1 Experimental
For a fuller explanation of the Vapourtec R-series equipment and KRAIC crystallisation
platform, please see Sections 2.5 and 2.7.1 respectively.
Uncontrolled Nucleation
Flow synthesis was carried out as described in Section 4.3.1. A feed solution of PyCN
was prepared to a concentration between 0.1 and 0.25 mol dm−3. The reactor column
was equilibrated and primed with H2O at 1 mL min
−1. The column was heated to
80 ◦C under 10 - 12 bar pressure. In coupling experiments, the output from the flow
synthesis of PZA was fed directly into a glass cross piece (1.25 mm ID) to undergo
segmentation before crystallisation in the KRAIC. Carrier fluid (Galden SV110) and
air were pumped using a pair of Ismatec (Reglo-Z series) gear pumps at set flow rates
(Appendix Table 9.1) through 1 mm ID perfluoroalkoxy alkane (PFA) tubing. The
effluent from the flow synthesis reactor was transported to the segmentation point
using a temperature-controlled jacketed tubing (J1) which was kept at 75 ◦C to avoid
early onset of crystallisation. The cross piece was kept submerged under a water bath
which was actively heated to 70 ◦C.
In initial experiments, termed ‘uncontrolled nucleation runs’ the output from the seg-
mentation bath was transferred into a 15 metre length (3.2 mm ID) FEP tubing via a
3.2 mm ID piece of marprene tubing. The segmented slugs were allowed to cool without
assistance to ambient conditions (Figure 4-5). The temperature profile for uncontrolled
nucleation runs is shown in the Appendix Figure 9-16. Once the feed cooled to ambient
conditions, the resting temperature remained steady between 18 and 20 ◦C, depending
on the external atmosphere. A neutral solvent (water) was used to help propel any
crystals out of the end-piece of the KRAIC. The neutral solvent was used to provide
additional velocity to the flow after carrier fluid recovery in the end-piece. The neutral
solvent is defined as a solvent that will not cause dissolution or crystallisation of the
product. The neutral solvent was turned on intermittently when needed to clear any
solid build-up. The neutral solvent in later runs was chilled with an ice bath to reduce
the observed dissolution of the product.
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Figure 4-5: Schematic diagram of the direct coupling of the flow synthesis and crys-
tallisation platforms in uncontrolled nucleation runs
Controlled Nucleation
The experimental parameters in later experiments (referred to as ‘controlled nucleation
runs’) were the same as those described in the uncontrolled nucleation runs with the
exception of the introduction of a controlled cooling step. The set-up is outlined in
Figure 4-6. The active cooling step consisted of an additional 1.2 m section of 3.2 mm
ID FEP tubing jacketed with silicone tubing (jacketed tubing 2, J2) which was actively
cooled using a circulatory bath. J2 was installed between the segmentation bath and
the 15 m main body of the KRAIC. A zero volume FEP union was used to connect J2
to the main crystalliser.
Figure 4-6: Schematic of the controlled nucleation run for coupling of the flow synthesis
and crystallisation platforms for pyrazinamide
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4.4.2 Platform Development
The initial experiment parameters are given in Table 4.4. These experiments aimed
to scope what parameters were important in producing an effective crystallisation for
PZA in a continuous manner.
Table 4.4: Experimental parameters for initial PZA investigations into coupled flow
synthesis and crystallisation






(mol dm−3) (mL min−1) (mL min−1) (min:sec)
PZA2 0.1 1.00 2.9 41:45
PZA3 0.25 1.00 2.9 41:45
PZA4 0.25 1.00 7.4 16:16
a: Total of synthesis, air and carrier fluid flow rates. Calculated from the RT, as volume of the
KRAIC is known to be 120.64 cm3
b: Residence time experimentally derived after segmentation
PZA2
The hydration reaction of PyCN to PZA was monitored off-line by taking a sample after
exiting the KRAIC. NMR analysis indicated that the synthetic reaction was proceeding
well. Table 4.5 shows the NMR results for uncontrolled nucleation. In the case of PZA2,
the sample was taken from the solution leaving the KRAIC. While the sample showed a
high water content, the identifiable peaks in the aromatic region indicated no remaining
starting material and confirmed the presence of PZA in solution.
Table 4.5: Proton NMR chemicals shift of pyrazinamide samples in uncontrolled nu-
cleation runs
Experiment Chemical Shift (ppm)
PZA2 (300 MHz, DMSO-d6) 7.78 (s, 1 H), 8.36 (s, 1 H), 8.67 (s,
1H), 8.78 (s, 1 H), 9.11 (s, 1 H)
PZA1.1 (300 MHz, DMSO-d6) 3.55 (H2O), 7.88 (s, 1 H), 8.29 (s, 1
H), 8.72 (dd, J 2.5, 1.5 Hz, 1 H), 8.86 (d, J 2.5 Hz, 1 H),
9.18 (d, J 1.5 Hz, 1 H)
NMR spectra of PZA2 in Appendix Figure 9-18
However, during PZA2 no crystallisation occurred within the KRAIC even after taking
steps to decrease the temperature of coil 1 using an ice bath. Work-up of the effluent
leaving the KRAIC using rotary evaporation did leave a white powder, which was
subsequently analysed by NMR and PXRD. The NMR peak shifts were in agreement
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with those reported in PZA1 and powder pattern was indicative of the expected α-PZA
polymorphic form (Figure 4-8).
PZA3
In PZA3, the concentration of the precursor PyCN was increased to 0.25 mol dm−3.
Crystallisation in the KRAIC was visible in coil 1, within the first 20 minutes after
switching feed. Coil 1 is approximately 5 metres in length, so crystallisation was occur-
ring early in the residence time. Here, crystallisation began before a complete RT had
passed through the system. As the transfer tubing from the pumps has a laminar flow
regime, the concentration of PZA in solution is unlikely to have reached steady state at
this point. The crystallisation was noted to be sporadic, with crystals appearing only
intermittently within slugs. Furthermore, the crystals that did form began to cause
blocking issues which affected the flow rates of the feed. Hence, an accurate solid re-
covery could not be determined. The system had to be stopped and cleared 25 minutes
into the run, 5 minutes after crystals had been observed to be growing in situ. How-
ever, PZA3 achieved the first instance of crystallisation in coupling experiments. This
confirmed that a concentration of 0.25 mol dm−3 was sufficient to provide adequate
supersaturation levels of PZA that would result in crystallisation at ambient tempera-
tures within the KRAIC. However, the low solid suspension and subsequent blockage
issues were problematic, the nature of the blockages suggested that the PZA crystals
were growing in a less than ideal morphology, which was leading to poor suspension in
the segmented flow and consequently quickly formed blockages.
PZA4
In PZA4 the flow rate of the crystallisation process was increased in order to provide
better mixing in the system and reduce the chances of a blockage forming. This was
achieved by raising the flow rate of the carrier fluid and air components, while the
RT of the synthetic process remained unchanged. In PZA4 crystallisation in the coils
occurred visibly after 17 minutes, occurring in the latter half of coil 2 of the KRAIC.
However a blockage began to form in coil 3, 29 minutes into the run. The blockage
was removed by applying hot air via a heat gun to the area to partially redissolve the
crystals. The run was continued, but required further interventions to remove small
blockages. The crystals were collected after exiting the KRAIC, but an accurate solid
recovery could not be taken as the blockage affected the flow rates.
In order to better understand why the PZA crystals were causing issues, analysis of
the particle sizes under an optical microscope was carried out. Images were taken
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that showed the PZA crystals had a tendency to form long elongated needle structures
(Figure 4-7). Based on crystal size relative to the particle sizing grid, some crystals
were growing regularly up to 1 mm in length. Some of the crystal growth reached close
to the size of the tubing (3.2 mm ID). Table 4.6 shows the particle size distribution
from optical microscopy measurements. The crystals show a large size distribution,
indicating a non-uniform dispersion. The particle size distribution (PSD) indicates that
the majority of crystals have a width between 118 and 150 µm and a length between 702
and 1032 µm. Therefore the crystals are forming in the KRAIC with an average length
close to 1 mm and a width around 0.1 mm. However, the maximum length measured
was 2.5 mm. Its likely that these elongated crystals are what led to blockages despite
the low solid loadings in each slug. Once the crystals had grown to a size sufficient
to begin touching the walls of the tubing, this perhaps provided an easier pathway for
nucleation via the reactor wall, leading to a sudden growth in crystals and subsequent
solid build-up.
Figure 4-7: Optical image of PZA4 crystals with scale bar (DIV = 0.1 mm)
Table 4.6: Particle size analysis of PZA4
Length Width Particle Distribution
(µm) (µm) (µm)
Average 867 134 501
Standard deviation 585 58 554
95% confidence limits 702 - 1032 118 - 150 390 - 611
Full range 160 - 2590 55 - 375 55 - 2590
PXRD analysis of PZA4 (Figure 4-8) resulted in noisy powder pattern, but seemed to
indicate the preferential growth of the γ-PZA polymorph over the thermodynamically
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favourable α-PZA form. This was in contrast from those isolated from PZA2 and liter-
ature, which showed the α form in the absence of crystallisation in the KRAIC. PZA2
crystals were isolated by rotary evaporation using the same method used during the
development of the flow synthesis. In contrast, the results from PZA4 would indicate
that continuous crystallisation in the KRAIC platform was influencing polymorphic
behaviour.
Figure 4-8: Powder diffraction pattern of PZA2, PZA4 and simulated patterns for α and
γ polymorphic forms of PZA. Note that PZA4 is enhanced to allow easier comparison.
From these results, it was clear that greater control over the crystallisation process
would be necessary to ensure successful integration of the two continuous manufacturing
platforms. In particular, the large crystal size and shape was leading to blockage issues
even at low yields. In order to eliminate these issues and allow a greater solid recovery,
a secondary, cooling step was introduced to the process to influence the particle size
and morphology. In this way, a coupling of flow synthesis and continuous crystallisation
could be achieved without downstream processing issues.
4.4.3 Controlled Nucleation
The experimental parameters for the controlled nucleation runs are outlined in Table












































































































































































































































































































































































































































PZA5 was the initial screening experiment with the new controlled nucleation set-up.
As such, the concentration was lowered to 0.2 mol dm−3 as it was thought that this may
avoid further blockage issues at the reduced temperatures. It was also identified that
the air and carrier fluid pumps were not working at capacity during the uncontrolled
nucleation runs. As such, they were cleaned and repaired. Unfortunately this had the
effect of changing the actual pump flow rates of the carrier fluid and air, despite being
set to the same rate as previous experiments. In addition, pulsation and sudden drops
in pressure (likely due to oscillations caused by pumping through a packed column)
meant that it was not possible to determine an accurate RT for PZA5. Crystallisation
of PZA did not occur within the KRAIC, even after the temperature of J2 was reduced
from 15 to 5 ◦C. It was determined that the concentration of PZA was too low in
solution. This was adjusted in later experiments to raise the supersaturation. The
filtrate from PZA5 was collected and excess solvent removed using a rotary evaporator,
which resulted in a white product. NMR analysis confirmed that the product was PZA
(Table 4.8).
Table 4.8: Proton NMR chemicals shift of PZA5
Experiment Chemical Shift (ppm)
PZA5 (300 MHz, DMSO-d6) 7.89 (1 H, br. s), 8.29 (1 H, br. s), 8.71
(1 H, dd, J 2.5, 1.5 Hz), 8.85 (1 H, d, J 2.5 Hz), 9.18 (1 H, d,
J 1.5 Hz)
NMR spectra of PZA5 in Appendix Figure 9-19
PXRD analysis (Figure 4-9) shows that PZA5 is a mixture of the α and γ form of
PZA. This indicates that there is some competition between the two forms during the
crystallisation process. It is interesting that a physical mixture of two polymorphs is
formed after subjecting the effluent from the KRAIC to rotary evaporation, rather than
the pure α form seen in PZA1 and PZA2. This indicates that it is an aspect of the
KRAIC crystallisation process that is changing the preference for the solid form. While
no visible crystallisation could be seen during the run, it is possible some microcrystals
formed either inside the KRAIC or at the end-piece.
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Figure 4-9: Powder X-ray diffraction pattern from the extracted solid in PZA5
PZA6
In the second screening experiment, PZA6, the concentration was raised to 0.25 mol dm−3,
as used in PZA3 and PZA4. The MnO2 catalyst column was replaced and repacked to
reduce the pulsations exhibited in the crystalliser. An accurate RT for the crystallisa-
tion was measured at 27 minutes 38 seconds. PZA6 showed no crystallisation with J2
set at 15 ◦C over one full RT. The circulator was then reduced to 10 ◦C. Crystallisation
within the KRAIC occurred in coil 1, rung 3 at around 30 minutes after switching feeds
and 50 seconds after the circulator had reached 10 ◦C (Figure 4-10).
Figure 4-10: First instance of controlled crystallisation in flow synthesis and segmented
flow crystallisation of pyrazinamide
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As the system began to equilibrate to the new temperature profile, crystals were noted
to appear as they were leaving J2. The slight increase in concentration with respect to
PZA5 resulted in the first instance of in situ crystallisation after successful flow syn-
thesis with no blockages encountered throughout the operational period. However, the
yield was only 0.8 % after collecting for 40 minutes. The reduced yield was determined
to be a side effect of the neutral solvent delivery, which appeared to be redissolving
the product. In most KRAIC based crystallisation processes the neutral solvent is
essential for ensuring no encrustation around the crystalliser outlet. However, as this
was proving a detriment to the solid recovery, in future runs neutral solvent was only
switched on briefly whenever solid mass began to build-up around the end-piece.
During PZA6, the average slug size was monitored during the crystallisation. The re-
sults are summarised in the Appendix Table 9.2. The average slug has volume of 0.08
± 0.01 mL. The values show a good consistency and indicate that the segmentation is
regular. Therefore, each slug should be crystallising under similar conditions, however
while monitoring 60 slugs only 30 showed observable crystal growth at the outlet. This
indicates the system may not have fully equilibrated. It is likely that changing the
temperature of the cooling step led to some deviation in the process. In fact, crystal
growth became more regular towards the end of the counting period. Furthermore, this
method only takes into account the presence of observable crystals by eye; the intro-
duction of a monitoring technique such as Raman spectroscopy would provide a more
accurate hit rate for crystallisation in each slug. Unfortunately not enough product
was isolated to carry out any reliable analysis of the polymorphic form using PXRD or
DSC methods but the product was confirmed to be PZA via NMR spectroscopy (Table
4.9).
Table 4.9: Proton NMR chemicals shift of PZA6
Experiment Chemical Shift (ppm)
PZA6 (300 MHz, DMSO-d6) 7.88 (1 H, br. s), 8.28 (1 H, br. s), 8.67
- 8.79 (1 H, m), 8.86 (1 H, d, J 2.5 Hz), 9.18 (1 H, d, J 1.5 Hz)
NMR spectra of PZA6 in Appendix Figure 9-20
PZA7
In PZA7, PyCN concentration was increased to 0.28 mol dm−3. The column from PZA6
was reused without replacement. The residence time after segmentation was very close
to the previous experiment at 27 minutes 28 seconds. J2 was set to 10 ◦C and the
system was allowed to pump pure solvent for 45 minutes to ensure the temperature
of J2 had reached full equilibrium. Crystallisation occurred in the 2nd rung of coil 1
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of the KRAIC, 8 minutes after switching the feed line. This extended back towards
J2 over time, stabilising within the first RT, with observable crystals forming halfway
round the 1.2 m coil (Figure 4-11). This was consistent for the remainder of the run.
Every slug showed crystallisation upon exiting the jacketed tube. The solid recovery
over the collection period was 28.5 %, leading to a productivity of 0.6 g h−1. During the
hour long collection period, no blockages occurred within the crystalliser. The samples
were extracted with vacuum-assisted filtration and allowed to dry before analysis.
Figure 4-11: Initial nucleation within the cooled J2 tubing jacket during controlled
nucleation run, PZA7. Crystal growth becomes visible to the naked eye within the
upper rung of the cooling jacket.
The increase in concentration of PyCN was enough to significantly increase the super-
saturation ratio at 10 ◦C, to the extent that spontaneous nucleation and visible crystal
growth could be seen within the first 2 minutes of a residence time (RT). Furthermore,
the high concentration improved the consistency of crystal growth in the slugs as well as
leading to a much improved yield compared to PZA6. Despite the significant increase
in solid loading, no blockages were encountered during the duration of the experiment.
Optical images of the crystals were taken under a microscope (Figure 4-12). The
crystals are clearly significantly smaller than those isolated from PZA4. This indicates
that the addition of a cooling step influences the size and shape of the crystals. The
rapid heat loss provides a drive towards nucleation. This provides numerous points
for crystals to grow and hence reduces the likelihood that crystals will grow to sizes
exceeding the diameter of the tubing. This has significant advantages in processability
compared to the uncontrolled nucleation runs. Furthermore, the rapid heat loss is
facilitated by the high surface-to-volume ratio in a tubular crystalliser, which could not
be as easily applied in a batch crystallisation process, clearly highlighting an advantage
of tubular flow crystallisation over conventional batch crystallisation.
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Figure 4-12: Optical image of PZA7 crystals with scale bar (DIV = 0.1 mm)
The particles were too small to accurately measure size under an optical microscope so
a sample was taken for study using scanning electron microscopy (SEM). SEM images
were taken of the crystals formed during PZA7 and the images at various magnifications
can be seen in Figure 4-13. Particle size analysis was carried out on the SEM images
and results are summarised in Table 4.10. The average particle size was 83 µm. A
comparison of the elongated crystal axis of PZA4 and PZA7 shows a similar reduction
in average size from 867 to 145 µm, respectively. The SEM images of the crystals from
PZA7 show a rectangular shape, with one elongated axis.
Figure 4-13: SEM images of PZA7 at magnifications of a) x33 b) x70 c) x220 d) x350
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Table 4.10: Particle size analysis of PZA7 from SEM
Length Width Particle Distribution
(µm) (µm) (µm)
Average 145 21 83
Standard deviation 102 10 95
95% confidence limits 117 - 173 18 - 24 64 - 101
Full range 4 - 484 7 - 63 4 - 484
A sample of PZA7 was analysed by laser diffraction using the method outlined in
Section 2.15. The Malvern Mastersizer 3000 software version 3.36 fits the diffraction
data to an irregular sphere. The results from the particle size analysis data are depicted
in Figure 4-14. As the particles have a rectangular shaped morphology, the data will
reflect a combination of all orientations of the needle crystals with respect to the laser
beam.
Figure 4-14: Particle size distribution of PZA7 from laser diffraction measurements
On closer inspection of Figure 4-14, there is a clear peak maximum centred around
100 µm. This is maintained over several recorded scans. The size range of the crystals
was relatively large, ranging from 3 to 300 µm. This large range may be the result of
the non-spherical nature of the crystals. Using the particle size analysis from the SEM
images to interpret the data, it is likely that the lower range of the size class corresponds
to the crystal width (3 to 60 µm). The long axis in Table 4.10 has a range of 4 to 480 µm,
hence sizes above 60 µm may correspond to the crystal length. Above 300 µm and the
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size class begins to vary on repeated scans in Figure 4-14. This might correspond
to aggregates forming and breaking between PZA crystals in suspension during laser
diffraction analysis. These aggregates generally ranged up to 1 mm in size. Comparison
of these results with the particle size analysis from the SEM images indicates that the
results are a good approximation. The average particle size from Table 4.10 was close to
100 µm with a range of sizes within the observed laser diffraction analysis distribution
depicted in Figure 4-14.
Based on the results in PZA7, the introduction of a rapid cooling step increases the
temperature gradient significantly as expected; Figure 4-15 shows a comparison of
the temperature profiles of PZA7 and PZA4. As can be seen, the rapid temperature
loss and resulting lower temperature will contribute to increasing the supersaturation.
These factors contribute towards the onset of nucleation and crystal growth. Hence,
the cooling step raises the supersaturation level in the KRAIC to above the metastable
zone width (MZW) and into the labile zone, this resulted in spontaneous nucleation of
many crystal nuclei rapidly.
Figure 4-15: Cooling profile for the KRAIC in PZA4 and PZA7
As this provides several points for secondary nucleation, the crystals tend to grow
smaller. Generally, excessive nucleation promotes encrustation issues, however the
KRAIC benefits from a preferential wetting of the carrier fluid on the tubing. As a
result, the solution slugs never encounter the walls of the tubing and this prevents
encrustation. However, poor crystal suspension or elongated crystals can approach
the tubing diameter and this can lead to blockages. In PZA7, the reduced crystal size
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improves the processability of PZA compared to PZA4 as the smaller crystals no longer
exceed the diameter of the tubing and remain suspended in the solution slugs. Hence,
the result is that blockage issues were removed while solid recovery was simultaneously
improved.
PXRD was carried out on a sample of PZA7 after filtration. The diffraction pattern is
shown in Figure 4-16. It is apparent that the preferred polymorphic form is γ-PZA, in
contrast to the batch crystallisation process which promoted the α polymorph.
Figure 4-16: Powder diffraction pattern of PZA7 compared to simulated patterns of
the accessible polymorphic forms of pyrazinamide
The result is in line with the polymorphic forms identified in previous experiments
PZA4 and PZA5 both of which showed a mixture of α and the metastable γ polymorph
when isolated from the KRAIC. In PZA7 however, the form identified is exclusively
the γ form. Of particular interest, the γ polymorph of PZA is not usually accessible
from an aqueous cooling crystallisation process. In two separate pieces of work carried
out by Castro et al. and Hermanto et al., both authors report the preferential crys-
tallisation of the α polymorph from water.189,198 In particular, Hermanto noted that
during cooling crystallisation experiments, the α polymorph was the only accessible
polymorph, regardless of cooling rates. The results obtained along with the literature
cited indicate that the influence on polymorphic behaviour on PZA is likely due to the
KRAIC crystalliser. However, it is important to note that the cooling rates experienced
in the controlled nucleation runs here are significantly faster than the scope of the work
presented by Hermanto. In runs that showed blockages (e.g. PZA5) a mixture of α and
γ was detected, this perhaps indicates that nucleation on vessel walls leads to α-PZA
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expression, while the absence of the crystalliser walls and no blockages (PZA7) leads
to growth of γ-PZA. This observation is in line with previous work in the KRAIC that
has seen a similar polymorphic change with succinic acid when moving from a batch
to a segmented flow crystalliser and removing solid-liquid interfaces.131 Confirmation
of this relationship would require in situ polymorphic form analysis, which is outside
the scope of this thesis but marks a clear need for the development of technologies and
methodologies that could enable a better understanding of this phenomenon.
The change in polymorph is also reflected in the DSC trace, which shows a distinct lack
of thermal transitions before the melting point (Figure 4-17). This is in contrast to
Figure 4-4 from PZA1, which clearly shows an endothermic transition corresponding
to a switch from α to γ-PZA around 145 ◦C. The melting point peak minimum for
the PZA7 product corresponds to a value of 189.6 ◦C which is in agreement with the
melting point of PZA from PZA1 (190 ◦C).
Figure 4-17: DSC trace of PZA7, showing a melting point at 189.55 ◦C.
PZA8
The results from PZA7 indicated that a successful coupling of flow synthesis and con-
tinuous crystallisation was possible. However the solid recovery was still relatively low
compared to the batch crystallisation process which was 70 to 90 % on average. In
order to improve the solid recovery, PZA8 reduced the temperature of the cooling step
in order to increase supersaturation and hence increase overall crystallisation. The
cooling step was lowered from 10 to 5 ◦C and the resulting temperature profile is shown
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in Figure 4-18. The readings were taken using an external probe and indicate that
the temperature of J2 is close to the expected 5 ◦C. After this, the solution gradually
increases to ambient temperatures, stabilising at 21.7 ◦C.
Figure 4-18: Cooling profile of the KRAIC in PZA8
During the run, it was noted that the onset for crystallisation after switching the feed
to the PyCN solution was earlier than in PZA7. In PZA8, considerable crystal growth
was visible within the first 60 cm of J2, whereas in PZA7 the onset of crystallisation
occurred after the first 60 cm of J2. Crystallisation was noted to occur visibly in J2
within the first 7 minutes, similar to PZA7 (8 minutes) but solid loading was observably
higher within the slug. This is not unexpected as the cooling profile for PZA8 is steeper,
with a lower resting temperature. The residence time is also noted to be slightly longer
(Table 4.7), but this could be down to a fluctuation in pump performance or accuracy
in measuring the residence time. Unfortunately, the increased solid density in each
slug eventually led to a major blockage issue and the run needed to be stopped. The
blockage occurred 45 minutes into operation and was centred around the join between
the 15 m FEP tubing and J2 (Figure 4-19).
The join has the advantage of that it could be disconnected, cleared and reattached
without switching off the pumps. This allowed the run to continue for a further 30
minutes unimpeded and enabled collection of some product. However, the join was also
responsible for the blockage, acting as a solid surface for nucleation and encrustation.
Furthermore, the seam, while as flush as possible, may still act as a catching point for
dense crystals that are not suspended well in the slug. In the case of PZA8, the extra
solid loading before the join resulted in crystals getting caught at irregular intervals.
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Figure 4-19: Union between Jacket 2 (J2) and the 15 m FEP tubing in the KRAIC
This was not an issue in PZA7, which would suggest that the crystals were better
suspended or solid loading was lower in each slug when passing this point compared to
PZA8. Potentially this could be resolved by increasing the flow rate, but this would
have affected the residence time. Another solution and a possible improvement to the
design used in these experiments would be to directly jacket the first metre of the 15
metre FEP tubing. This would avoid the need for a join between J2 and the FEP
tubing and eliminate the unwanted surface interaction.
Some solid was recovered before the run blocked in PZA8 and was tested using PXRD
and DSC analysis (see Appendix 9-21 and 9-22 for corresponding graphs). The PXRD
pattern showed the formation of the γ form in-line, which was also the observed form
detected in PZA7. DSC analysis shows a clear melting point of 190 ◦C with no thermal
transitions indicating no polymorphic changes before melting. The lack of α-PZA may
be due to the fact that the crystals collected were isolated before the blockage occurred
and hence the polymorphic form maintained the γ phase.
Results from PZA8 would indicate the cooling step was too fast under the current
parameters, leading to blockages around the union between J2 and the FEP tubing.
Potentially this could be overcome by modifying the design to eliminate the union. In
this case, the PZA crystals only appeared to cause blocking issues around the join,
which would indicate that a greater solid recovery could be achieved by removing this
point.
PZA9
In PZA9, the J2 was switched off and was filled with only air. In this case, crystallisation
was allowed to proceed without active cooling, as in the uncontrolled nucleation runs,
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but with an additional 1.2 m tubing extension. The experiment aimed to determine
if the rapid cooling effect was causing the change in the polymorphic behaviour or
whether this could be attributed to the KRAIC design. The cooling profile can be seen
in Figure 4-20. In contrast to PZA8, the lowest temperature reading is found to occur
at the outlet of the KRAIC, with a reading of 20.8 ◦C compared to 10 ◦C in the rapid
cooling run. Unfortunately, over the course of the hour long run, no crystallisation
occurred in-line. This would suggest that the conditions were not sufficient to cause
spontaneous crystallisation.
Figure 4-20: Temperature readings and cooling profile of PZA9
PZA10
In PZA10 the coupling experiment was carried out using the same conditions as PZA7.
During the 40 minute priming period, the residence times for synthesis and crystalli-
sation were monitored. These are summarised in Table 4.11.
Table 4.11: Residence times and process volumes for PZA10
Location Residence Time Volume
(min) (mL)
Packed Column 1:56 1.9
Jacket 1 (J1) 2:11 1.8




From this, it is clear that the total time spent in the column was relatively short,
only 2 minutes. The crystallisation process is much slower than the synthetic reaction,
with a total time of 28 minutes. In direct coupling of flow synthesis and continuous
crystallisation this can cause difficulty due to the disparity in reactor volumes and
process times. However, in a segmented flow regime, the addition of an air and carrier
fluid allows control over the net flow of each set-up without detrimentally affecting the
downstream processing.
Crystallisation occurred in J2, around the half-way point at 6 minutes 30 seconds,
which is a similar to the induction time to PZA7 (7 minutes). Collection of product
was carried out for 1 hour, with no blockage issues. Crystallisation occurred in every
slug once steady state had been reached with the cloud point observed in J2 (Figure
4-21). Solid recovery was significantly improved, giving a yield of 57 % compared to
28.5 % in PZA7, representing a productivity of 1 g h−1. The large improvement was
likely due to a more robust process built on the observations of the previous attempts,
along with the installation of a renewed MnO2 catalyst column. Proton NMR of the
product indicated the isolated crystalline product matched the signals typical of PZA
(Appendix Figure 9-23).
Figure 4-21: Crystallisation of pyrazinamide in all slugs in coil 1 of the KRAIC in
PZA10
SEM was used to image a sample of crystals isolated from PZA10. The crystals have a
similar morphology to those produced during PZA7, showing one long axis resulting in
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rectangular plate-like shaped crystals (Figure 4-22). Particle size analysis was carried
out on the SEM images and the results are summarised in Table 4.12.
Figure 4-22: SEM images of PZA10 crystals at magnifications of a) x30, b) x230, c)
x270 d) x370
Table 4.12: Particle size analysis of PZA10
Length Width Particle Size
(µm) (µm) (µm)
Average 171 17 94
Standard deviation 115 8 112
95% confidence limits 135 - 207 15 - 20 69 - 119
Range 36 - 618 5 - 35 5 - 618
Particle size analysis of the SEM images (Table 4.12) indicates that PZA10 has an
average particle size of 94 µm which is similar to the crystals isolated from PZA7
(83 µm). The 95% confidence limits for the average length and width are within the
expected distribution from the laser diffraction experiments carried out on PZA7. Here,
a slightly wider range of lengths were detected but it is difficult to determine exactly
why this is the case. One possibility is the neutral solvent. In PZA7, the neutral solvent
was an aqueous solution at room temperature, but, it was noted halfway through the
run that the neutral solvent was causing dissolution of the product. In this repeat
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(PZA10), the neutral feed was kept off throughout the run as encrustation around the
end-piece was not an issue. Therefore the change in crystal size may be a consequence
of the improved solid recovery resulting from the reduction of product dissolution.
The polymorphic form was investigated using PXRD and DSC analysis and the results
are summarised in Figure 4-23 and Figure 4-24 respectively. As was the case for PZA7,
the γ polymorph is selectively isolated from the integrated process. The SEM images
depict rectangular, plate-like crystals as previously observed in PZA7. DSC analysis
lacks the thermal transitions associated with a phase change before the melting point,
confirming γ-PZA to be present throughout, while the large endothermic peak at 190 ◦C
matches the expected melting point. The sample of PZA10 was stored under ambient
conditions after extraction and the stability of the γ-form was monitored using PXRD.
The results are shown in Figure 4-23. As can be seen from the data collected, the
metastable form was still present after a 2 year period, indicating that the sample, if
left undisturbed, remains stable over an extended period.
Figure 4-23: PXRD pattern comparison of PZA10 after 2 years under ambient storage
conditions
PZA10 confirms that that the integrated production and crystallisation of the γ-form
of pyrazinamde is effective and can be repeated with similar results. Furthermore, the
greater solid recovery suggests that the process could be significantly improved with
more optimisation. In particular, solid recovery values were calculated from depletion
of the feedstock, assuming 100% conversion of the starting material to PZA. If the
system was allowed to reach steady state before beginning collection, then solid recovery
186
Figure 4-24: DSC trace of PZA10, showing melting peak at 190.02 ◦C
would likely improve over this period. Ideally, the system should be run for several more
residence times, with separate collection periods allowing for an averaged solid recovery
to be determined.
PZA11
A final attempt was made to isolate pyrazinamide crystals without the addition of
controlled temperature stage in J2. The experiment was run at an increased concen-
tration of PyCN (0.32 mol dm−3) to encourage spontaneous crystallisation without the
controlled cooling step. This would allow for insights into the cooling effect on poly-
morphism. Unlike in PZA10, crystallisation occurred around the exit of J2 after 8
minutes. Unfortunately, the crystals caused a blockage 25 minutes into the run (within
the first RT). An external heat gun was applied to clear the blockage and the air flow
rate was increased to extract the crystals before another blockage could develop. Solid
recovery over this period was 12.2%. A sample was analysed using PXRD, results are
summarised in Figure 4-25. In this case, PZA11 consists of a mix of the α and γ forms.
Comparison of the DSC traces for PZA11 and PZA1 (α-PZA) indicate that a small
peak is present above the baseline in PZA11 (Figure 4-26) which matches the expected
α to γ transition. This correlates with the PXRD data.
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Figure 4-25: PXRD of PZA11, showing a physical mixture of the gamma and alpha
forms
Figure 4-26: Endothermic peak in DSC traces of PZA11 (150.6 ◦C) and PZA1 (151.5 ◦C)
indicating the α to γ transition in PZA. The DSC run for PZA11 was kept below 175 ◦C
to avoid losing the phase transition to the baseline due to the large melting point peak.
Evaluation of this suggests that the mechanism for growth of the α form may be related
to surface interactions with the tubing, as the α form has only been extracted from the
KRAIC when major blockages have occurred. The results in PZA11 therefore indicate
the α polymorph formation in the KRAIC is related to nucleation on the vessel walls,
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rather than the cooling profile. This behaviour correlates with the fact that during
both controlled nucleation in PZA8 and uncontrolled nucleation in PZA4, gave only
γ-PZA as neither run suffered a major blockage.
4.5 Chapter Conclusions
This work constitutes a novel bench-top scale coupling of the flow chemical production
of the drug substance PZA with integrated, in-line crystallisation process. Both the ad-
vantages of flow synthesis and continuous crystallisation are maintained by decoupling
the net flow rates of the processes. Initial research resulted in poor crystallisation pro-
cessing and a low overall solid recovery. The introduction of a controlled cooling step
resolved blockage issues and improved the solid recovery. This was achieved through a
rapid cooling step, which induced nucleation and reduced crystal size. The resultant
five-fold smaller crystals of PZA were easily isolated without blockage issues. Poten-
tially, the PZA crystals produced by this route could be incorporated into formulation
after isolation. Furthermore, as a consequence of the crystallisation technique, the γ
polymorph of PZA was selectively obtained. Literature indicates that γ-PZA shows en-
hanced dissolution and solubility properties compared to the thermodynamically stable
α form.198 This might be of industrial interest, as the γ-form is not usually accessible
from a purely aqueous solution and may display an improved bioavailability compared
to the α-form; the only example of acquiring the γ form from an aqueous solution was
described by Zhang et al., where a group of sulfonamide compounds were used as tem-
plates for the preferential crystallisation of the γ polymorph.199 The work presented
demonstrates the first crystallisation to selectively produce the γ polymorph from an
purely aqueous solution, without the need for templates that would require off-line
separation. This work presents a more streamlined production process for scale-up of a
potentially desirable polymorph. However, further investigation is needed, particularly
to determine the driving force for this preferred growth mechanism. It is a previously
encountered phenomenon in the KRAIC to access unexpected polymorphic forms how-
ever, the exact mechanism is not well understood.131 One possible explanation is that
the distinct lack of primary nucleation sites or surface interactions within the KRAIC is
the cause for the polymorphic selectivity. It is also possible that the surface boundary
between the solution slugs and the air/carrier fluid is acting as a nucleation pathway
for the metastable polymorph. It is difficult to study this phenomenon in situ, however
such a study may shed some light on the possibilities for continuous crystallisation
platforms allowing accurate control and selectivity towards a desired solid form.
The work presented in this chapter illustrates a bespoke working example of an inte-
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grated synthesis and continuous crystallisation process. However there are still clear
limitations. For example, in-line reaction monitoring and crystallisation monitoring
techniques would be extremely useful in further optimisation of the process. Using
available technology such as infra-red or Raman techniques would offer greater under-
standing of the process as well as determination of the optimum RT to achieve the
greatest solid recovery and productivity. Monitoring of the synthetic reaction could be
done in real-time, which would greatly improve the downstream crystallisation repro-
ducibility. Another useful feature would be to include multiple temperature controlled
zones in the KRAIC. In this work, a cooling step before running at ambient tempera-
tures was enough to deliver selective solid form control. However, in a more complex
crystallisation process being able to run processes below ambient temperatures over an
extended period, or maintaining a step-wise temperature gradient would allow greater
versatility in the KRAIC platform. In the long-term, extending the process to demon-
strate continuous work-up after crystallisation would be a useful feature in addressing
other significant gaps in integrated continuous manufacturing (CM), for example the
addition of continuous filtration or formulation technologies as outlined in work by
Heider et al.144 Greater versatility in the available tools for engineering continuous
crystallisation and work-up will allow for more integration with synthesis, which will






The work in this chapter forms part of the M4 (Make, Measure, Model, Manipulate)
Metastable materials programme, which aimed to develop switchable materials. These
switchable materials could be manipulated by the application of an external stimulus to
change their properties. Amongst the systems developed, a series of multi-component
crystals were produced which displayed thermochromic properties. The study in this
chapter was carried out in conjunction with Dr. Anuradha R. Pallipurath, Dr. Pierre-
Baptiste Flandrin and Dr. Lauren Hatcher.
5.1.1 Background and Aims
Thermochromism refers to the phenomenon where a material changes colour in response
to a change in temperature. A material which undergoes a colour change in response
to temperature has the potential for applications in imaging, sensing and smart de-
vices.106,107 A family of related, multi-component halo-aniline:3,5-dinitrobenzoic acid
(35DNBA) molecular crystals were identified and characterised by Jones et al. at the
University of Bath, which displayed thermochromic properties.110 The coloured cocrys-
tals were found to be metastable and convert via proton transfer to a more stable salt
form on heating. These pairs of cocrystal/salt complexes included 4-iodoaniline:3,5-
dinitrobenzoic acid, 4-iodo-2-methylaniline (4I2MA):35DNBA and 4-bromo-2-methyl-
aniline (4Br2MA):35DNBA (Figure 5-1). In each case, the neutral and salt form were
grown using slow evaporative crystallisation. However repeatable isolation of the de-
sirable chromatic cocrystal was not always possible.
Figure 5-1: Thermochromic behaviour of halo-aniline:35DNBA cocrystals110
To improve the reproducibility of the crystallisation, the research presented here aimed
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to investigate whether the use of flow chemistry and crystallisation platforms would
allow scale-up and better control over the crystallisation of thermochromic materi-
als. Some of the initial investigations were carried out by University of Bath Mas-
ters project student, Alex Mildon under the supervision of Dr. Pierre-Baptiste Flan-
drin. In their work, they successfully scaled-up and reproduced the 4-iodoaniline:3,5-
dinitrobenzoic acid cocrystal and salt forms. The isolated cocrystal was also shown to
be thermochromic and readily transformed to the colourless salt on heating. However,
production of 4Br2MA:35DNBA complexes was not investigated and the chromatic
4I2MA:35DNBA cocrystal could not be produced. Therefore the work presented in
this thesis aimed to investigate the use of flow crystallisation in the production of
the multi-component systems of 4I2MA:35DNBA and 4Br2MA:35DNBA (Figure 5-2).
The research focused on development of a suitable crystallisation process for translation
into flow. Once identified, a series of efforts were made to control the formation of the
multi-component crystals to preferentially form the elusive thermochromic cocrystals
in a more consistent procedure with scale-up potential.
(a)
(b)




Initial production of the thermochromic cocrystals began by replicating the slow evapo-
ration procedure for the formation of 4I2MA:35DNBA and 4Br2MA:35DNBA cocrystal
and salt forms reported by Jones et al.109,110 The method used is described in Section
2.6.1. The conditions for producing the neutral and salt forms of the different cocrystal
complexes are outlined in Table 5.1.
Table 5.1: Slow evaporation conditions reported for production of cocrystal complexes
of 4I2MA and 4Br2MA with 35DNBA110






























Using the conditions described by Jones et al, both the salt and neutral forms of
the cocrystals could be replicated using evaporative methods. Of particular note, the
production of Cc1 and Cc3 (the salt forms of 4Br2MA:35DNBA and 4I2MA:35DNBA
respectively) were accessible in multiple solvents and across several temperatures. This
is not surprising as the colourless salt complex is the most stable form. In contrast, Cc2
and Cc4 (the chromatic, metastable cocrystals) repeats of the evaporative method did
not always produce the desired chromatic complex. Solid form analysis was carried out
on a sample of Cc2 isolated from slow evaporation using the conditions described in
Table 5.1. The resulting powder X-ray diffraction (PXRD) pattern is shown in Figure
5-3, which is compared to simulated PXRD patterns taken from literature for Cc1 and
Cc2.110
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Figure 5-3: PXRD pattern for Cc2 produced from evaporative crystallisation, com-
pared to simulated patterns from single crystal X-ray diffraction (SCXRD) acquired
by Jones et al.
As can be seen from the figure, there is close similarity between the neutral form of
4Br2MA:35DNBA and the sample isolated from slow evaporation at 40 ◦C. There is a
clear distinction between the diffraction patterns for the neutral (Cc2) and salt (Cc1)
forms of 4Br2MA:35DNBA, which corresponds to a change in the crystal structural
arrangement. The measured diffraction intensity from the slow evaporation Cc2 sam-
ple is quite weak, but further sample preparation to improve this could not be carried
out, as grinding the isolated sample would cause a shift to the salt form. As noted
by Jones et al. repeat experiments did not always result in production of the same
complex. In this case, slow evaporation at 40 ◦C did result in the desired Cc2 form,
but it was produced as a powder, rather than the block crystal reported. This in-
consistent behaviour was commonly encountered by Jones et al. during crystallisation
attempts of Cc2 under similar conditions. This highlights the difficulty in isolating
the metastable, thermochromic cocrystal and provides further evidence of the need to
replace the evaporative method.
The differential scanning calorimetry (DSC) trace for the slow evaporative sample of
Cc2 is shown in Figure 5-4. The sample shows a endothermic peak that corresponds to
a melting point at 129.9 ◦C, close to the value reported by Jones et al. for a transformed
sample of Cc2 (128.6 ◦C). It is worth noting that Jones et al. were unable to determine
the phase transition from Cc2 to Cc1 using DSC measurements, due to the rapid
transformation of Cc2 to Cc1 with time. The transformation was confirmed visually
using hot stage microscopy (HSM) in literature. In this repeat, the powder form of
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Cc2 did show an exothermic phase transition just above the DSC baseline, with an
onset of 82.4 to 125.3 ◦C. However, this is significantly shifted and over a larger range
compared to the expected value of 61 to 83 ◦C reported by Jones et al. from HSM
measurements. The shift may be due to the difference in morphology. Unfortunately,
the powdered form of Cc2 was opaque and no visible colour switch could be seen
during HSM measurements to confirm thermochromism in the powder form.
Figure 5-4: DSC trace of Cc2 produced from evaporative crystallisation, showing a
melting point of 130.9 ◦C and possible phase transition
For 4I2MA:35DNBA, slow evaporation of 4I2MA and 35DNBA in acetonitrile (ACN)
resulted in red, plate-like crystals. These were analysed using HSM and DSC. The
DSC trace is shown in Figure 5-5. An exothermic peak is observed in DSC analysis
from 48.7 to 75.4 ◦C. This is close to the reported phase transition from Cc4 to Cc3
by Jones et al. (45 to 65 ◦C). The endothermic peak corresponds to a melting point
and has an onset temperature of 117.9 ◦C. Jones et al. reported a value of 114 ◦C for
the 4I2MA:35DNBA cocrystal complex. Thus, the results are in general agreement.
Figure 5-6 shows analysis using HSM, which was carried out as described in Section
2.12. A link to the video can be found in the Appendix Section 9.3. Here, the ther-
mochromic behaviour is exhibited as a single-crystal-to-single-crystal (SCSC) phase
transition from 94.9 to 100.5 ◦C resulting in a loss of crystallinity and the red colour.200
This is followed by a melt and recrystallisation at 122.1 ◦C which corresponds to the
loss of the cocrystal and recrystallisation of the 35DNBA coformer. The shift in the
transition point compared to the DSC data may be related to analysis of the bulk ma-
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Figure 5-5: DSC trace of Cc4 produced from evaporative crystallisation, showing a
melting point of 120.3 ◦C and an exothermic event at 48.7 to 75.4 ◦C.
terial compared to a single crystal. A difficulty with reproducing the thermochromic
behaviour in these cocrystals, was the variability in observed transitions. This may
be due to differences in experimental set-up or variations in crystallisation conditions.
As the framework of this work was to translate evaporative methods into a more con-
sistent methodology, evaporative crystallisation was not pursued further. There was
insufficient material to complete a PXRD experiment but the red colour and melting
point in comparison to the pure starting materials of 4I2MA (Appendix Figure 9-24b)
and 35DNBA (Appendix Figure 9-24c) suggested the formation of 4I2MA:35DNBA in
the Cc4 form.
Figure 5-6: HSM images of thermal events for Cc4 isolated from slow evaporation.
The red colour is lost from 94.9 to 100.5 ◦C. The crystal melts at 122.1 ◦C.
While analysis of crystals isolated from evaporative methods indicated the complexes
of 4Br2MA:35DNBA and 4I2MA:35DNBA could be replicated under the conditions
outlined in Table 5.1, the isolated products were often poorly crystalline and incon-
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sistent with the block crystals described in literature. This is often the case when
producing metastable or multi-component crystal systems.201 Furthermore, scaling up
of an evaporative crystallisation process is difficult due to the inherent limitations of
the technique, making it better suited to small scale, screening investigations.202,203
For the thermochromic organic complexes, the metastable form of Cc2 was difficult to
acquire consistently as the transition of Cc2 to the thermodynamically more stable C-
c1 form occurs under ambient conditions over time.110 Therefore, the aim of this work
was to replace the evaporative methods with an alternative crystallisation technique
that could offer better control over crystallisation conditions, as well as the potential to
scale-up production. In pursuit of this, previous work in the group had identified that
an antisolvent methodology could be applied to replicate halo-aniline cocrystals from
evaporative experiments.204 These structures were analogous to the desired 4Br2M-
A:35DNBA and 4I2MA:35DNBA complexes. Hence, efforts concentrated on applying
antisolvent crystallisation techniques for the production of Cc1, Cc2, Cc3 and Cc4
complexes.
5.2.2 Antisolvent Crystallisation
The experimental method used for antisolvent crystallisation in batch experiments is
outlined in Section 2.6.2. In solvent screening tests, water was found to act as suit-
able antisolvent due to the low solubility of the coformer components, 4Br2MA, 4I2MA
and 35DNBA. As such, antisolvent crystallisation experiments concentrated on solvents
miscible with water and which had shown success in the formation of at least one of
the multi-component complexes during evaporative crystallisation experiments. The
first successful formation of 4Br2MA:35DNBA form Cc2 was achieved during antisol-
vent crystallisation under ambient temperatures. To determine if temperature played
a role in the preferential crystallisation of Cc2 over Cc1, antisolvent crystallisation
experiments were repeated under controlled conditions. The results for temperature
dependent antisolvent experiments are shown in Table 5.2.
Table 5.2: Antisolvent crystallisation results at various temperatures
Experiment Temperature (◦C) Coformer Form
TC1.1 40 4Br2MA Cc2
TC1.2 30 4Br2MA Cc2
TC1.3 20 4Br2MA Cc2
TC1.4 10 4Br2MA Cc2 to Cc1
TC1.5 5 4Br2MA Cc1
Conditions: 4Br2MA (50 mg) and 35DNBA (56 mg) in methanol (MeOH) 1 mL. Addition of 2 mL
equivalents of antisolvent (water) to precipitate. No stirring.
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As can be seen from Table 5.2 a trend emerges, with a switch occurring from formation
of Cc2 to Cc1 as temperature decreases. This is visually observed as the change in
colour from orange to colourless, as depicted in Figure 5-7.
Figure 5-7: Antisolvent crystallisation of 4Br2MA:35DNBA at different temperatures
Of particular importance was sample TC1.4, which initially comprised of a mixture of
orange and colourless crystals upon precipitation. However this changed over time, be-
coming completely colourless within 45 minutes (Figure 5-8) under ambient conditions.
Figure 5-8: Colour change observed for sample TC1.4
For TC1.1 to TC1.3 no colour change was observed within the same time period, under
the same conditions. However, removal of the solvent under vacuum in some cases
did trigger the transformation from orange to colourless and a shift from Cc2 to Cc1.
This shift appears to indicate that the presence of the colourless complex will seed the
transition of the whole sample over time and may indicate that the metastable, neutral
form (Cc2) has a relatively small energy barrier for transitioning to the salt form (Cc-
1). Even samples that visibly appeared unchanged after filtration would slowly switch
under ambient conditions from the chromatic complex to the colourless complex over
days, weeks or months. It may be that some Cc1 is present but not visible to the
naked eye in these cases. Certainly, it was observed that the transformation occurs
more rapidly in samples with a visible Cc1 presence. In contrast, some Cc2 samples
that were not separated from the solvent/antisolvent medium did not change colour,
so long as Cc1 was not present to initiate the change. In these cases, the samples
were left to evaporate at room temperature until dry. In these cases, the orange colour
remained stable if undisturbed for up to 1 year under ambient conditions (Figure 5-9).
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Figure 5-9: Orange crystals of 4Br2MA:35DNBA produced from a batch antisolvent
crystallisation at 30 ◦C (a later repeat of TC1.2). Photos taken 6 months and 1 year
later using an optical microscope.
Solid form analysis was carried out on TC1.2, TC1.4 and TC1.5. Unfortunately, TC1.1
and TC1.3 changed from orange to colourless during extraction emphasising again the
metastable nature of the Cc2 complex. The results for PXRD analysis are shown in
Figure 5-10.
Figure 5-10: PXRD of antisolvent crystallisation samples of 4Br2MA:35DNBA in com-
parison to simulated PXRD patterns of the relevant complex
As seen, the complexes isolated match the PXRD patterns generated from SCXRD
data reported by Jones et al., suggesting the formation of both complexes is possible
from antisolvent methods. However, TC1.2 does show signs of conversion of Cc2 to
Cc1, but this is believed to have been initiated during sample preparation for PXRD
analysis. The onset temperature and melting points for each sample are shown in Table
5.3. DSC traces for TC1.2, TC1.4 and TC1.5 are shown in Appendix Figure 9-25.
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Table 5.3: Melting points for DSC traces in antisolvent crystallisations of 4Br2MA:3-
5DNBA
Experiment Melting Point






a DSC traces for TC1.2, TC1.4 and TC1.5 are shown in Appendix Figure 9-25. b DSC traces for
starting materials are in the Appendix Figures 9-24a and 9-24c
As was the case with the samples isolated from slow evaporation, the DSC traces show
a clear endothermic peak that corresponds to a melt at 130 ◦C. The melting points are
distinct from the starting materials and close to the onset temperature in literature for
the complex Cc1 (128.6 ◦C). Thermal analysis and PXRD data are therefore in general
agreement. The close melting point of TC1.2 with TC1.4 and TC1.5 would suggest
that a phase transition from Cc2 to Cc1 may have occurred in TC1.2 during heating.
This may correspond to a display of thermochromism. Figure 5-11 shows an magnified
view of two possible transitions in the DSC trace of TC1.2 before the melting point.
Figure 5-11: Possible phase transitions in TC1.2. The melting endothermic event is
visible at the far right of the trace (129 ◦C)
An exothermic event is visible above the baseline from 81.1 to 112.7 ◦C. This is fol-
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lowed by a small endothermic event at 117.9 ◦C. The exothermic event shows an onset
temperature similar to that seen for the slow evaporation sample of 4Br2MA:35DNBA,
as shown in Figure 5-4. This may correspond to a possible switch from Cc2 to Cc1.
The small endothermic peak at 117.9 ◦C has not previously been observed and may
constitute a thermal event that may have been lost to the baseline in earlier evap-
orative measurements. This is not unsurprising, as computational modelling studies
by Jones et al. calculated the formation energy difference between Cc2 and Cc1 to
be 8.51 kJ mol−1.110 This is in the range of a typical polymorphic transition but the
difference between the neutral and salt forms of 4Br2MA:35DNBA was the lowest of
all the halo-aniline:35DNBA neutral/salt pairs reported for the computational studies.
Hence, the transition enthalpy from Cc2 to Cc1 may be small and difficult to detect
accurately using standard DSC experiment. The possible thermal transitions detected
in the DSC trace for TC1.2 could not be cross-referenced with HSM as TC1.2 con-
verted to Cc1 after PXRD and DSC measurements. However, further discussion of the
switching properties of 4Br2MA:35DNBA cocrystals can be found in Section 5.3.4.
For the neutral complex/salt pair, Cc3 and Cc4 the antisolvent crystallisation was
tested in ACN, MeOH and ethanol (EtOH) over a range of temperatures from 4 to
40 ◦C. Key experiments are shown in Table 5.4.
Table 5.4: Antisolvent crystallisation results at various temperatures
Experiment Temperature Solvent Coformer Form
(◦C) (4R2MA)
TC1.6 40 ACN 4I2MA Cc3
TC1.7 RT EtOH 4I2MA Cc3
TC1.8 30 MeOH 4I2MA Cc5
Conditions: 4I2MA (46 mg) and 35DNBA (56 mg) in 1 mL of solvent. Addition of 2 mL equivalents of
antisolvent (water) to precipitate. No stirring.
For Cc3 and Cc4 production using ACN as a solvent with H2O as an antisolvent
was not effective. The addition of the antisolvent gave rise to an emulsion of red oil.
Even after the addition of excess water, 4I2MA:35DNBA did not readily crystallise
(Figure 5-12). For TC1.7, a mixture of colourless/purple powder was obtained. This
was common across a range of solvents and temperatures. However, in TC1.8 a series
of yellow crystal clusters were obtained, indicating that antisolvent crystallisation at
30 ◦C in MeOH favoured the formation of a possible new crystal form.
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Figure 5-12: Optical microscopy of TC1.6, TC1.7 and TC1.8 after antisolvent crystalli-
sation
These yellow crystal clusters rapidly transformed to colourless crystals on extraction,
in a similar manner observed with Cc2. Unfortunately, unlike Cc2 samples, attempts
to isolate the yellow crystal cluster from solution seeded the transition to Cc3 before
analysis could take place. The cluster did remain stable if left submerged in solution
and left undisturbed. The solvent was allowed to fully evaporate and TC1.8 remained
sufficiently stable after this to perform solid form analysis. PXRD analysis was carried
out on TC1.8 and compared with TC1.7, the results are shown in Figure 5-13.
Figure 5-13: PXRD patterns for TC1.7 and TC1.8 compared to simulated data for
Cc3 and Cc4 from literature.109
The diffraction pattern obtained from TC1.7 shows a match with the simulated salt
form of 4I2MA:35DNBA. This confirmed that the colourless crystals seen in optical
microscopy images for TC1.7 corresponded to Cc3. None of the antisolvent crystalli-
sation methods tested reproduced the red, thermochromic cocrystal Cc4 as seen in
slow evaporation. However, the crystals produced in TC1.8 matched neither of the
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two known forms of 4I2MA:35DNBA. The difference in the optical properties of the
crystals along with the PXRD pattern suggested that a new cocrystal may be present.
A crystal from TC1.8 was analysed using SCXRD; the structure was solved with the
help of Dr. Lauren Hatcher. The structural data can be viewed in Appendix Table 9.4.
Analysis of the structure indicated that a new complex of 4I2MA:35DNBA (denoted
herein as Cc5) had been produced. The SCXRD data was used to generate a simulated
PXRD pattern which was compared to the PXRD pattern for the bulk TC1.8 (Figure
5-14). The data showed a relatively good match, suggesting that the crystal was
representative of the bulk. However, the crystal was only weakly diffracting and hence
the quality of the measured PXRD pattern needs improving at higher 2θ angles.
Figure 5-14: PXRD pattern for TC1.8 compared to simulated PXRD pattern for Cc5
from SCXRD data.
TC1.8 was tested for thermochromic behaviour using thermal analysis. The DSC traces
of TC1.8 and TC1.7 are shown in Figure 5-15a and 5-15b respectively. Observations in
the DSC analysis of TC1.8 and TC1.7 show matching endothermic peaks representing
melting points at 121.2 ◦C and 123.0 ◦C respectively. The values are close to the melting
point observed for the slow evaporation sample of 4I2MA:35DNBA (120.3 ◦C) providing
confirmation that TC1.8 is a complex of 4I2MA:35DNBA. However an exothermic event
unique to TC1.8 is also observed from 96.8 to 106.4 ◦C. This potentially corresponds
to a phase transition or recrystallisation event.
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(a) TC1.8. Exothermic peak with an onset of 96.8 ◦C indicating a possible phase transition or
recrystallisation. Endothermic event at 121.2 ◦C corresponding to a melt.
(b) TC1.7. Endothermic peak at 123.0 ◦C corresponding to a melting point.
Figure 5-15: DSC traces of TC1.8 and TC1.7
HSM of TC1.8 is shown in Figure 5-16, in which the sample was heated from 35 to
150 ◦C at 5 ◦C min−1. During heating on the HSM, TC1.8 visibly undergoes a phase
transition, passing through a melt and recrystallisation step at 92.5 to 100.9 ◦C. The
sample then melts completely from 117.6 to 121.6 ◦C. The remaining colourless needle
crystals correspond to the starting material 35DNBA, which displays a higher melting
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point than the cocrystal (205.4 ◦C). Based on the results obtained, it is probable that
the exothermic event in Figure 5-15a corresponds to a phase transition from Cc5 to the
colourless Cc3 complex before the melt. This behaviour is slightly different from Cc4,
as Cc5 does not display the SCSC phase transition observed in Cc4 from evapora-
tion experiments and instead passes through a melt-recrystallisation phase transition.
Potentially, Cc5 could display the same SCSC behaviour, as the mechanism behind
the phase transition from Cc5 to Cc3 is likely to be the same as that of Cc4 to Cc3
(i.e. proton transfer), but this has not been investigated further. However, the ther-
mochromic behaviour of the Cc5 to Cc3 during the phase transition is discussed in
Section 5.3.4.
Figure 5-16: Thermal events during HSM of TC1.8. Phase transition occurs from 92.5
to 100.9 ◦C. The sample begins to melt at 117.6 ◦C
5.3 Continuous Crystallisation
Based on the results so far, the antisolvent approach could successfully reproduce both
4Br2MA:35DNBA complexes Cc1 and Cc2 as well as 4I2MA:35DNBA complex Cc4
and the new complex, Cc5. Of particular interest was the production of Cc2, which
had previously shown the irreversible thermochromic transition to Cc1, but could not
be consistently produced by slow evaporation. In contrast, antisolvent crystallisation of
4I2MA:35DNBA did not readily produce thermochromic cocrystals. It was therefore
deemed more beneficial to stick to 4Br2MA:35DNBA for production via flow crys-
tallisation, as Cc2 could be consistently produced unlike 4I2MA:35DNBA cocrystals;
Cc5 and Cc4. Therefore, efforts during continuous crystallisation aimed to reproduce
Cc2 in flow and test whether the thermochromic behaviour reported in evaporative
crystallisation of single crystals of 4Br2MA:35DNBA could be replicated.
5.3.1 Platform Development
The batch antisolvent crystallisation tests, cross-referenced with previously reported
slow evaporation experiments, suggested that high temperatures facilitated the forma-
tion of Cc2, while crystallisation at lower temperatures leads to the formation of Cc1.
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Hence, the crystalliser platform must be capable of careful temperature control. In
batch, the crystallisation process was rapid and the addition of the antisolvent resulted
in precipitation of the solid within 1 to 3 minutes. Therefore the current conditions did
not require the crystalliser to accommodate long residence times (RTs). Of further con-
sequence was mixing as initial studies in the development of the antisolvent technique
indicated that vigorous stirring or sonication during precipitation would result in the
transition of Cc2 to Cc1, even at high temperatures. Based on these observations, a
gentle mixing regime was required. Therefore a temperature controlled segmented flow
crystalliser based on the kinetically regulated automated input crystalliser (KRAIC)
(described in Section 2.7.1) was developed to accommodate the elevated temperature
antisolvent crystallisation. A schematic diagram of the segmented flow, antisolvent
crystalliser is shown in Figure 5-17.
Figure 5-17: Schematic diagram for the segmented flow crystalliser for 4Br2MA:35D-
NBA production. Photographs can be found in Appendix Figure 9-28.
5.3.2 Experimental
The air and carrier fluid (Galden SV110) were pumped using Ismatec (Reglo-Z series)
gear pumps using perfluoroalkoxy alkane (PFA) (1 mm inner diameter (ID)) tubing.
The feed and antisolvent were pumped using Vapourtec SF-10 peristaltic pumps or
the Vapourtec R2+ pump module. Jacketed tubing (1.5 mm ID) PFA was used to
heat and transport the feed and antisolvent from the feedstock to the cross piece.
The temperature of jacketed tubings 1 to 4 were controlled using a Grant R3 TX150
circulator unit. A polyether etherketone (PEEK) cross piece (1 mm ID) was used to
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segment the feed by the addition of air and carrier fluid. Antisolvent was added to the
segmented stream using a polypropylene (PP) Y-piece (2.8 mm ID) placed after the
cross piece. The cross piece and Y-piece were submerged within a heated water (or
ice) bath to control temperature. The segmented flow then moved into jacketed tubing
4 (J4), a fluorinated ethylene propylene (FEP) tube with a length of 1.2 m (3.2 mm
ID). An end-piece was used to recover the carrier fluid. A neutral solvent (1:2 v/v%,
MeOH:H2O) was used to provide additional velocity for removal of any precipitated
solid after carrier fluid recovery, without redissolving the product. In later runs, the
feed solution was collected and stored in 20 mL glass sample vials for off-line extraction
rather than direct filtration from the crystalliser outlet.






















































































































































































































































































































5.3.3 Results and Discussion
TC2
In TC2 the aim was to determine if temperature could be used to form Cc2 and Cc1
selectively. Hence, experiments were run at controlled temperatures of 20 ◦C, 40 ◦C and
4 ◦C. Based on results from batch antisolvent experiments, it was expected to observe
a switch from formation of Cc2 at high temperatures to Cc1 at low temperatures. In
all three runs, the end-piece was present and a neutral solvent (1:2 v/v%, MeOH:H2O)
was used. The RT and run times for each experiment are shown in Table 5.6.
Table 5.6: RTs for TC2, antisolvent crystallisations in segmented flow
Experiment RT Run Time Total No. of RTs
(min:sec) (min:sec)
TC2.1 01:13 3:16 2.7
TC2.2 01:02 12:46 12.4
TC2.3 00:37 04:30 7.3
In TC2.1, the temperature of J4 was kept at 20 ◦C. The system ran for just 2.7 RTs
before a blockage formed in the Y-piece. During this period, crystallisation occurred on
addition of the antisolvent. Crystallisation was clearly seen to form the distinct orange
colour of Cc2 in-line. Collection was carried out using a Büchner filtration set-up.
Interestingly, the typical orange colour associated with Cc2 which was present within
the J4 tubing jacket readily switched to the colourless form typically seen for Cc1 on
contact with the filter paper. This behaviour was similar to that observed in batch
antisolvent experiments, where Cc2 would sometimes switch to Cc1 during removal of
the solvent via filtration. A sample was thus collected after switching off the neutral
solvent and removing the end-piece (to remove any triggering of the transition caused
by the presence of Cc1 encrustation in the outlet). For this sample, a collection vial
was used. The precipitate initially remained orange, but gradually turned colourless
on the benchtop, analogous to the behaviour observed in TCF1.4.
In TC2.2, the temperature of the tubing jackets (J1 to J4) and the water bath were
increased to 40 ◦C. Crystallisation occurred rapidly after switching to the feedstock,
with visible orange crystals forming within the second RT. Collection was carried out
using sample vials periodically, three minutes into the run and continued until the
run ended after twelve minutes. However, only colourless crystals formed in this case.
This was revealed to be the result of encrustation in the Y-piece. As the Y-piece is
the point of contact between the feedstock and antisolvent, back mixing may have led
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to the formation of Cc1 encrustation, which is likely to have seeded solution slugs
and promote Cc1 formation despite the higher temperatures. The encrustation was
cleared by briefly switching the antisolvent feed to pure MeOH. After switching back
to H2O, orange crystals began to precipitate again, but they could not be isolated from
collection without switching to colourless crystals.
Perhaps the most interesting result was observed during TC2.3, where all tubing jack-
ets (J1 to J4) were lowered to 4 ◦C and the water bath was cooled with ice to 0.5 ◦C.
Precipitation occurred within 1.5 RTs at the reduced temperature and to compensate,
the air flow rate was increased to reduce the chance of a blockage forming. Crystalli-
sation and collection started at the end of the first RT and continued until the end of
the run. As was the case was TC2.1 and TC2.2 (after removal of the encrustation),
orange crystals precipitated from the solution in situ (Figure 5-18).
Figure 5-18: Photograph of 4Br2MA:35DNBA precipitation in a) segmented flow at
4 ◦C and b) at the crystalliser outlet
The formation of orange crystals at reduced temperature is in contrast to findings
from batch antisolvent crystallisation tests, where precipitation below 10 ◦C favoured
the formation of colourless crystals. Unfortunately, the orange crystals could not be
isolated as they switched to colourless on hitting the filter paper. However, samples
were taken every minute in glass vials and the observed colour was noted. These are
shown in Table 5.7. J4 subsequently blocked five minutes into the run.
Table 5.7: Evaluation of observed colour with time for antisolvent crystallisation in







a Samples collected over 30 second periods
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The clear trend is a switch over time from orange to colourless crystal formation. This
is likely a consequence of the build-up of encrustation around the Y-piece and end-piece
which begins to cause the transition from orange crystals to the colourless form. Even
orange samples collected in glass vials which appeared to be uncontaminated to the
naked eye, began to switch to colourless on the bench. Solid form analysis was carried
out on the product isolated from TC2.1. The PXRD pattern is shown in Figure 5-
19 and compared to TC1.5 (batch antisolvent crystallisation at 5 ◦C), showing good
agreement. The result would therefore confirm that the colourless isolated crystals
from flow match the structural arrangement of 4Br2MA:35DNBA in salt form (Cc1).
Figure 5-19: PXRD patterns of 4Br2MA:35DNBAisolated from antisolvent crystallisa-
tion in flow at 20 ◦C and batch antisolvent crystallisation at 5 ◦C
Based on the observations during the TC2 runs, it is interesting to note that the driving
force for initial crystallisation of Cc2 over Cc1 is not temperature dependent in these
segmented flow experiments. This is in contrast to batch antisolvent crystallisation,
where temperature readily influenced the preference for precipitation of the salt or
neutral form of 4Br2MA:35DNBA. This may suggest that the formation of Cc2 is
influenced by addition rate of the antisolvent. This was not investigated in TC2, but the
addition rate of an antisolvent has been previously observed to affect both polymorphic
selectivity and multi-component crystal formation in other systems.205–207 In batch, it
could be the case that the same trend is also present. It was observed that while
temperature did have an strong influence on 4Br2MA:35DNBA formation in batch,
sometimes Cc2 could be formed at lower temperatures. However, this only occurred
in rare cases. This may reflect the fact that the antisolvent was added manually, which
could lead to variability in the addition rate and could be influencing nucleation and
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growth rate. In this case, the advantage of using pumps and flow crystallisation would
be to remove this inconsistency. Changing the addition rate should be considered in any
future study concerning the antisolvent crystallisation of 4Br2MA:35DNBA or similar
multi-component complexes.
TC3
In TC3, the system was set to 40 ◦C using the same concentration of feedstock as TC2.1,
however the air flow rate was increased. This was to reduce encrustation around the
Y-piece by increasing net flow and help prevent back mixing from occurring into the
Y-piece. In TC3, the neutral solvent was switched to air only or off. The additional
flow rate did reduce encrustation around the Y-piece, however encrustation around the
tubing outlet continued to be a problem. Samples TC3.1 to TC3.5 were collected at
the times indicated in Figure 5-20. A similar trend to TC2.3 was observed, where
orange coloured crystals would form in-line and could initially be isolated without
transitioning. The encrustation would build-up and cause the change from orange to
colourless in all further samples. After 7 minutes, the outlet of the tubing was cleaned
with acetone. The resultant isolated precipitate returned to the orange crystals (Figure
5-20).
Figure 5-20: Sample vials from TC3
The orange crystals from sample TC3.4 were successfully isolated and analysed after
collection from the continuous crystalliser. This was achieved by allowing the solvent
to slowly evaporate instead of filtering. Solid form analysis was carried out to confirm
the presence of Cc2 and PXRD results are shown in Figure 5-21. TC3.1 crystals
unfortunately transitioned to colourless before PXRD analysis was carried out. TC3.4
matched the PXRD pattern expected for Cc2. This was the first instance of successful
work-up of the product extracted from flow and confirmed that the orange crystals
observed in-line were the desired neutral 4Br2MA:35DNBA cocrystal, Cc2. TC3.1
remained Cc2 after production in the flow crystalliser but transitioned to colourless
crystals on filtration. PXRD also confirmed that the colourless crystals matched Cc1
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and indicated that the observed transition is analogous to the thermochromic behaviour
described by Jones et al.. As Jones et al. stated, the thermochromism displayed by
4Br2MA:35DNBA and other halo-aniline cocrystals is the result of a proton transfer
from 35DNBA to the halo-aniline component.109 This in turn, leads to changes in
the crystal packing arrangement which causes the loss in colour. The results from
antisolvent crystallisation experiments would indicate that the loss of colour in 4Br2-
MA:35DNBA can be triggered by other external stimuli, not just temperature, which
may help to explain the difficulty in isolating Cc2 without switching to Cc1.
Figure 5-21: PXRD of TC3 vials in comparison to the simulated 4Br2MA:35DNBA
cocrystals Cc1 and Cc2
On the extraction of 4Br2MA:35DNBA
Other attempts were made to extract the metastable Cc2 product directly from seg-
mented flow, but the application of vacuum filtration or gravity-assisted filtration re-
sulted in the transformation of Cc2 to Cc1. As such, collection vials were the only
way to successfully isolate Cc2 from flow. However, filtration or oven drying (50 ◦C)
often stimulated the transition, making isolation of the solid product particularly diffi-
cult. Oddly it was observed that material causing blockages in-line would often remain
bright orange in colour, suggesting Cc2 remained stable within the confines of the tub-
ing/crystalliser or solvent, until dislodged (Figure 5-22). The most successful method
for isolation was simply to leave the vials to evaporate under ambient conditions until
dry. If undisturbed, the Cc2 form remains stable, but this is both impractical and
time consuming.
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Figure 5-22: Blockage in the segmentation bath at 10 ◦C
The sensitive nature of Cc2 means a careful work-up procedure is required for ex-
traction and this provides a significant barrier to continuous processing. Further work
should also consider raising the temperature of the water bath to prevent encrustation
and blockages in the Y-piece. This would help reduce seeding Cc1 formation. Ideally,
back mixing into the Y-piece should be minimised, as the localised high antisolvent
environment often caused encrustation build-up. Another difficulty was encrustation
around the end-piece, this could be potentially improved by extending the RT in J4.
The crystals would then have more time to grow in the controlled environment and
hence nucleation on the end-piece would be less likely to occur. Regular switching of
the neutral solvent or antisolvent to MeOH could also help to clean the problematic
areas within the crystalliser design and prevent Cc2 from switching to Cc1.
Thermochromic behaviour of TC3
HSM was carried out on samples TC3.1 and TC3.4. In the case of TC3.1, HSM
was taken before the samples transitioned to Cc1. A selection of images are shown
in Figure 5-23 depicting key thermal events. The samples were heated from 35 to
150 ◦C at 5 ◦C min−1. As can be seen, a loss of colour begins to occur in TC3.1 from
69.5 to 114.5 ◦C. The sample also begins to lose crystallinity, but does not proceed
through a melt until 130.5 ◦C. This indicated that Cc2 crystals of 4Br2MA:35DNBA
isolated from flow crystallisation can display the SCSC phase transition as displayed
in evaporative samples isolated by Jones et al. However the transition occurs over a
215
longer temperature range than depicted in Figure 5-1 (67 to 84 ◦C). This may simply
be reflecting the fact that analysis of evaporative methods looked at heating individual
crystals whereas here, multiple crystals are heated simultaneously. Hence the more
important comparison may be that the colour change onset temperature is very similar.
(a) TC3.1 (taken before sample transition to Cc1). Thermochromism occurred between 69.5
to 114.5 ◦C before a melt at 130.5 ◦C.
(b) TC3.4. Thermochromism occurs from 91.0 to 118.4 ◦C and a melt-recrystallisation transi-
tion occurs at 118.4 to 120.1 ◦C. Another melt occurs at 130.8 ◦C
Figure 5-23: HSM images of TC3.1 (before switching to Cc1), TC3.2 and TC3.4.
Samples were heated from 35 to 150 ◦C at 5 ◦C min−1
For TC3.4, the sample does not display thermochromic behaviour until 91 ◦C, after
which crystals transition from yellow to colourless up to 118.4 ◦C. Unlike in TC3.1,
some of the sample then subsequently undergoes a melt-recrystallisation phase transi-
tion at 118.4 to 120.1 ◦C followed by a second melt at 130.8 ◦C. This indicated that
the thermochromic phase transition was more complex than first envisioned. Further
thermal analysis was carried out using DSC to confirm the melt-recrystallisation phase
change in TC3.4 (Figure 5-24). The DSC trace shows a sharp endothermic at 118.3 ◦C
followed by an immediate exothermic peak at 121.6 ◦C. This is followed by another en-
dothermic peak at 129.8 ◦C. The first exothermic and endothermic peaks closely match
the melt-recrystallisation period depicted in HSM for TC3.4 and it is likely this corre-
sponds to the transition from Cc2 to Cc1. The second endothermic peak at 129.8 ◦C
is close to the melt observed in Figure 5-23b. The major difference between TC3.1 and
TC3.4 measurements was the time allowed for solvent evaporation after collection. For
TC3.1, the sample was still wet, while TC3.4 was left to evaporate until dry. Further
discussion of the effects of drying and the switching properties of 4Br2MA:35DNBA
crystals isolated from antisolvent methods is continued in Section 5.3.4.
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Figure 5-24: DSC of TC3.4, showing a melt and recrystallisation event at 117.5 ◦C
followed by a second melting point at 129.8 ◦C
To summarise the work, segmented flow crystallisation was used to successfully produce
the metastable Cc2 in situ using antisolvent crystallisation methods. However, isola-
tion of Cc2 using traditional filtration techniques often led to the irreversible switching
of Cc2 to the non-thermochromic, stable Cc1 form. Attempts were made to success-
fully isolate the product but the sensitivity of Cc2 meant that the best method was to
allow the sample to slowly evaporate after collection. This in turn was shown in TC3 to
influence the thermochromic behaviour of 4Br2MA:35DNBA crystals and shifted the
onset temperature for the colour change. Furthermore in TC3.4, the thermochromic
phase transition was shown to occur via both a SCSC phase transition and via a melt-
recrystallisation phase transition. In a broader context, the design of the small jacketed
segmented flow crystalliser could facilitate rapid screening of temperature controlled
antisolvent, flow crystallisations. Its application in non-ambient crystallisation experi-
ments should be considered for other systems such as pharmaceuticals in future work.
5.3.4 Switching Properties of Isolated Multi-component Crystals
Jones et al. noted that block crystals of Cc2 from slow evaporation will readily switch
to Cc1 and the transition can be facilitated by temperature. HSM was used to deter-
mine if similar behaviour is seen in the crystal from antisolvent crystallisation. This
was confirmed to be the case for samples TC3.1 and TC3.4 isolated from flow crystalli-
sation, however drying of the sample in TC3.4 led to a change in thermochromic phase
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transition behaviour.
To investigate this further, batch antisolvent crystallisations were repeated using the
same method described in Section 2.6.2; the results are shown in Table 5.8. However,
the residual solvent following crystallisation was left to slowly evaporate, rather than
extracting the precipitate via filtration, to better reflect the flow crystalliser sample
conditions.







a: Confirmation of neutral 4Br2MA:35DNBA form, Cc2, determined by PXRD. See Appendix
Figure 9-30 for diffraction patterns
The samples were then subjected to DSC up to 150 ◦C and the resulting traces are
shown in Figure 5-25.
Figure 5-25: DSC traces for batch antisolvent crystallisation samples after drying
In all cases, the TCF4 samples show a clear melt-recrystallisation phase transition
occurring at 118 ◦C, before the melting point at 130 ◦C. This is in agreement with
TC3.4 (Figure 5-24) and in contrast to the sample reproduced from slow evaporation
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(Figure 5-4), which did not show a melt-recrystallisation phase transition before the
melting point. However, this does match the small transition at 117.9 ◦C in TC1.2
(Figure 5-11) during batch antisolvent crystallisation. Visual analysis of the phase
transition was carried out using HSM however, the trend was less straightforward than
the DSC traces. Figure 5-26 shows images from HSM analysis of TCF4.
(a) TC4.1. Heated from 35 to 150 ◦C.
(b) TC4.2. Heated from 35 to 115 ◦C and held for 10 minutes before cooling.
(c) TC4.3. Heated from 35 to 115 ◦C and held for 10 minutes before cooling.
(d) TC4.4. Heated from 35 to 150 ◦C.
Figure 5-26: HSM images of TC4 thermal events. All samples were heated at 5 ◦C min−1
For TC4.1 and TC4.4 the samples were heated from 35 to 150 ◦C. In both cases, a
clear melt-recrystallisation transition occurred at 118.3 ◦C and 122.4 ◦C, respectively.
This was followed by a full melt at 130.4 ◦C and 131.4 ◦C, respectively. In this case, the
results reflected the thermal events observed in the TC4 DSC traces (Figure 5-25) very
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well. For TC4.2 and TC4.3 HSM runs under the same conditions, different results were
obtained. For TC4.2, the crystals began to decompose at 100 ◦C without recrystallising
or melting, while TCF4.3 readily melted at 119 ◦C without recrystallising (Appendix
Figure 9-31). Repeat analysis while holding at 115 ◦C (close to the transition point
in the DSC) showed that both TC4.2 and TC4.3 could convert to the colourless form.
However TC4.2 in particular, showed a resistance to change, only partially transitioning
to the colourless form.
These observations from thermal analysis in combination with the behaviour difference
seen in TC3.1 and TC3.4, suggested that the thermochromic phase transition may be
influenced by macroscopic effects. Unlike TC3.1, samples from TC4 were allowed to dry
similar to TC3.4. This resulted in the thermochromic transition occurring via a sharp
melt-recrystallisation phase transformation, rather than a SCSC phase transition. As
the major difference between TC3.1 and TC4 samples was the lack of moisture, H2O
may play a role in enabling the SCSC transition. To test the effects of solvent on the
thermochromic phase transition in Cc2, a sample of TC4.2 was subjected to HSM after
the addition of 20 µl of water. Images of thermal events in the HSM can be seen in
Figure 5-27. The results show that a loss of colour via a SCSC transition in response
to temperature from 72.0 to 80.5 ◦C. Furthermore, no visible melt-recrystallisation
transition occurs at 118 ◦C in this case. This would indicate that the SCSC phase
transition behaviour is enabled by the presence of water.
Figure 5-27: HSM images of TC4.2 thermochromic behaviour in the presence of water.
Heated from 35 to 115 ◦C and held at 115 ◦C for 10 minutes.
In a further study, the HSM experiment was repeated with a sample of 4I2MA:35DN-
BA, Cc5 from TC1.8, which had previously shown a melt-recrystallisation event at 90
to 105 ◦C in thermal measurements (see Section 5.2.2 for full details). As with TC4.2,
TC1.8 was subjected to 20 µl of water on a glass slide before heating. Figure 5-28 shows
the thermal events observed on heating to 150 ◦C. As with TC4.2, TC1.8 shows that a
SCSC phase change replaces the melt-recrystallisation transition. However, Cc5 begins
to transform slowly to colourless crystals even before the sample is actively heated,
which reflects its lower stability compared to Cc2. In contrast to Cc4 in literature,
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which shows the thermochromic transition occurring from 45 to 65 ◦C, TC1.8 loses
colour from 32.0 to 50.8 ◦C. Similar to Cc4 however, is that the sample loses its colour
as a wave, spreading from the highlighted area in Figure 5-28. This extends across
the crystals at the physical point where they make contact. The sample then melts
at 120 ◦C, similar to previous 4I2MA:35DNBA complexes. A link to the HSM videos
discussed here can be found in the Appendix Section 9.3.
Figure 5-28: HSM images of TC1.8 thermochromic behaviour in the presence of water.
Heated from 32 to 150 ◦C at 5 ◦C min−1
The role of solvent in the thermochromism displayed by TC1.8 and TC4.2 is not well
understood and significant further investigation is required. The results would sug-
gest that the presence of moisture in the macroscopic domain facilitates SCSC phase
transitions and lowers the transition temperature. Potentially, this could lead to 4Br-
2MA:35DNBA or 4I2MA:35DNBA cocrystals whose thermochromic behaviour is ‘dor-
mant’ at temperatures below 100 ◦C, until switched ‘on’ by moisture. This could lead
to wider utility in their potential as switchable materials or humidity sensors, although
effectively extracting the metastable chromatic crystals of Cc2 and Cc5 remains a
considerable challenge.
5.4 Chapter Conclusions
In this chapter, the experimental investigation concerned the production of two halo-
genated multi-component cocrystal systems, 4Br2MA:35DNBA and 4I2MA:35DNBA,
which displayed thermochromic properties in previous sample from slow evaporative
crystallisation experiments. The aim of the work was to transfer the slow evaporation
method to a more consistent and scalable crystallisation technique, in particular, the
transfer from a batch process into a flow crystallisation platform would be desirable in
terms of production and product consistency.
Initial work concentrated on replicating the cocrystal systems Cc1 and Cc2 (4Br2M-
A:35DNBA) and Cc3 and Cc4 (4I2MA:35DNBA) by replicating the batch evaporative
methods used in their initial isolation. However, while the technique did produce the
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multi-component complexes, the results were inconsistent in reproducing the desirable
metastable Cc2 and Cc4 forms. Investigations extended to transferring the current
evaporative crystallisation to a more reproducible method. In pursuit of this, it was
found that H2O was an effective antisolvent for producing the metastable cocrystal
of 4Br2MA:35DNBA, however some difficulty was encountered in isolating the desired
form. It was found that temperature controlled antisolvent methods were most ef-
fective in batch for isolating the orange 4Br2MA:35DNBA cocrystal. In pursuit of
the metastable form of 4I2MA:35DNBA (Cc4), antisolvent crystallisation in MeOH
produced a new polymorphic form (Cc5) which was isolated and characterised using
thermal and X-ray diffraction methods. However its particularly low stability made it
undesirable for transference into a flow crystallisation process at this stage.
For 4Br2MA:35DNBA, the batch antisolvent method was transferred to a temperature
controlled segmented flow crystalliser platform which showed partial success in stabil-
ising the form. Initial crystallisation produced the desired Cc2 complex in situ, but
the crystals were often seeded by Cc1 encrustation within the end-piece or Y-piece.
However, careful collection of the precipitate and evaporation of the solvent allowed
isolation and characterisation of the orange coloured crystals. Results showed that
isolated crystals from flow matched the Cc2 crystal isolated from slow evaporation.
While the flow crystallisation approach is significantly more robust and scalable than
the initial evaporative method employed, the difficulty with isolating Cc2 effectively
provides a bottleneck in the work-up procedure. Considerable work in understanding
the switchable behaviour of the neutral cocrystal, particularly on effective isolation, is
required. A possible understanding may lie in the relationship between the effect of
solvent on the thermochromic phase transition in the crystal structure. Results from
thermal analysis of the dry cocrystal and the wet cocrystal of 4Br2MA:35DNBA, Cc2
and 4I2MA:35DNBA Cc5 indicates that the SCSC thermochromic phase transition
first chracterised by Jones et al. may be facilitated by the presence of moisture, per-
haps at the particle domain scale. In the absence of moisture, a melt-recrystallisation
event is observed. The mechanism for this behaviour is beyond the scope of this work,
but thermochromism that is mediated by moisture has been previously observed in
polymeric films and inorganic structures.106,208,209
In terms of the crystallisation process, an antisolvent segmented flow crystallisation was
successful in producing the 4Br2MA:35DNBA cocrystal form in situ. The temperature
controlled segmented flow crystalliser, analogous to the KRAIC, was developed to fa-
cilitate antisolvent crystallisation under variable temperatures. The platform could be
developed further and applied to other crystallisation processes to produce desirable
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kinetic or metastable polymorphs that require careful temperature control. While in-
tegration with upstream processing was not attempted within this body of work, the
segmented flow platform was developed from a holistic mindset and has the potential
to be incorporated in a wider continuous manufacturing (CM) framework. Therefore,
future work should consider the application of a small, high throughput, temperature
controlled segmented flow crystalliser for cooling or antisolvent crystallisation processes







The work carried out in this chapter constitutes a three month placement at the As-
traZeneca (AZ) Research and Development Department, Macclesfield, UK. The project
was conducted under the supervision of Dr. Amy Robertson and Dr. Anna Jawor-
Baczynska with the help of the Right Particle Team. The project aimed to evaluate
the potential of continuous crystallisation for a commercially relevant active pharma-
ceutical ingredient (API). In particular, the process was under consideration for im-
plementation of an integrated manufacturing process. The work in this chapter will
describe the development and evaluation of the continuous crystallisation process of an
API salt within this context. In order to protect the identity of the API no structural
data can be given of the product. Instead, this chapter will concentrate on the process
and possible benefits of working within a continuous framework.
The aim of the project is to investigate how effective a continuous crystallisation process
would be at producing a commercially relevant API salt. The work was to demonstrate
a continuous procedure for production of the salt form, without incurring any detri-
ment to the desired physical properties. Therefore the design of the crystallisation
processes needed to achieve physical characteristics of consistent, high quality which
were within the acceptable production parameters. However, preserving crystal quality
and key physical attributes when transferring from a batch to a continuous process is
a challenging task.
Evaluation of the process was to be carried out by comparing a sample taken from the
current batch process with that of a sample taken from the continuous crystallisation
procedure. The merits of the continuous crystallisation process would be evaluated with
respect to current manufacturing procedure. Optimisation of a process for production
of an API is important step in meeting critical quality attributes (CQA) as well as for
process efficiency. In particular, crystallisation of the API is important in ensuring the
efficiency of downstream processing. For example, a wide particle size distribution may
slow the filtration and drying procedure which can significantly impact the total time
required for the manufacturing process.91
6.2 Background
During this work, two distinct approaches were carried out to produce the API salt.
Initial investigations focused on using high throughput mixing in a tubular crystalli-
sation procedure. The second approach involved the operation of continuous stirred
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tank reactors (CSTRs) in periodic steady state operation. Tubular, high throughput
crystallisers benefit from very high mass and heat transfer and can have a marked
influence on the particle size, polymorphic behaviour and morphology of a crystallisa-
tion while also offering some of the highest process efficiency. In periodic steady state
operation of a CSTR, addition and removal of suspensions is carried out at a high
flow rate over short periods of time, rather than continuously. By using high slurry
velocities in the transfer lines, problems such as blocking and fouling experienced with
continuous CSTR can be avoided. The use of periodic CSTR operation for crystalli-
sation has been previously demonstrated for paracetamol and the cocrystal system,
urea:barbituric acid.112,123
The crystallisation process under consideration at AZ is shown in Figure 6-1. The
crystalline product is produced by a reactive crystallisation between the free base API
and the acid coformer succinic acid (SA). Upon mixing, spontaneous formation of the
salt product in solution occurs, which rapidly precipitates. For the purposes of this
thesis, the resultant product will be referred to as succinate salt (SAB) (where ‘B’
represents the API component).
Figure 6-1: Reaction for the production of the succinate salt
In the batch production of SAB the process proceeds by adding the free base to SA
suspended in acetone. Crystallisation readily occurs during charging of the second
component. As a consequence, the mixing environment is constantly changing during
crystallisation and this results in the formation of excessive fines and a wide particle size
distribution. It was noted that the filtration of SAB is slow during the washing stage
and proved to a bottleneck in the overall process. As such, an improved crystallisation
process could potentially enhance efficiency and productivity of the API salt. In this
context the effectiveness of the two different continuous crystallisation approaches will
be evaluated, with particular attention paid to changes in the crystal size, shape,
distribution and filtration properties as well as the applicability of each set-up to a
scaled-up crystallisation process. Furthermore, the work was produced from a holistic
viewpoint and aimed to ensure that the development of the continuous crystallisation




Solubility measurements for the API salt SAB were carried out using the Technobis
Crystal 16 apparatus. The Crystal 16 employs turbidity measurements to measure
dissolution. Samples are subjected in parallel to a heating and cooling temperature
programme. For each sample, a transmission vs time plot is generated and analysed
in order to determine clear and cloud points. The clear point is defined as the point
at which 100 % of light is transmitted. This is assumed to indicate complete particle
dissolution.
In this work, 1.5 cm3 glass vials of varying concentrations of SAB in acetone were pre-
pared with stirrer bars. The samples were heated using the same temperature profile.
The samples were heated from 25 to 55 ◦C, held at 55 ◦C for 10 minutes and then cooled
to 0 ◦C. The heating and cooling rate was set to 0.1 ◦C min−1 and the stirring speed was
kept at 700 rpm throughout the run. Data was processed using CrystalClear (v.1.0.0)
software. The clear point for each concentration was measured and the corresponding
temperature reading was used to construct a solubility vs temperature plot.
6.3.2 Tubular Mixer Crystallisation
Continuous crystallisation experiments using a mixer piece were carried out at the As-
traZeneca site in Macclesfield. The set-up is outlined in Figure 6-2. Stages 1 and 2
consisted of 500 mL jacketed feed vessels and stage 3 was a 1 L jacketed holder vessel.
Two Masterflex peristaltic pumps, equipped with Masterflex tubing (3.1 mm inner di-
ameter (ID)) were used to transfer the acid and base solutions from the feed vessels
(stage 1 and 2 respectively). The flow rate for each pump was calibrated using pure
acetone and Masterflex tubing (3.1 mm ID). A pump calibration curve of pump incre-
ments vs time was used to set the desired flow rates in all experiments (see Appendix
9-32). The acid and base solutions were combined in a Y or cross piece (3.1 mm ID)
where the components are rapidly mixed. The output was then transferred to the hold-
ing vessel (stage 3) for 20 minutes before collection, stirring at 300 rpm throughout the
experiment. After this dwelling period, the contents of stage 3 are removed and the
resultant slurry was filtered under vacuum to isolate the solid for analysis. One further
acetone wash was applied to the residual solid in stage 3 and isolated using filtration
under vacuum. The samples were allowed to dry overnight and the yield is calculated
from the total solid isolated.
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Figure 6-2: Schematic for the reactive crystallisation in a mixer piece
6.3.3 Continuous Stirred Tank Reactors
CSTR experiments were carried out using the system set-up at the AstraZeneca Re-
search and Development site, Macclesfield (Figure 6-3 and Figure 6-3b). The periodic
CSTR set-up consisted of two 500 mL jacketed feed vessels (stage 1 and stage 2) and
two 160 mL jacketed CSTR vessels (stage 3 and 4). Each CSTR (stages 3 and 4) was
operated at a working volume of 100 mL. Two Masterflex peristaltic pumps, equipped
with Masterflex tubing (3.1 mm ID) were used to transfer the acid and base solutions
from the feed vessels to the first CSTR (stage 3). Transfer between stages 3 and 4, as
well as stage 4 and collection was facilitated by a controlled high vacuum system. The
vacuum was applied manually at set intervals, by quickly opening and closing valves 2
(V2) and 3 (V3). Valve 1 (V1) was not used during these investigations. A dip tube
was positioned between stages 3 and stage 4 as well as stages 4 and collection to allow
the transfer of a calibrated volume (10 mL) of solution between vessels. The time be-
tween transfers was dictated by the residence time (RT) within each vessel. A total of
ten transfers per CSTR per residence time were carried out. The temperature of each
stage was controlled actively by three JULABO chiller units. One chiller was connected
to stages 1 and 2 in tandem, while separate chillers were provided for stages 3 and 4.
A thermocouple probe was installed in each vessel to maintain accurate temperature
control.
A concentration of 10 w/w% base solution in acetone was prepared to 500 mL from a
stock solution of 40 w/w%. A stoichiometric amount of the acid coformer was dissolved
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(a) Schematic for the reactive crystallisation in the CSTR system
(b) Picture of the reactive crystallisation in the CSTR set-up
Figure 6-3: AstraZeneca periodic CSTR system
in 500 mL of acetone in stage 2. The temperature of both was actively controlled at a
set stirring rate. Where seeds of the salt form were used, these were suspended in stage
1. Once equilibrated, each solution was pumped through the peristaltic pumps at a
specified flow rate into stage 3. Once the volume of stage 3 reached 100 mL, V2 was
opened and closed to transfer 10 mL of slurry to stage 4. This was repeated periodically
until stage 4 reached the specified volume of a 100 mL. At this point, V2 and V3 are
opened in tandem for the rest of the experiment. At the end of the experiment, the
contents of stages 3, 4 and the collection vessel are combined and removed. The slurry
is then filtered using vacuum filtration to isolate the solid for analysis. An acetone
wash is applied in stages 3 and 4 to remove any residual solid in the system, a second
filtration is applied and a total yield calculated for each run. The start-up calculations



















































































































































































































































































A method was devised for particle size analysis using a Malvern Mastersizer 3000
equipped with an Aero S dry powder dispersion. Dispersion of the powder is achieved by
accelerating particles using compressed air. The particles are then pulled through to the
Mastersizer 3000’s laser diffraction chamber (using a vacuum source) for measurement.
Sample feed rate is set using a vibrating feeder, which maintains a desired sample
concentration. In experiments discussed below, the sample was first subjected to a
molecular sieve with a 1 mm grid, in order to reject any large clumps of solid. Of the
fine powder obtained, a small amount of sample was then transported to the Aero S
feed tray. A method was developed using the Malvern Mastersizer software, the feed
rate for all samples was set to 25 or 50, while the compressed air was applied at 2 or
3 bar. All samples were run in triplicate and the percentile particle size distribution
values (Dv(10), Dv(50) and Dv(90)) are calculated from the average of these repeats.
SEM
High resolution scanning electron microscopy (SEM) images were collected using a
Hitachi TM-1000 scanning electron microscope operating with an accelerating voltage
of 15 kV. A small amount of sample was mounted onto an aluminium stub using a sticky
carbon tab. The samples were coated with gold using a Quorum Q150R sputterer to a
target thickness of 10 nm.
6.3.5 Filtration
Filtration times were analysed during collection. The following procedure was used to
compare results. A 1 L Büchner flask with a 9 cm diameter filter area was equipped with
a WhatmanTM filter paper. All filtrations were performed under a reduced pressure of
approximately 0.7 bar. The filter paper was initially wet with a few drops of acetone
to adhere the filter paper to the funnel. The slurry was then poured while shaking
continuously to avoid settling, onto the filtration unit. Once there was enough slurry
on the paper, the vacuum and a timer were started simultaneously. The filtration time
(t) was recorded as the time taken for the filtrate to go below the cake surface. The
total volume of the effluent (V ) was measured with a 1 L graduated measuring cylinder.
The weight of the solid extracted was measured after drying overnight.
Filtration analysis was carried out with the help of Dr. Claire MacLeod and Dr. Clare
Mayes. The cake resistance (α) was calculated by simplifying the modified Darcy’s
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The second component concerns the behaviour of the filter paper; as the resistance of
the filter paper will be much smaller than the cake, this component can be ignored for





Where P is the pressure (Pa), µ the viscosity (Pa s), C is the mass fraction (kg m3),
V is the volume (m3), A is the area of the filter (m2) and t is time (seconds). In this
comparison, the cake is assumed to be incompressible.
6.3.6 Thermal Analysis
Thermal analysis was investigated using a Thermal Advantage DSC Discovery instru-
ment. Between 1.0 and 8.0 mg of sample was weighed into a Tzero aluminium pan.
Samples were sealed by crimping an aluminium lid before being transferred to the au-
tosampler. The heating and cooling profile was programmed and interpreted using the
TRIOS Software (v4.2.1) under a stream of nitrogen gas.
Thermal gravimetric analysis (TGA) was investigated using a Thermal Advantage TGA
Discovery instrument. Between 1.0 to 5.0 mg of sample was weighed into a TGA
platinum 100 µL pan. Samples were loaded onto an autosampler for measurement.
The pan was transferred to the furnace chamber and subjected to a heating profile
programmed on using TRIOS software (v4.2.1) under an inert nitrogen atmosphere.
6.3.7 Process Analytical Technology
In situ measurements of the particle size and crystallisation induction time were mon-
itored using process analytical technology (PAT), with the help of Dr. Anna Jawor-
Baczynska, Dr. Lauren Agnew and Dr. Andre Powell at the AstraZeneca Research
and Development site, Macclesfield.
Raman Spectroscopy
The method and data processing of Raman measurements was carried out by Dr.
Andre Powell. A Raman (RXN1, Kaiser Optical Inc. series) immersion probe was
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used to implement in situ steady state measurements and crystallisation induction
times of SAB. Before the experiment, the laser was calibrated with a sample of SAB,
succinic acid, acetone and free base solution. The spectra were compared and non-
overlapping peaks were identified for measuring the SAB salt concentration. The probe
was submerged in stage 3 CSTR and the crystallisation was monitored throughout
the experiment between 804 and 1670 cm-1. When fouling occurred, the probe was
briefly removed from the CSTR and cleaned with ethanol before being re-submerged.
Multivariate curve resolution was carried out in Matlab software to separate the pure
components from the raw data. The output was plotted in Microsoft Excel.
Focused Beam Reflectance Measurements
The method and data processing of focused beam reflectance measurements (FBRMs)
was carried out by Dr. Anna Jawor-Baczynska. A Mettler Toledo FBRM probe (S400
series) was mounted into stage 4 of the CSTR set-up. The probe was submerged
below the solution suspension during the steady state experiment and particle size was
tracked throughout the run. Data collection was carried out at a scan speed of 2 m s−1.
Data was interpreted using the Mettler Toledo iC FBRM V4.4 software and plotted in
Microsoft Excel.
6.4 Results and Discussion
6.4.1 Solubility of the Salts
As SA is readily used in salt crystallisation experiments, its behaviour in a variety of
solvents is well known. The solubility of SA in acetone from literature is shown in
Figure 6-4.211 As can be seen from the graph, SA has a relatively high solubility in
acetone. At 20 ◦C SA is expected to dissolve up to 25 mg mL−1. The equation generated
from the solubility curve was used in later crystallisation experiments to prepare the
SA concentration. This was to ensure that the acid coformer remained fully dissolved
in the feed vessels and prevented precipitation in the feed line, which might lead to
blockages in the peristaltic pump. The solubility of SAB was investigated using the
Crystal 16 technology as outlined in Section 6.3.1. From the turbidity measurements
taken, a solubility plot was generated. The results are depicted in Figure 6-5. The curve
indicates that the solubility of SAB would double for every 10 ◦C rise in temperature.
However, while SAB shows a high temperature dependence on solubility, it shows a
very low overall solubility in acetone. The solubility curve indicates that even at 55 ◦C,
less than 10 mg mL−1 would be expected to dissolve.
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Figure 6-4: Solubility of the coformer succinic acid in acetone, values calculated from
literature211
Figure 6-5: Solubility diagram of the SAB determined by turbidity measurements in
the Crystal 16
Based on these results, it is clear that the solubility of the corresponding acid coformer
is at least an order of magnitude higher than the salt form. As the free base API
is also freely soluble in acetone, a relatively high concentration of the acid and base
can be dissolved as a feed solution. In the context of moving production into a flow
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environment, the reactive crystallisation will proceed readily when mixing the acid
and base streams together. While mixing will cause some dilution of the resulting
product concentration, the low solubility of the salt in comparison to the individual
components will ensure there is a considerable drive towards precipitation within the
expected working parameter range. Furthermore, the low solubility of the salt would
be expected to minimise loss to the liquor. Flow crystallisation experiments in this
work were developed to maintain undersaturation with respect to the acid and base
components while ensuring a supersaturated environment for salt formation to drive
precipitation.
6.4.2 Tubular Mixer Crystallisation
Initial experiments aimed to evaluate the effect of mixing on the crystallisation of SAB.
A simple crystallisation platform was developed to perform the reactive crystallisation
in flow. The set-up is outlined in Figure 6-2 and described in Section 6.3.2. The
operating parameters for the mixer piece crystallisation runs are outlined in Table 6.2





















































































































































































































































































































































































































































































































































































In comparison to a batch process, mixer pieces reduce the required time to homogenise
a mixture. In the case of rapid crystallisation procedures, inefficient mixing can lead
to a wide particle size range, which in turn can lead to problems with downstream
processing.212 In the batch production of SAB the process proceeds by charging the free
base into a vessel of SA suspended in acetone. Crystallisation proceeds readily during
addition of the base. During addition, the concentration and mixing environment is
constantly changing, this results in a wide particle size distribution. As a result the
filtration of SAB is slow, limiting the speed of the overall process. By combining
the acid and base feeds simultaneously in a mixer piece, the consistency of the mixing
environment and the concentration of the components would be maintained throughout
the process. This could potentially improve the quality of the product.
The first attempt at crystallisation in flow (AZ1), used a cross piece for the mixing of
the feeds (Figure 6-6). In this case, the acid feed was split and applied perpendicular to
the base feed. The flow rate of the acid was applied at twice the feed rate of the base to
ensure that at the cross piece, all flow rates would be the same. While the batch process
uses a 40:60 w/w% free base:acetone solution, the equivalent amount of SA required
to crystallise SAB exceeds the solubility of SA in acetone at 25 ◦C. As the feed lines
from stages 1 and 2 cannot be actively heated, it was deemed necessary to dilute the
stock base solution to half the concentration. This way, stoichiometric amounts of SA
required should remain fully dissolved at room temperature. This prevented unwanted
encrustation and blockages in the feed lines.
Figure 6-6: Schematic for the continuous reactive crystallisation using a cross piece
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Unfortunately despite these precautions, the system almost immediately blocked upon
combining the acid and base solutions in the cross piece. Formation of the salt was
exceedingly rapid and blocked the mixer piece within a minute. While some sample
could be isolated for analysis, the run could not continue and an accurate yield was
not calculated. The rapid nucleation was the result of a high relative supersaturation.
Using the equation from Figure 6-5 the saturation of SAB at room temperature is
0.69 mg mL−1. Using this value and by calculating the expected concentration of SAB
after mixing, the relative supersaturation ratio (σ) of SAB was approximately 155,
assuming the cross piece was at the same temperature as the feed (20 ◦C). This provides
a huge drive towards precipitation, which leads to encrustation in the tubing before
reaching the holding vessel (stage 3). It was also noted that splitting of the acid
solution before the cross piece did not result in equal flow rates perpendicular to the
base solution when reaching the cross piece. This was likely due to gravity and the
positioning of the cross piece, which created one easier pathway for the fluid to travel
along. While this could be overcome by careful design (introduction of a back pressure
regulator (BPR)) or control of the flow rates and positioning of the cross piece, it
would be difficult to accurately control. This would create unwanted inconsistencies in
repeated runs.
In AZ2 and AZ3 the design was simplified to eliminate the cross piece, instead the feeds
would be combined in a Y-piece mixer. The set-up is depicted in the experimental,
Figure 6-2. To try to avoid immediate blockages, the concentration of the free base was
reduced to 10:90 w/w% in acetone and equivalent molar amounts of SA were prepared
in solution. The temperature of the feed vessels was raised to 40 ◦C to reduce relative
supersaturation. While no active temperature control was applied to the Y-piece or
tubing, the flow rates were likely sufficient to ensure the solution remained above room
temperature upon mixing. The even addition of the flow rates in the Y-piece also
aimed to improve consistency and help prevent back-mixing in the union which lead to
crystal build-up in AZ1.
With these changes to the parameters, AZ2 was successful in running continuously until
feed depletion. The slurry was held at 0 ◦C for 20 minutes to maximise crystallisation
and solid recovery before filtration. The product was isolated with a total calculated
yield of 86%. The yield is relatively good and based on the low solubility of SAB
in acetone, the residual solid could be recovered with repeated washings. While the
production of the process was improved significantly, a large amount of crystalline
material was visible around the outlet of the tubing and within the transfer line from
the mixer piece to holding vessel (Figure 6-7).
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Figure 6-7: Photographs of crystal build-up around Y-piece and tubing outlet in AZ2
In order to try to improve the mixing and reduce encrustation further, AZ3 was run
under the same parameters but at five times the overall flow rate. The experiment
aimed to determine if turbulent mixing and high throughput could reduce particle size
distribution and help to prevent encrustation in-line. Using the literature values for
the dynamic viscosity and density of acetone, along with the experimental flow rate
and mixer piece ID an approximate Reynolds number (Re) was determined for AZ1 to
AZ3 using Equation 1.2. The calculated values for Re are depicted in Table 6.4.





Calculated from the combined flow rates in Table 6.2 using the dynamic viscosity and density of
acetone at 25 ◦C
Based on these values, AZ1 and AZ2 would show a laminar mixing regime, while AZ3
would show transitional/turbulent mixing. As anticipated, the increased flow rates
helped to reduce encrustation in the transfer line. Observations showed that unlike in
previous runs, the internal diameter of the tubing remained clear and unobstructed,
with the exception of some encrustation around the tubing outlet. However, the feed
solution was depleted in only three minutes. These observation indicated that while
production of the salt was possible in a continuous mixer platform, very high flow rates
would be required to avoid blockages, which may not be applicable with larger scale
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production. Furthermore, copious amounts of material would be required to run the
system for an extended period to determine if encrustation would build-up significantly.
As with AZ2, the slurry in AZ3 was held in stage 3 at 0 ◦C for 20 minutes before
extraction. The total solid recovery was 86% which suggests that a high throughput
can be maintained with the same overall yield. The high solid recovery, regardless of
the flow rate, may be a consequence of the long holding time in stage 3, relative to the
run time. Potentially, a larger difference in yield might be exhibited if after mixing the
combined feed was directly filtered.
Crystal Morphology
Analysis of the crystal morphology in AZ1, AZ2 and AZ3 was carried out using SEM.
A comparison is made with a sample supplied by AZ of SAB taken from the batch
process. The images are shown in Figure 6-8.
Figure 6-8: SEM images of SAB in a) Batch b) AZ1 c) AZ2 d) AZ3 after isolation at
x100 magnification
As can be seen by comparing the batch and continuous samples, there is a clear change
in morphology. The batch process consists of a series of platelets, with the largest
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appearing to be over 300 µm in length. In contrast, samples isolated from AZ1 to AZ3
appear to show a spherical shape, around 100 µm in diameter. The size varies, but the
general trend appears to indicate that AZ1 is smaller than AZ2 and AZ3, while AZ2
and AZ3 appear similar in size. Closer inspection of the spherical structures is shown
in Figure 6-9.
Figure 6-9: SEM images of SAB in a) Batch b) AZ1 c) AZ2 d) AZ3 after isolation at
x500 magnification
As can be seen, the particles isolated from the mixer process appear to consist of ag-
glomerates. Individual platelets can be identified within the agglomerate spheres and
in general, it appears that the spherical structures consist of an assembly of crystalline
platelets. From a visual perspective the individual platelets within these agglomer-
ates show a similar morphology to the batch sample of SAB, which indicates the same
crystalline form may be present. The structure of the agglomerates, along with the
high supersaturation ratios during crystallisation, suggests that the change in struc-
ture compared to the batch sample may be a consequence of rapid crystallisation.
Interestingly, the amount of visible fines is far lower in the continuous process than in
the batch reference. In general, agglomerates are usually undesirable as the formation
of agglomerates can trap solvent and other impurities within the structure, which can
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compromise the purity of the dried product.213 However, in some cases the formation
of regular agglomerates can be advantageous, as these structures can display improved
filtration properties compared to fines and needles, which increases the efficiency of
the downstream operations. Inspection of the surface of each sample gives further
indication of the low number of fines present compared to batch (Figure 6-10).
Figure 6-10: SEM images of SAB in a) Batch b) AZ1 c) AZ2 d) AZ3 after isolation at
x3000 magnification
Many of the surfaces of the larger particles in the batch sample are littered with small,
ill-defined particles. In contrast, the particles within the isolated agglomerates appear
better defined and while some smaller fine particles can be seen within the agglomerate
structure, they appear more clearly as plate-like structures. The surfaces and edges of
the batch samples appear rougher and more coarse than the smoother surfaces visible
in the continuous crystallisation samples. While it is difficult to discern the exact
cause of the lack of agglomerates in the batch process without a fuller understanding
of the procedure, the changes in size and shape in the continuous crystallisation can be
attributed to the changes in the protocol. As the batch process is known to require long
filtration times with agitation, this could potentially lead to breaking of the particles,
which in turn leads to the rough surfaces observed. Without an extensive study of
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the crystalline material before and after filtration, it is difficult to determine what
influence the filtration step has on changes to the crystal shape in batch. However, the
large ranges in plate sizes and non-uniformity of the particles in the batch sample do
suggest that the supersaturation changes during crystallisation and is playing a role
in crystal growth. The more consistent flow process produces a more uniform particle
shape, albeit in the form of agglomerates. The agglomerates are likely formed as a
consequence of the very high relative supersaturation levels.
Particle Size
Particle size analysis was carried out using the method described in Section 6.3.4. A dry
method was used to quickly and reproducibly determine the sizes of the agglomerates
to compare them to the batch particle size distribution (PSD). Initial observations
indicated the sample had a tendency to clump together. This was observed as a peak
in the PSD above 1000 µm which did not remain consistent during repeated scans
of the same sample. Furthermore, SEM images indicated that agglomerate sizes did
not exceed 1 mm. As such, the discrepancy was likely due to adherence of the solid
sample during measurements. To avoid the anomaly, efforts were taken to eliminate
the variable peak. A molecular sieve was used prior to measuring, to reject clumps
larger than 1 mm. Measurements were taken in triplicate using a high feed rate and
air pressure to separate the particles. Despite the precautions taken, the PSD should
be taken as an approximation and general trend, rather than absolute values.
Example scans of the PSD of the batch, AZ1, AZ2 and AZ3 samples are shown in
Figure 6-11. The batch sample shows a broad PSD typical of a sample with a range of
crystal sizes. This corresponds well with the various sizes of plate-like crystals observed
in the SEM images. The distribution is centred close to 10 µm which indicates a
large number of fines present in the sample. In contrast, the continuous crystallisation
samples show a bimodal distribution. The two peaks centre around 10 µm and 100 µm.
Using the SEM images to interpret the data, it is likely the 100 µm peak represents the
agglomerates. The smaller peak therefore corresponds to individual crystals broken off
from the agglomerates or dispersed fines. Comparing the batch and continuous samples,
in terms size range, the PSD of all samples taken from the continuous processes are
within the scope of the batch reference. However, the samples produced continuously
show a higher uniformity.
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Figure 6-11: Particle size distribution in batch, AZ1, AZ2 and AZ3
The D-values (Dv(10), Dv(50) and Dv(90)) represent the intercepts in the size distri-
bution at 10%, 50% and 90% of the cumulative volume density. For the batch and
mixer samples, these are summarised in Table 6.5. The values quoted are calculated
from the average and standard deviation of at least three repeats.
Table 6.5: Particle size distribution percentiles for samples of SAB taken from AZ1,
AZ2, AZ3 and the batch reference
Experiment Dv(10) Dv(50) Dv(90)
(µm) (µm) (µm)
Batch 4.64 ± 0.26 25.0 ± 1.95 204 ± 21.0
AZ1 6.86 ± 1.00 47.8 ± 3.29 96.6 ± 1.62
AZ2 8.41 ± 0.13 70.2 ± 3.11 181 ± 32.7
AZ3 9.84 ± 0.14 65.5 ± 0.33 137 ± 1.1
D-values for the batch sample show a trend that favours the finer particles, as the
Dv(50), or median value of the distribution is around 25 µm, while the Dv(90) value
is close to 200 µm. The fact that the median value is relatively small compared to
the Dv(90) value, is an indication of the broadness of the distribution, along with a
favouring towards a smaller particle size. In the case of the flow samples, Dv(50) values
are larger, with the cumulative volume lying more centrally compared to the Dv(90)
value. Interestingly, AZ1 shows the smallest particles produced in flow. The values are
significantly smaller than AZ2 and AZ3, this may reflect the difference in the mixer
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type (cross piece vs mixer piece) or the difference in the supersaturation level upon salt
formation. In terms of mixing, despite the difference in Re for AZ2 and AZ3, only a
small change is observed in the Dv(50) value. However, the faster mixing in the AZ3
does provide a tighter distribution. As AZ1 particles were much smaller, it’s likely that
the type of mixer piece or the supersaturation level play a more significant role in the
PSD than the flow rate under the current conditions.
Thermal Analysis
A comparison of the differential scanning calorimetry (DSC) and TGA traces for AZ3
and the reference sample of SAB can be seen in Figure 6-12. The scales are omitted in
the interests of sample confidentially.
Figure 6-12: Comparison of DSC and TGA traces for AZ3 and the batch sample of
SAB
The large peak in the DSC trace indicates the melting point of the salt. A good overlap
is observed between the two samples produced in batch and flow. This is complemented
by a similar change in the weight loss observed during the TGA trace. This provides
confirmation that the product produced is the desired salt form and displays similar
physical properties to the batch. A minor discrepancy is observed in the DSC trace
of the batch sample above the melting point, corresponding to a sharp drop in heat
flow and gradual return to the baseline. As this is not reflected in the TGA, it is
likely a system error and can be ignored. A repeat would prbably remove the anomaly.
The TGA also does not show any mass loss with respect to solvent trapped in the
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agglomerates of AZ3. If this was the case, it would appear as a change in the mass
loss trace that was not present in the batch sample. However, for the detection of
very low concentrations of residual solvents, additional techniques would be needed to
confirm the solvent/impurity level is within specification. TGA-mass spectrometry or
high performance liquid chromatography (HPLC) would be effective ways to identify
and compare the level of impurity retention in the agglomerate structures.214
Conclusions
In terms of platform development, the use of tubular mixing pieces allows consistent
control over the mixing environment under high supersaturation concentrations. The
process could be potentially integrated with upstream continuous manufacturing. For
instance, the output from the free base synthesis could be directed into stage 1, with
molar equivalents of SA prepared in stage 2. Downstream filtration could also be
facilitated by automated and controlled withdrawing of the suspension from stage 3,
either periodically or continuously. The use of a mixer piece allows rapid mixing of
the acid and base solution which produces the desired SAB salt form. The solution
crystallises with a high throughput forming a series of spherical agglomerates made
from numerous well defined plate-like structures. The flow process results in a PSD that
is significantly more uniform than the batch process, though the overall agglomerate
structures are larger than the median batch crystal size. However this in turn, reduces
the amount of fines in the filtered product. Despite the potential advantages of the
more uniform PSD, the required flow rates to ensure no blockages occur during the run
are difficult to maintain effectively, particularly over an extended period. The amount
of encrustation around the tubular outlet within the short run time would eventually
cause performance issues or blockages in-line. A possible alternative set-up would be
to introduce temperature control to the feed-lines and mixer piece. This could reduce
the amount of encrustation and allow a higher concentration of SA and the free base
to be used, increasing production. However, as the solubility of SAB is very low in
acetone the effectiveness of temperature control may be fairly limited. Based on the
high supersaturation levels and encrustation observed, a mixer piece crystallisation
process is unlikely to be practical. Therefore, a system capable of handling high solid
loadings and encrustation was sought as an alternative.
6.4.3 Periodic Continuous Stirred Tank Reactor Crystallisation
CSTRs are the most common form of continuous crystallisers currently investigated.
Compared to tubular crystallisers, they are much more reminiscent of batch crystallis-
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ers and generally considered a more straightforward approach to transferring a batch
process to a continuous process. The effectiveness of CSTRs on the crystallisation of
pharmaceutical drugs has been previously demonstrated.124 Furthermore, they have
been successfully integrated into a end-to-end continuous production process for phar-
maceutical production.27
A traditional CSTR is operated by the continual addition of the feedstock and removal
of the slurry. But there has been recent examples showing the use of periodic CSTRs
crystallisers.123,215 In this mode of operation, periodic addition and removal of suspen-
sions is carried out using a high flow rate over short periods of time. The advantages
of using periodic operation are the extended dwelling periods within each vessel and
the reduction in sedimentation within feed lines. In periodic operation, the system
reaches a “controlled” steady state after an induction period, in which perturbations
in the system have reached a minimum. The aim of this work was to evaluate the
effectiveness of a periodic CSTR crystallisation process on the reactive crystallisation
of SAB. The process developed in the mixer piece experiments was transferred to the
CSTR set-up to allow for comparison between the two techniques.
Platform Development
The CSTRs set-up is outlined in Figure 6-3a and described in Section 6.3.3. The
operating parameters for the CSTR crystallisation runs are outlined in Table 6.1. The












































































































































































































































































































































































































































































































































































































From the results of the solubility measurements and the initial mixer crystallisation
experiments, it was determined that the reactive crystallisation experiments would be
performed in the CSTR set-up at a set temperature of 20 ◦C across all stages. This
would prevent a cooling profile from influencing the particle size. This was also the
lowest possible temperature that could effectively dissolve the required molar equiv-
alent amounts of the acid coformer. Furthermore, the low solubility of the API salt
meant that maintaining a low temperature to maximise yield was not necessary, as
the expected additional loss to liquor would be marginal, while the required energy
to maintain a reduced temperature would be high. As the CSTR platform is more
sophisticated than the previous approach, the simplified experimental parameters were
also used to reduce the number of variables. As described in the experimental section
6.3.3, periodic transfer of the suspension was facilitated by a vacuum that was operated
manually, while feed addition of the acid and free base was controlled by peristaltic
pumps. This set-up was maintained throughout all experiments.
In AZ4, the acid and free base are added simultaneously. This approach was maintained
throughout all experiments with the exception of AZ8 (acid start-up) and AZ10 (base
start-up). AZ4 attempted to transfer the process which had shown promise in AZ3,
into the CSTR set-up. As the periodic operation of a CSTR system is less prone to
blockages, a slower flow rate could be used. The base and acid were combined within
the vessel (stage 3), to avoid any potential encrustation in feed lines. Based on the
combined flow rate and operating volume of the CSTR system, a total residence time
of 20 minutes was maintained throughout the experiment. This ensured the process
could be run steadily, over a longer period, while maintaining a similar total process
time to mixer crystallisation experiments. The total run time for AZ4 was 96 minutes;
equivalent to 4.8 residence times. Crystallisation occurred within seconds of combining
the free base and acid in stage 3. During the operational period, a total of 48 vacuum
transfers were performed. Under the conditions described in Table 6.6, AZ4 suffered no
blockage in-line. Transfer between vessels was rapid and the suspension did not adhere
to the walls of the tubing. A small amount of residual product was noted to be left
behind, however, at no point did the solid residue accumulate during the operational
period. After extraction of the suspension, it was noted that extensive encrustation
occurred in stage 3 of the CSTR platform, while almost no observable encrustation was
present in stage 4 (Figure 6-13)
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Figure 6-13: Encrustation in stage 3 and 4 after SAB production in the CSTR set-up
The high encrustation in the first vessel is the result of the high supersaturation levels
and is analogous to encrustation observed within the tubing lines seen in the mixer
experiments. However, the lack of noticeable encrustation in stage 4 indicates that
nucleation occurred predominantly in stage 3, while stage 4 promoted crystal growth.
Despite the large amount of encrustation, no noticeable drop in performance was ob-
served during the run, though visibility in stage 3 was substantially reduced. The total
solid recovery after washing was calculated to be 69.3%. As the encrustation in stage 3
could not be removed during the acetone washing stage, this likely corresponds to the
missing yield. Overall, the process proved much more effective than the mixer piece
experiments, as the process was robust enough for an extended operational period. The
major issue observed was the high amounts of encrustation exhibited in stage 3. While
this did not impede the crystallisation over the operational period, it could eventually
cause issues in transfer of the suspension or effect the quality of the crystalline prod-
uct. As such, investigations focused on controlling the amount of encrustation, whilst
analysing any changes in the extracted product particle size and shape.
In AZ5, SAB seeds were introduced to the system. The addition of seeds has been
shown to be an effective method for controlling salt crystallisation and particle size.216
In order to effectively deliver seeds to the CSTR, the free base solution was used as a
suspension vessel. The seeds used were taken from the batch SAB reference. As the salt
is only weakly soluble in acetone, the 10:90 w/w% free base:acetone solution could be
easily saturated with SAB at the required temperature. The w/w% of seed added was
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calculated as a percentage of the expected output of SAB. In order to keep the crystals
suspended without entangling the feed lines, stage 1 was continuously stirred at a low
speed (25 - 50 rpm). The free base solution provided a convenient medium for transfer
of the seeds in flow, the low solid loading was compatible with the peristaltic feed pumps
and kept within the process specifications. As with AZ4, the process proceeded well,
with no notable obstruction in the feed delivery or transfer during the crystallisation.
The solid recovery was 75.9%, indicating the addition of seeds to the free base solution
increases the crystallisation yield by more than 5%. The process had a similar run
time of 80 minutes. No noticeable change was perceived in the amount of encrustation
visible in stage 3, despite the addition of seeds. Most likely the low seed loading could
not offset nucleation on the walls of the vessel.
In AZ6, the stirring rate and seed loading was increased to 600 rpm and 1 w/w% re-
spectively. The faster stirring rate and higher seed loading were used to determine if
encrustation could be mitigated by increasing seed loading and reducing sedimenta-
tion. The higher stirring rate also aimed to ensure the suspension was more evenly
distributed, so that transfer between Stages 3 and 4 was not preferentially removing
smaller, better suspended crystals. This was notable when comparing PSD between
the main collection and the acetone washing stage of the process for AZ4. The differ-
ence between the PSD of the sample from the main collection and the wash are clearly
visible in Figure 6-14.
Figure 6-14: Particle size distribution difference between the main collection and wash
stage in AZ4
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In comparison with AZ5, AZ6 had a similar overall yield suggesting that the additional
seed loading did not increase solid recovery. However, the sedimentation was deemed
much improved at 600 rpm with a visibly more uniform suspension observed during
the run. As a consequence, very little solid was collected from the acetone wash after
removal of the main collection. The fraction of product collected in the washing step
in AZ4 and AZ5 was 10.2 % and 2.8 % respectively, while in AZ6, this was reduced to
1.7 %, reflecting the reduction in sedimentation.
Despite the minor improvements in AZ6, a reduction in encrustation in stage 3 was not
discernible from previous runs. In AZ7, stages 1, 2 and 3 were heated to 40 ◦C, while
stage 4 remained at 20 ◦C. The stirring rate was held at 300 rpm and a seeding loading of
1 w/w% was used. As the nucleation vessel was heated, the initial crystallisation should
be less supersaturated. The high seed loading and temperature aimed to help mitigate
the encrustation in the vessel. Initial relative supersaturation was reduced from 124
to 24. Solid recovery remained at 75.4 %, close to the value achieved in AZ5 and AZ6.
The yield therefore was not majorly effected by the higher initial temperature. A small
reduction in the onset of encrustation was observed, but no major improvement was
seen by the end of the run. The slower stirring speed did lead to sedimentation in
the vessel after an extended period. Future experiments could potentially investigate
whether increasing the initial temperature further might improve encrustation, (i.e.
heating to 55 ◦C would reduced the relative supersaturation to 7) but as the solubility
of the API salt is low in acetone, it is unclear how much of a difference this would make
to encrustation over extended periods. Furthermore the current set-up has no method
of controlling the temperature in the feed-lines. This capability could be incorporated
in later designs to improve control, but could not be carried out within the scope of
this work. As such alternative methods were sought to influence nucleation.
In AZ8, the start-up procedure was investigated. The seed loading and stirring rate
used were the same as AZ5. However, rather than filling stage 3 with the acid and
base solutions simultaneously, the vessel was allowed to half-fill with the SA solution
first. The SA pump was then switched off and the free base added. Once stage 3 had
filled, both pumps were switched on and the run continued in the same manner as
the other periodic CSTR experiments. The idea was to provide a more dilute system
at the beginning of operations, thereby reducing the likelihood of excessive nucleation
on the walls of the vessel. The more gradual increase in supersaturation compared to
previous runs may help to decrease encrustation and promote nucleation via seeding
(Figure 6-15).
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Figure 6-15: Calculated relative supersaturation ratios in AZ5, AZ7 and AZ8 during
the start-up procedure, assuming 100% production of SAB
Using this approach, encrustation appears to have been improved during the initial
stages of the process. This was maintained for the first residence time (Figure 6-16).
However, after 30 minutes there was little visible difference between the amount of
encrustation observed in previous runs. It is possible that encrustation could have
been reduced inside the vessel, but this is difficult to tell without in situ monitoring.
The overall yield was maintained at 75%.
Figure 6-16: Encrustation in AZ8 at time 0, 3 and 30 min
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Crystal Morphology
Images of AZ4, AZ5, AZ6 and AZ7 are shown in Figure 6-17. AZ8 SEM images are
included in the Appendix (Figure 9-33) but showed little difference to AZ5, so have
been omitted for clarity. As can be seen from the images obtained, the isolated samples
show the same spherical agglomerates observed in the mixer experiments. However,
the size is more variable. AZ4, representing the unseeded experiment, appears to show
agglomerates larger than those observed in AZ5 and AZ6 where seeding was used. AZ6
appears to show a larger proportion of fines than AZ5 which is unsurprising as the high
shear rates generated by the increased stirrer speed may be causing the agglomerates
to break. In the case of AZ7, the particles are much more varied in size.
Figure 6-17: SEM images of SAB in a) AZ4 b) AZ5 c) AZ6 d) AZ7 after isolation at
magnifications of x100
As was the case with the mixer experiments, the agglomerates consist of the individual
platelets of various sizes (Figure 6-18). The plate-like morphology of the agglomerate
components is consistent with the morphology of the batch process sample. Since the
relative supersaturation ratio is similar to the mixer piece experiments, it is unsurprising
that the morphology is unchanged in the CSTR runs. There are however, visibly
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more fines in samples taken at higher stirring rates and seeding experiments than
the unseeded runs. The agglomerates also appear larger than those visualised from
the mixer experiments. The trend appears to indicate that a higher stirring speed
reduces the size of the agglomerates (AZ6), while a heightened temperature on the
initial crystallisation widens the distribution of size of the agglomerates (AZ7).
Figure 6-18: SEM images of SAB in a) AZ4 b) AZ5 c) AZ6 d) AZ7 after isolation at
magnifications of x500
The particulates within the isolated agglomerates from continuous CSTR runs appear
as well defined as previously noted in mixer experiments (Figure 6-19). Even with the
changes in the apparatus and parameters, the surfaces and edges of the samples all
exhibit similarly smooth faces and edges to the mixer experiments. As isolation in all
runs has resulted in agglomerates, this may reflect a preference for the formation of
agglomerates regardless of the crystalliser. However, these structures are not present in
the batch sample so particle size and shape should be controllable by careful selection
of the crystallisation and extraction procedure.
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Figure 6-19: SEM images of SAB in a) AZ4 b) AZ5 c) AZ6 d) AZ7 after isolation at
magnifications of x3000
Particle Size
An example scan of the PSD of the AZ4, AZ6, AZ7 and AZ8 are shown in Figure
6-20. The periodic CSTR samples show a bimodal distribution reminiscent of the
mixer piece experiments. However, while the general shape of the PSD is similar,
broadening is particularly prominent for AZ7. In the case of the fines peak, AZ6 shows
the highest proportion of smaller particles, which corresponds well with the SEM images
and would be expected considering the higher stirring rate and seed loading used. The
isolated particles remain within the range of sizes isolated from the batch reference.
The uniformity is good in the cases of AZ4 and AZ6, though AZ7 shows a broadening of
the size range, with a trace similar to the batch. This could indicate that temperature
plays a significant part in the size distribution. Maintaining a constant temperature
may promote more uniform particles, but in the form of spherical agglomerates.
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Figure 6-20: Particle size distribution of AZ4 to AZ8
The D-values for experiments A4Z to AZ8 are summarised in Table 6.8. The values
quoted are calculated from the average and standard deviation of at least three repeats.
Comparison of the D-values with the mixer experiments indicates that the agglomerates
from the CSTR are generally larger than the mixer piece samples. The D-values with
the exception of AZ6 show a median of between 130 and 170 µm, while the median
for AZ6 is below 100 µm and approaches the values observed in AZ2 and AZ3. This
perhaps indicates that a higher stirring rate promotes a mixing regime that is similar
to that from the mixer piece unions.
Table 6.8: Particle size distribution percentiles for samples of SAB taken from AZ4 to
AZ8 and the batch reference
Experiment Dv(10) Dv(50) Dv(90)
(µm) (µm) (µm)
AZ4 22.3 ± 2.26 167 ± 4.76 366 ± 8.46
AZ5 15.4 ± 0.17 143 ± 4.51 330 ± 3.06
AZ6 9.28 ± 0.29 85.5 ± 1.10 198 ± 7.27
AZ7 13.4 ± 1.65 127 ± 8.38 492 ± 17.4
AZ8 19.7 ± 0.95 161 ± 11.4 391 ± 28.3
Comparison between AZ4 and AZ5 suggests that seeding causes a slight shift in the
distribution to a lower value, but only has a marginal effect, making a larger difference
to the overall yield. While the change in Dv(90) values is only moderate in AZ4 and
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AZ5, there is a clear difference with AZ6 and AZ7. Based on this, the likely outcome is
that higher stirring speeds favours smaller agglomerate formation, while higher initial
temperatures favour larger agglomerate formation. This in contrast to AZ1, AZ2 and
AZ3 where the change in temperature and Re caused little change in the particle
distribution. Here the effect of stirring speed and temperature is far more pronounced.
Based on these studies, the spherical agglomerate size could be potentially tuned to
a desired size and distribution by adjusting mixing, temperature and seeding. As the
stirring rate is independent of the flow rate in a CSTR, this provides an advantage
over the mixer piece process. Furthermore, the use of CSTRs in series provides better
mixing and temperature control than an equivalent sized batch process, allowing greater
control over crystal size distribution.
Filtration
The agglomerates produced during the continuous flow experiments have been observed
to filter quickly. In all cases with the exception of AZ4, the filtrate passes through the
cake in less than a minute. As a comparison, the batch sample was suspended in acetone
to an equivalent mass fraction. The time taken to filter each solution was measured
and the results are summarised in the Appendix Table 9.5. From the data acquired
experimentally, the cake resistance was calculated using Darcy’s Law as outlined in the
experimental section 6.3.5. The results are summarised in Figure 6-21.
Figure 6-21: Cake resistance for AZ4 to AZ8 and the batch sample of SAB
As can be observed from the graph, the specific cake resistance of the batch sample was
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an order of magnitude larger than the values calculated for the periodic CSTR runs.
The only exception is AZ4, however a poor vacuum seal lead to higher cake resistance
than anticipated and this would likely be rectified in a repeat measurement. While this
clearly shows an improvement in small scale filtration experiments, further investigation
would be required to confirm whether the particles would perform better at scale. This
is important as the compressibility of agglomerates under pressure filtration can lead
to performance issues. This is particularly the case when agitation is introduced to
the cake layer.217 While a low cake resistance is only one factor that contributes to
the performance of a particle during filtration, clearly the agglomerates in flow display
measurably faster filtration that could be of benefit. Of particular interest would
be whether agglomerates might be useful in integrated processes, where continuous
crystallisation feeds directly into a continuous extraction unit. Often filtration is a
bottleneck, in looking to integrate continuous manufacturing, a slow filtration could
have a detrimental effect on the upstream methodology. If the agglomerates are free
of unwanted impurities, it is possible that spherical shape may be more effective in a
integrated continuous processes than finer crystals.
Sonication
AZ9 aimed to investigate the effect of ultrasound on the encrustation noted to occur
regularly in stage 3 during crystallisation. While AZ8 showed that this could be reduced
by initially filling the vessel with SA solution to reduce early supersaturation, it did
not provide a long term solution. The encrustation is excessive on the walls of the
vessel and is typical of crystallisation processes with a high supersaturation and rapid
nucleation process. This can be detrimental to the system in the long term, leading to
blocking issues, reduced solid form control and extended washing and cleaning periods.
While this has not been a problem with the current operational time frame, ideally
this should be reduced as much as possible. To counter the encrustation, an additional
ultrasound system was installed into stage 3. The ultrasound was submerged halfway
into the vessel and switched on at 50% power output before pumping the solution.
Sonication was applied throughout the experiment. A comparison of the stage 3 after
the run in AZ5 and AZ9 is shown in Figure 6-22.
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Figure 6-22: Effect of ultrasound on encrustation in stage 3
As can be seen, there is a visible reduction in encrustation around the interior of
the vessel when sonication is applied and therefore ultrasound was effective at reducing
encrustation. During observation of the run the suspension of solids was also improved,
which would suggest that smaller particles are being formed. This would be expected
as sonication has previously been shown to be effective at reducing particle size and
encrustation.130,218 The addition of sonication also slightly increased the overall yield
by 2 to 3%. This is likely due to a better suspension leading to easier extraction
and reduction in residual solid in the vessel. However the application of ultrasound
had an adverse effect on the agglomerates. This was observed as significant increase
in filtration time. SEM images confirm that breakdown or a reduction in agglomerate
formation occurred, as more fines were present (Figure 6-23). The addition of sonication
likely prevented the forming or facilitated the breakdown of the agglomerates. As a
consequence the filtration time was increased. The reduction of agglomerate formation
due to ultrasound has been previously demonstrated by Narducci et al. for adipic
acid.219
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Figure 6-23: SEM images of SAB in AZ9 at a) x100 b) x500 c) x1000 and d) x3000
magnifications
The overall pattern for the PSD is changed compared to previous runs. (Figure 6-24).
The typical bimodal distribution is lost in favour of a much higher volume density
of fine crystals. The D-values from laser diffraction measurements are summarised in
Table 6.9. The median volume density (Dv50) indicates that at least 50% of particles
detected were smaller than 12.3 µm. While a very broad distribution (Dv(90) = 762 µm)
is indicated, based on the SEM and lack of agglomerates it likely this was an anomaly,
caused by adhesion of the smaller particles which failed to break-up before detection.
In this case, an alternate methodology could be developed to give better measurements,
such as suspending the sample in a solvent medium before detection.
Table 6.9: Particle size distribution percentiles after sonication
Experiment Dv(10) Dv(50) Dv(90)
(µm) (µm) (µm)
AZ9 3.49 ± 0.02 12.3 ± 0.10 762 ± 33.2
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Figure 6-24: Particle size distribution of AZ9
Overall, sonication did effectively reduce the amount of encrustation present in stage
3, however this had an adverse effect on the agglomerate structures. As a consequence
of the much smaller particles formed, an increase in filtration time was observed. If
the faster filtration time associated with the spherical agglomerates was to be desired,
ultrasound would need to be kept to a minimum. A possible alternative approach
might be to apply sonication periodically, rather than continuously. In this manner,
the agglomerate structure may remain intact, while still reducing the amount of en-
crustation. However, a further issue with ultrasound is the long term scale-up.220 This
is due to the fact that while ultrasound probes deliver a very high intensity at the point
of delivery, the sound energy density rapidly decreases with distance. As such, their ef-
fectiveness becomes increasingly non-homogeneous as vessels are scaled-up. Therefore,
the cost benefit of ultrasound generally decreases for larger vessels. As SAB is currently
produced on a multi-kilogram scale, the application of this technology for continuous
crystallisation scale-up is fairly limited. The experiment does highlight that encrus-
tation and agglomerate reduction controls can be introduced and may be applicable
to some smaller scale processes, particularly where the agglomerate structures are not
advantageous.
Steady State
Up to this point, the work has demonstrated that using a periodic CSTR system may
be a feasible approach for the crystallisation of SAB. However, some encrustation and
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sedimentation issues have been encountered, particularly in the stage 3 CSTR. Based on
the results thus far, an optimised process was considered to overcome these issues. The
results from AZ5 indicated that the addition of seeds to the free base was an effective
and simple method for boosting solid recovery. AZ6 showed that a higher stirrer speed
would help to suspend particles and reduce agglomerate sizes without causing excessive
breakage. AZ8 indicated that pre-filling with the SA solution resulted in a initial
reduction in encrustation with little immediate impact on the filtration speed.
AZ10 aimed to demonstrate that the system could be run over a longer period without
issue. The conditions are described in Table 6.7. In this case, AZ10 was run at 600
rpm, with a 0.5 % seed loading in order to reduce sedimentation and maximise the
yield respectively. Rather than pre-fill with the acid as in AZ8, AZ10 tried pre-filling
the first CSTR with the free base/seed solution. This more closely reflected the batch
production method, reduced the initial supersaturation ratio and ensured that a larger
proportion of SAB seeds were present at the beginning of the salt crystallisation. To
determine when a controlled state of operation was reached, steady state behaviour
of the periodic CSTR was investigated using process analytical technology (PAT). An
immersible Raman probe was placed in stage 3 and FBRM probe in stage 4. The
Raman probe would measure the onset of crystallisation, while the FBRM probe would
determine particle size in situ. In this way, a better understanding of the system
could be carried out while also evaluating the performance and productivity over an
extended period. During the run, crystallisation proceeded over the 4 hour period with
no blockages or issues occurring with the transfer of the slurry. Initial filling with the
base solution resulted in a reduction in encrustation initially, but fouling was still high
after 4 hours. Despite this no notable drop in performance was observed. The system
was run for over 12 RTs, with an overall 69% yield achieved (Table 6.10).
Table 6.10: Sample yield per collection period in AZ10




A 60:00 83.9 1 - 3
B 37:00 51.8 3 - 5
C 58:00 74.5 5 - 8
D 58:00 76.0 8 - 11
E 20:00 30.4 12
Total 243:00 69.0 12
A graph of the Raman data of relative concentration vs absolute time is depicted
264
in Figure 6-25. As can be seen from the graph, initially, a high amount of natural
light is seen, this is during the base charging phase. As the acid is added, the light
rapidly decreases and the number of counts for the solid phase of SAB rises. After
30 minutes the signal has stabilised, indicating that steady state has occurred in stage
3. Unfortunately, after an hour, the probe becomes fouled by encrustation and the
proportion of signal from the solution phase is lost. The probe was later cleaned during
switching of the collection vessels, where the signal can be seen to return to the same
level as before fouling. Unfortunately, fouling of the probe meant a large proportion of
the signal was lost. The fact that the signal returned to the same level after cleaning
is a good indication that a steady state was achieved.
Figure 6-25: Raman monitoring and probe fouling in AZ10
The signals gathered for the FBRM probe in stage 4 are shown in Figure 6-26. Over
the course of the run, each trace shows a distinct oscillating wave pattern. There are
also some fouling issues, but these are less pronounced than in the Raman tracking.
This would be expected, as nucleation and encrustation are more pronounced in the
first vessel. The oscillating pattern does suggest that some minor disturbance to the
system is occurring, however this is not unexpected as transfer to and from the vessel
is occurring at regular intervals. Overall disturbances become minimised after 1 hour
of operation, which suggest the system has reached a controlled state of operation.
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Figure 6-26: Particle tracking and probe fouling in AZ10
In terms of particle size, an interesting trend emerges when comparing the chord lengths
at different time stamps (Figure 6-27).
Figure 6-27: Chord length changes with time in AZ10
At the beginning of the run, the chord lengths show a broad distribution, centred close
to 10 - 20 µm. As the run proceeds, this gradually changes to a bimodal pattern, with
two peaks centred on 4 - 5 µm and 40 - 50 µm. While the exact values are lower than
those previously encountered in off-line PSD measurements, the pattern observed is
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reminiscent of the measurements taken on the laser diffractometer. According to the
data, the bimodal pattern is formed and maintained throughout the run after 1 hour.
This is a clear indication that the system reached steady state within this time period.
Offline analysis was carried out using SEM and laser diffraction measurements. A
comparison of the crystals in sample A (before steady state) and sample C (steady
state reached) clearly shows that the fine crystals are predominately formed in the early
stages of the crystallisation process (Figure 6-28). The agglomerates are preferred once
the system has reached steady state. Previous runs therefore consisted of a mixture
of the two preferred structural arrangements. It would be interesting to determine if
the preference for fine structures in the early stages of the run is an effect of the initial
dilution, or whether the formation of the agglomerates is related to the encrustation
build-up on the interior walls.
Figure 6-28: SEM images at x100 and x500 magnification for AZ10 samples: A, (a)
and (b) and C (c) and (d)
The offline PSD pattern and the corresponding D-values for each collection are shown
in Figure 6-29 and Table 6.11 respectively. Based on the results, the Dv(90) values are
close in size to those found in AZ6, reflecting the effect of the higher stirring rate. The
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PSD traces are reminiscent of those seen in Figure 6-27, with a preference for smaller
particles in sample A, followed by the typical bimodal distribution thereafter. The
median D-value shifts as the run progresses, from 34.5 µm in Sample A to around 70
to 90 µm in Sample B to E, are in agreement with chord length measurements.
Figure 6-29: Offline PSD traces across AZ10 samples
Table 6.11: Particle size distribution percentiles in AZ10
Sample Dv(10) Dv(50) Dv(90)
(µm) (µm) (µm)
A 4.96 ± 0.08 34.5 ± 1.13 187 ± 14.9
B 12.3 ± 0.39 87.0 ± 1.45 172 ± 11.5
C 10.9 ± 0.45 85.8 ± 1.25 172 ± 4.34
D 9.01 ± 0.12 76.6 ± 0.42 160 ± 2.21
E 9.71 ± 0.34 72.2 ± 3.40 157 ± 25.7
AZ10 showed clear indication that particle size changes with time, with a preference
for agglomerates once the system reached a controlled state of operation. Despite
encrustation on the interior of stage 3 continuing to occur, AZ10 ran until feed depletion
without any pump or blockage issues. PAT techniques confirmed that steady state was
achievable within 1 hour. While further filtration analysis was not carried out, it




In this work, a case study was carried out on the continuous crystallisation of a com-
mercially relevant API salt. During the course of this study two continuous processes
approaches were considered; a tubular mixer system and a two-stage CSTR system op-
erating in periodic withdrawal mode. Based on the early work with the mixer pieces,
the tubular reactor set-up was concluded to be effective for salt crystallisation only
at high velocity flow rates. In comparison periodic CSTR production showed better
potential for continuous crystallisation scale-up and integration. In the latter, all ex-
periments ran for at least 80 minutes (4 residence times) without issues, giving an
appreciable yield between 70-80%. In AZ10, the system was shown to be capable of
running for 12 RTs without downtime. AZ10 confirmed that steady state was achieved
in 1 hour using PAT. From the data generated, a 0.5% w/w seed, 600 rpm stirring rate,
with equal pumping regimes and a set temperature of 20 ◦C shows the most promise
for further development. During the course of the project, the isolated product was
noted to form spherical agglomerates with high uniformity that filtered rapidly. The
agglomerate structures were replicated in the tubular mixer piece and CSTR set-up, in-
dicating there formation was a consequence of the high relative supersaturation, rather
than crystalliser equipment. The cake resistance of the agglomerates tested was shown
to be lower than the batch reference, indicating a possible benefit of reduced extrac-
tion times using the flow process. However, further analysis of the compressiblity is
required, particularly with the use of the conventional industrial techniques, such as
pressure filtration and agitation.
A number of potential issues still remain, however. A top priority is the encrustation,
which was noted to be very high in the first CSTR (stage 3) but almost non-existent
in stage 4. Sonication was shown to reduce encrustation in stage 3 but prevented
agglomerate formation, which impacted filtration times. A possible solution would be to
raise the temperature in stage 3 and pre-fill with the free base solution/seed suspension.
This might reduce the amount of encrustation, but a high stirrer rate may be necessary
to avoid broadening of the particle sizes. Furthermore, the feed lines would need to be
temperatures controlled. This would also facilitate safely increasing the concentration
of the free base and acid; improving productivity. While TGA measurements did
not indicate the inclusion of solvent into the agglomerate structure, a more sensitive
technique might be needed to ensure that solvent inclusion levels do not affect product
quality.
In terms of integration with upstream and downstream technologies, the periodic CSTR
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system would be well placed for in-tandem process design. Stages 1 and 2 could be fed
from a designed flow synthesis platform, with continuous withdrawing into stage 3. An
in-line filter has previously been demonstrated in stage 4 of the periodic CSTR set-up
and this could be incorporated for isolation of the product.221 The current set-up still
requires manual operation of the valves to control periodic transfer, for integration with
other technologies, aspects of the system would need to be automated to allow greater
accuracy when transferring the solid suspension. Even so, the periodic CSTR platform
has proven to be versatile in observing and controlling particle size for a relevant
commercial product. Ultimately, the use of periodic CSTRs in crystallisation shows
promise in integrated manufacturing and would be a useful tool for the production of





The pressure from societal and environmental factors to deliver green processes while
meeting consumer demand is an increasingly challenging issue, requiring complex and
comprehensive improvements across the industrial supply chain. In Chapter 1, contin-
uous manufacturing (CM) was outlined as a cleaner and more efficient manufacturing
procedure which is likely to be a key fixture in replacing batch manufacturing meth-
ods for pharmaceutical and fine chemical production. However, pharmaceutical and
fine chemical production is a multi-step procedure, with a complex supply chain under
strict regulatory control measures. Therefore, delivering green processing using CM
is a challenging problem. To overcome current limitations it is necessary to develop
new technologies and processes and a deeper understanding of the scope of CM from
a pharmaceutical and fine chemical production perspective. A key problem is bridg-
ing the perceived gaps in CM, such as between upstream synthesis and downstream
crystallisation technologies. This is a current bottleneck in CM and forms the primary
motivation for the research presented in this thesis. A greater understanding along
with the development of continuous crystallisation and other downstream processes
that can be integrated with upstream flow synthesis platforms will contribute to the
adoption of novel end-to-end continuous sustainable chemical production.
In Chapter 3, the development of an integrated continuous synthesis and crystallisa-
tion process for paracetamol (PCM) was pursued. A one-pot synthetic method starting
from the key intermediate 4-hydroxyacetophenone (4HAP) was replicated in batch and
investigated for transfer into a flow environment. The most effective method involved
flowing the starting material through a packed bed column, filled with the key reactant
and catalyst hydroxylamine hydrochloride (HOA). The process showed high selectiv-
ity to the PCM product, with reaction monitoring showing a conversion of 72% and
selectivity of 97% at peak performance. However, issues occurred with leaching of the
HOA component into the reaction stream which caused blockages. To overcome this,
the reaction was separated into two distinct steps; oximation of 4HAP to 4-hydroxy-
acetophenone oxime (4HAPO) and a subsequent Beckmann rearrangement of 4HAPO
to PCM. Oximation of 4HAP was successfully implemented in a tubular flow reactor
using HOA and sodium acetate (NaAc) which had previously been demonstrated in
batch. This approach showed potential for integration as the product could be crys-
tallised directly from the reactor output. The extracted product (4HAPO) from the
oximation step was then be redissolved and combined with the homogeneous organocat-
alyst trifluoroacetic acid (TFA) in flow to produce PCM in 70 to 80 % isolated yield.
In effect, a possible route to PCM from 4HAP was developed which translates the
important chemical steps into a continuous environment. However, the need for the
development of in situ separation and extraction technologies limited the integration
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of flow synthesis steps and downstream crystallisation in the procedure. A continu-
ous crystallisation profile was designed for the intermediate 4HAPO in ethanol/water
mixtures. A compact segmented crystalliser (mini-KRAIC (m-KRAIC)) was designed
that reduced reactor space footprint and allowed integration between the crystallisa-
tion and synthetic procedures for 4HAPO production. A cooling crystallisation profile
was tested for 4HAPO in the m-KRAIC with partial success, but controlled nucleation
within the tubular crystalliser proved difficult. A semi-batch model did show the direct
crystallisation of high purity 4HAPO from the flow chemistry effluent, which opens the
door to potential coupling of the flow process with a series of continuous stirred tank
reactors (CSTRs). This was determined to be a more suitable route to a successful
integration of flow synthesis and continuous crystallisation for 4HAPO.
In Chapter 4 a novel bench-top scale coupling for the flow chemical synthesis of the
drug substance pyrazinamide (PZA) was integrated with a segmented flow crystalliser
(kinetically regulated automated input crystalliser (KRAIC)). Initial research resulted
in poor crystallisation processing, however, the introduction of a controlled cooling
step resolved blockage issues and raised productivity to 1 g h−1. The rapid cooling was
shown to induce nucleation and reduce crystal size by an average of 80%. The resul-
tant crystalline PZA showed better processability and improved solid suspension. As a
consequence of the crystallisation technique, the γ polymorph of PZA was selectively
obtained. γ-PZA shows enhanced dissolution and solubility properties compared to the
thermodynamically stable α form.198 This work demonstrated the first cooling crystalli-
sation to selectively produce the γ polymorph from a purely aqueous solution without
additives. However, the mechanism for the selection of metastable γ polymorph is
poorly understood. The development of in-line structural analysis for continuous crys-
tallisation would be key in understanding the crystal growth and polymorph selectivity
observed and would enable greater control and understanding in integrated CM pro-
cesses. The potential of in situ structural analysis of crystals produced in segmented
flow crystallisation procedures is currently under investigation in a collaboration be-
tween the University of Bath, Chick Wilson group and the Diamond Light Source
facility and may be applied to the crystallisation of PZA in the future.
Chapter 5 investigated the production of two thermochromic multi-component com-
plexes, 4-bromo-2-methylaniline (4Br2MA):3,5-dinitrobenzoic acid (35DNBA) and 4-
iodo-2-methylaniline (4I2MA):35DNBA. The neutral cocrystal form of 4Br2MA:35DN-
BA and 4I2MA:35DNBA could not be consistently replicated using batch evaporative
methods. In pursuit of a scalable and more reliable method, H2O was found to be an
effective antisolvent. Temperatures 20 ◦C, 30 ◦C and 40 ◦C in antisolvent crystallisation
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experiment were shown to selectively produced the desired orange, 4Br2MA:35DNB-
A cocrystal. The thermochromic metastable form of 4I2MA:35DNBA could not be
reproduced using antisolvent crystallisation, but a new polymorphic form of 4I2MA:3-
5DNBA was isolated and characterised using thermal and X-ray diffraction methods.
For 4Br2MA:35DNBA, the batch antisolvent method was transferred to a temperature
controlled segmented flow crystalliser platform. Antisolvent crystallisation produced
the desired chromatic cocrystal in situ. However, the crystals were often seeded by
encrustation within the outlet or during extraction, leading to the irreversible tran-
sition to the non-thermochromic salt form of 4Br2MA:35DNBA. Careful collection of
the precipitate and evaporation of the solvent allowed characterisation of the orange
coloured crystals from flow. Results showed that isolated crystals matched the desired
neutral cocrystal of 4Br2MA:35DNBA. However, discrepancies were observed in the iso-
lated cocrystal thermochromic behaviour, with an observed melt-recrystallisation event
present that superseded the previously observed single-crystal-to-single-crystal (SCSC)
phase transition. Results from thermal analysis of the dry and wet cocrystals of 4Br-
2MA:35DNBA and the new form of 4I2MA:35DNBA, showed that the thermochromic
transition may be enabled by the presence of moisture on the particle domain scale.
The mechanism for this behaviour is not fully understood and future work should look
to develop a deeper understanding of this phenomenon. The results of this study would
help to establish an effective mechanism for the isolation of the metastable cocrystals.
This could be then fed into a continuous isolation or work-up procedure which could
be integrated with the flow crystallisation procedure developed during this work.
Finally, Chapter 6 consisted of a case study developing a continuous crystallisation
procedure for a commercially relevant active pharmaceutical ingredient (API) salt.
Particular emphasis was placed on the development of a crystallisation procedure which
could fit within an integrated continuous manufacturing process. During the course of
this study, two continuous processes were considered; a continuous flow tubular mixer
system and a two-stage CSTR system operating in periodic withdrawal mode. The
tubular reactor set-up suffered from large amounts of encrustation as a result of the
rapid supersaturation in the formation of the salt and was concluded to be only effective
at high velocity flow rates. In comparison, periodic CSTR production showed better
potential for continuous crystallisation scale-up and integration. The latter operated
consistently for twelve residence times (RTs) without downtime and an overall solid
recovery of 70 % was achieved for the API salt. Steady state measurements were taken
using process analytical technology (PAT) and a psuedo-steady state was shown to be
established within three RTs. From the data generated, a 0.5% w/w seed loading, 600
rpm stirring rate, set temperature of 20 ◦C and equal pumping regimes for the acid and
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base solutions produced an isolated product in the form of spherical agglomerates. The
spherical agglomerates showed a high uniformity and as a consequence, filtered rapidly.
The cake resistance of the agglomerates tested was shown to be one order of magnitude
lower than the batch reference, indicating a possible benefit in the form of reduced
extraction times using the flow process over the batch. However, encrustation during
nucleation of the salt remained an issue. Sonication was shown to reduce encrustation,
but prevented agglomerate formation, which caused filtration times to increase. Even
so, production of the API using periodic CSTRs crystallisation showed considerably
promise due to the high consistency and potential for spherical agglomerate control. In
terms of development, the current CSTR set-up requires manual operation and would
benefit from automation and integration with other technologies. This would allow
for greater accuracy when transferring the solid suspension. By improving the ease of
use, the attractiveness of continuous processes will lead to the adoption of continuous
manufacturing in early research development work flows. This will help to curb the
retention of outdated batch technologies in fine chemical and pharmaceutical industry,
improving long term sustainability.
The work presented in this thesis highlights how the application of flow technology
can be used to facilitate significant improvements and control in the production of fine
chemicals, ranging from well established pharmaceutical compounds such as PCM and
PZA to novel multi-component complexes such as 4Br2MA:35DNBA and 4I2MA:35D-
NBA and a current commercial API salt. During this research, the direct crystallisation
from flow synthetic production of 4HAPO and direct continuous crystallisation of PZA
was shown. These provide examples of how green chemistry practices and efficient
synthetic procedures can facilitate the direct integration of upstream and downstream
processing in CM. This avoids the need for in-line work up or separation and helps
to simplify complex processes. However, purification and separation cannot always be
avoided, as was the case for the amidation of PCM from 4HAPO. A major challenge
in integration is the design and development of continuous separation and extraction
technologies. The development of more technologies than can separate complex reaction
mixtures would overcome some of the limitations of coupling between flow synthesis
and crystallisation procedures.
Another consideration is the development of procedures from a holistic viewpoint. It is
often the case that reaction optimisation and crystallisation procedures are developed
independently and without consideration of the downstream or upstream implications.
Taking a wider view and developing a work flow that encompasses end-to-end man-
ufacturing may be an important step in speeding up the development of integrated
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continuous manufacturing. Workflows and guides have begun to appear for flow chem-
istry29 and continuous crystallisation222 independently, but a framework for end-to-end
or integrated production is not common practice.
While the application and development of flow synthesis is becoming increasingly more
pronounced and versatile, continuous crystallisation is less well established. Here the
continued optimisation of novel crystallisers will increased understanding and adoption
of CM practices. Future work should consider establishing a segmented flow crystalliser
design that can accommodate non-ambient temperatures. The design used in Chapter
5 for the thermochromic multi-component complexes could be scaled up, providing a
more versatile segmented flow crystalliser. The KRAIC could also be developed to
deliver seeds to the system. One of the limitations in the crystallisation of 4HAPO
using the m-KRAIC was the lack of nucleation. If a reliable seed dosing feed could be
applied consistently to each slug solution, then greater control could be exerted over
the crystallisation procedure.
Finally, the continued development of cheap, modular and versatile continuous pro-
cesses and platforms will accelerate the engineering of end-to-end or multi-step CM on
the lab scale. This will promote a base understanding of CM and lead to the wider
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(141) A. G. O’Brien, Z. Horváth, F. Lévesque, J. W. Lee, A. Seidel-Morgenstern and
P. H. Seeberger, Angewandte Chemie - International Edition, 2012, 51, 7028–
7030.
(142) R. Godawat, K. Brower, S. Jain, K. Konstantinov, F. Riske and V. Warikoo,
Biotechnology Journal, 2012, 7, 1496–1508.
(143) R. L. Hartman, J. R. Naber, S. L. Buchwald and K. F. Jensen, Angewandte
Chemie - International Edition, 2010, 49, 899–903.
(144) P. L. Heider, S. C. Born, S. Basak, B. Benyahia, R. Lakerveld, H. Zhang, R.
Hogan, L. Buchbinder, A. Wolfe, S. Mascia, J. M. Evans, T. F. Jamison and
K. F. Jensen, Organic Process Research and Development, 2014, 18, 402–409.
(145) B. P. Loren, M. Wleklinski, A. Koswara, K. Yammine, Y. Hu, Z. K. Nagy, D. H.
Thompson and R. G. Cooks, Chemical Science, 2017, 8, 4363–4370.
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Figure 9-1: Calibration curve for the absorption vs concentration measurements for
Eosin Y in ethanol (EtOH) at a fixed wavelength of 478 nm
Figure 9-2: NMR spectra from reaction monitoring of PCM10, 4-hydroxyacetophenone
(4HAP) = 7.81 to 7.84 ppm and 6.84 to 6.86 ppm, 4-hydroxyacetophenone oxime (4-
HAPO) = 7.44 to 7.49 ppm and 6.74 to 6.79 ppm
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Figure 9-3: Nuclear magnetic resonance (NMR) monitoring between 6 to 10 ppm for
4HAPO production in PCM11.1
Figure 9-4: NMR spectrum for PCM12 product after recrystallisation
293
(a) PCM14.1 (b) PCM14.2
(c) PCM14.3
Figure 9-5: NMR monitoring of 4HAPO in PCM14
294
(a) PCM14.1 (6 to 10 ppm) (b) PCM14.2 (6 to 10 ppm)
(c) PCM14.3 (6 to 10 ppm)
Figure 9-6: NMR monitoring between 6 to 10 ppm for 4HAPO production in PCM14
Figure 9-7: PCM15.2 (6 to 11 ppm)
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(a) PCM15.1 (b) PCM15.2
(c) PCM15.3
Figure 9-8: NMR spectrum of the isolated product in PCM15
(a) PCM16.1 (6 to 11 ppm) (b) PCM16.2 (6 to 10 ppm)
Figure 9-9: NMR monitoring for the flow synthesis of paracetamol (PCM) in PCM16
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(a) PCM16.1 (b) PCM16.2
Figure 9-10: NMR spectra for the isolated product from PCM16
Figure 9-11: NMR spectra between 6 and 10 ppm at different time stamps during
HAPO1
297





Figure 9-13: NMR spectra of the isolated product from HAPO8 a) Start-up b) Steady
state and c) Shutdown
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Figure 9-14: Powder X-ray diffraction (PXRD) spectra of HAPO8 and HAPO Form I
from simulated single crystal X-ray diffraction (SCXRD) data
Figure 9-15: Differential scanning calorimetry (DSC) trace of HAPO8 samples
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9.2 Pyrazinamide
Table 9.1: Set pump rates for pyrazinamide (PZA) coupling experiments
Experiment Feed Air Galden
(mL min−1) (mL min−1) (mL min−1)
PZA1 1.00 - -
PZA2 1.00 2.1 2.1
PZA3 1.00 6.3 2.1
PZA4 1.00 6.3 2.1
PZA5 1.00 6.3 2.1
PZA6 1.00 6.3 2.1
PZA7 1.00 6.3 2.1
PZA8 1.00 6.3 2.1
PZA9 1.00 6.3 2.1
PZA10 1.00 6.3 2.1
PZA11 1.00 6.3 2.1
Figure 9-16: Typical cooling profile in PZA, uncontrolled nucleation experiments
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Figure 9-17: NMR of PZA1, showing the NMR shifts for the isolated pyrazinamide
sample
Figure 9-18: NMR spectrum for PZA2 after isolation from continuous synthesis and
crystallisation
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Figure 9-19: NMR spectrum for PZA5 after isolation from continuous synthesis and
crystallisation
Figure 9-20: NMR spectrum for PZA6 after isolation from continuous synthesis and
crystallisation
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Table 9.2: Average solution volume per slug and crystal appearance in the PZA6




(mL) (mL) (mL) (mL)
28 0 2.0 2.0 0.07
12 4.4 5.4 1.0 0.08
10 5.6 6.4 0.8 0.08
10 6.6 7.4 0.8 0.08
13 7.4 8.6 0.8 0.06
12 8.8 9.6 0.8 0.06
27 0 2.0 2.0 0.07
13 2.4 3.6 1.2 0.09
12 3.8 4.8 1.0 0.08
10 5.0 5.8 0.8 0.08




Figure 9-21: PZA8 PXRD pattern compared to accessible polymorphs of PZA
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Figure 9-22: PZA8 DSC trace, endothermic peak at 190 ◦C corresponds to the product
melting point




Hot Stage Microscopy Videos
A link has been provided for access to the hot stage microscopy (HSM) videos for
samples TC1.8, TC3, TC4 and Figure 5-6:
https://www.dropbox.com/s/fdqqsf8j1y9xdvq/Scott_Daniel_ThesisAppendix_HSM.
zip?dl=0
(a) DSC trace of 4-bromo-2-methylaniline (4-
Br2MA)
(b) DSC trace of 4-iodo-2-methylaniline (4I2-
MA)
(c) DSC trace of 3,5-dinitrobenzoic acid (35D-
NBA)
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Figure 9-25: DSC of antisolvent crystallisation samples of 4Br2MA:35DNBA in batch
Figure 9-26: Asymmetric unit for 4I2MA:35DNBA, Cc5 crystal structure
Figure 9-27: Crystal packing along the c axis for 4I2MA:35DNBA, Cc5 structure
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Table 9.3: Hydrogen bonding in TC1.8, 4I2MA:35DNBA, Cc5 structure
Atoms Bond Distance Bond Angle Bond Type
(Å) (◦)
O5–H5 · · · O6 2.694(7) 172(8) Hydrogen
N1–H1B · · · O1 3.13(1) 163(9) Hydrogen
C7–H7C · · · O2 3.59(1) 162.8 Hydrogen
I1 · · · O4 3.190(4) - Halogen
I1 · · · O4 3.654(4) - Halogen
C4 · · · C14 3.365(9) - π · · · π
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Table 9.4: Crystal data and structure refinement for 4-iodo-2-methylaniline:3,5-dinitro-
benzoic acid (4I2MA:35DNBA), Cc5 crystal
Sample TC1.8
Compound 4I2MA:35DNBA
Formula [C7 H8 I N][C7 H4 N2 O6]
Formula weight 445.17
T (K) 150.00
Radiation Cu-Kα (λ = 1.541 84 Å)
Crystal system Triclinic















Crystal size (mm3) 0.29× 0.104× 0.015
2θ range for data collection (◦) 5.924 to 136.378
Index ranges −8 ≤ h ≤ 7,−8 ≤ k ≤ 8,−17 ≤ l ≤ 17
Reflections collected 12256
Independent reflections 2715 [Rint = 0.0570, Rsigma = 0.0338]
Data/restraints/parameters 2715/168/218
Goodness-of-fit on F2 1.215
Final R indexes [I>=2σ (I)] R1 = 0.0442, wR2 = 0.1111
Final R indexes [all data] R1 = 0.0457, wR2 = 0.1117





(b) Segmentation and antisolvent addition in a
water bath
(c) Crystalliser outlet and carrier fluid
recovery
Figure 9-28: Photographs of the jacketed segmented flow crystalliser used in Chapter
5 antisolvent crystallisation experiments
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(a) TC3.1 (taken after sample transitioned to
Cc1).
(b) TC3.2
Figure 9-29: DSC traces of TC3 4Br2MA:35DNBA samples
Figure 9-30: PXRD pattern for TC4, produced from batch antisolvent crystallisation
and compared to the simulated pattern for the neutral 4Br2MA:35DNBA complex,




Figure 9-31: HSM images of TC4.2 and TC4.3 heated from 35 to 150 ◦C at 5 ◦C min−1
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9.4 Continuous Salt Crystallisation
Figure 9-32: Calibration plot for Masterflex pumps in Chapter 6
Table 9.5: Evaluation of filtration times of SAB isolated from AZ4 to AZ8 and the
batch reference
Experiment Mass Volume Time Mass Fraction
(g) (mL) (sec) (g mL−1)
Batch 17.39 430 51 40
AZ4a 35.34 940 90 38
AZ5 35.20 500 11 70
AZ6 36.42 860 16 42
AZ7 35.26 820 17 43
AZ8 34.22 840 30 41
Filter diameter = 9 cm, 0.7 bar reduced pressure
a Poor seal led to incomplete vacuum
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Figure 9-33: Scanning electron microscopy (SEM) images of succinate salt (SAB) in
AZ8 at magnifications of a) x100 b) x500 c) x3000
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